Converted by EDGARwiz

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

0001080602-11-000017.txt : 20111214 0001080602-11-000017.hdr.sgml : 20111214 20111214170956 ACCESSION NUMBER: 0001080602-11-000017 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20110831 FILED AS OF DATE: 20111214 DATE AS OF CHANGE: 20111214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Allezoe Medical Holdings Inc CENTRAL INDEX KEY: 0001080602 STANDARD INDUSTRIAL CLASSIFICATION: METAL MINING [1000] IRS NUMBER: 980413066 STATE OF INCORPORATION: DE FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33090 FILM NUMBER: 111261676 BUSINESS ADDRESS: STREET 1: 1800 NW CORPORATE BOULEVARD STREET 2: SUITE 201 CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 321-452-9091 MAIL ADDRESS: STREET 1: 1800 NW CORPORATE BOULEVARD STREET 2: SUITE 201 CITY: BOCA RATON STATE: FL ZIP: 33431 FORMER COMPANY: FORMER CONFORMED NAME: STANFORD MANAGEMENT LTD DATE OF NAME CHANGE: 19990225 10-K 1 f10k8312011.htm FORM 10-K Converted by EDGARwiz

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-K


x	ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the fiscal year ended: August 31, 2011


¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from to .

Commission File Number

001-33090

ALLEZOE MEDICAL HOLDINGS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

98-0413066

(State or Other Jurisdiction of

Incorporation or Organization)

(I.R.S. Employer

Identification Number)

1800 NW Corporate Boulevard, Suite 201, Boca Raton, FL 33431

(Address of Principal Executive Offices)

(321)-452-9091

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

¨ YES x NO

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

¨ YES x NO

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

x YES ¨ NO

Indicate by check mark if disclosure of delinquent filers in response to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “accelerated filer and large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act)

YES [ ] NO [X]

The Aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed fourth fiscal quarter, August 31, 2011 was $79,845,622.

There were 173,324,482 shares of the Registrant’s $.001 par value common stock outstanding as of December 2, 2011.

Table of Contents

ALLEZOE MEDICAL HOLDINGS, INC.

FORM 10-K



Part I			1

Item 1.	Business	1
Item 1A.	Risk Factors	3
Item 1B.	Unresolved Staff Comments	9
Item 2.	Properties	9
Item 3.	Legal Proceedings	10
Item 4.	Removed and reserved	10

Part II			10

Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities	10
Item 6.	Selected Financial Data	11
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	11
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	19
Item 8.	Financial Statements and Supplementary Data	20
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	36
Item 9A.	Controls and Procedures	36
Item 9B.	Other information	37

Part III			37

Item 10.	Directors, Executive Officers and Corporate Governance	37
Item 11.	Executive Compensation	40
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	41
Item 13.	Certain Relationships and Related Transactions, and Director Independence	42
Item 14.	Principal Accountant Fees and Services	42
Item 15.	Exhibits and Financial Statement Schedules	43
	Signatures	43
	Certifications

ALLEZOE MEDICAL HOLDINGS, INC.

FORWARD LOOKING STATEMENTS

This annual report on Form 10-K contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause the results of the Company to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any projections of revenue, expenses, earnings or losses from operations or investments, or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. The risks, uncertainties and assumptions referred to above include risks that are described from time to time in our Securities and Exchange Commission, or the SEC, reports filed before this report.

The forward-looking statements included in this annual report represent our estimates as of the date of this annual report. We specifically disclaim any obligation to update these forward-looking statements in the future. Some of the statements in this annual report constitute forward-looking statements, which relate to future events or our future performance or financial condition. Such forward-looking statements contained in this annual report involve risks and uncertainties.

We use words such as anticipates, believes, expects, future, intends and similar expressions to identify forward-looking statements. Our actual results could differ materially from those projected in the forward-looking statements for any reason. We caution you that forward-looking statements of this type are subject to uncertainties and risks, many of which cannot be predicted or quantified.

The following analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes thereto contained elsewhere in this Form 10-K, as well as the risk factors included in this Form 10-K under Item 1A.

PART I


ITEM 1.	BUSINESS

Allezoe Medical Holdings, Inc. (the “Company” or “ALZM”) is a development stage company. The Company was organized under the laws of the State of Delaware as Stanford Management Ltd., on September 28, 1998. We formed our Company for the purpose of acquiring and developing mineral properties. On February 18, 2011, all of the mineral properties and related development and exploration activities were disposed of as part of a series of transactions resulting in the acquisition of Organ Transport Systems, Inc. (“OTS”).

The Company entered into a definitive Acquisition Agreement effective January 24, 2011 to acquire all of the issued and outstanding stock of Organ Transport Systems, Inc., a Nevada corporation based in Frisco, Texas (“OTS”). OTS is a biomedical company engaged in developing, patenting, and commercializing portable hypothermic, oxygenated preservation and transport technology for human organs. OTS plans to offer products to assist in human organ transplantation including its LifeCradle®® product line which assists with organ preservation. Under the terms of the Acquisition Agreement, the Company acquired 100 percent of the issued and outstanding shares of OTS in exchange for the issuance of 78,255,000 common shares of the Company representing sixty (60) percent of the resulting issued and outstanding common shares of the Company on a fully diluted basis, which shares will thereafter be non-dilutable and will always maintain a sixty (60) percent ownership in the Company. All outstanding liabilities of the Company at the time of the closing were discharged, paid or converted into equity and the then-existing mining operations of the Company were transferred at closing to Executor Capital, Inc., an unaffiliated Belize corporation, for the assumption of all such liabilities. The name of the Company also was changed to Allezoe Medical Holdings, Inc., to reflect its new business direction, and the trading symbol for its common stock was changed to "ALZM."

-1-

Current Business of the Company

We are a development stage company in the business of medical device development and marketing. Our business is, and will be, operated through subsidiary corporations, the first of which to be acquired is OTS.

OTS is a development stage company and was organized under the laws of the State of Nevada on July 13, 1999. It is a dynamic medical technology company based in Frisco, Texas. OTS has developed human organ preservation technologies designed to revolutionize the organ transplantation industry by dramatically improving the quality and increasing the availability of vital organs. OTS’s strategic goal is to be the worldwide leader of technologically advanced products and services for the entire organ preservation and enhancement market. The organ transplant market is approximately $9 billion in the U.S., of which $1.8 billion is spent on organ procurement and transportation alone.

OTS was incorporated in July, 1999 and has devoted substantially all of its efforts to the design and development of the LifeCradle®. The LifeCradle® is comprised of two principal components: a portable platform and an organ specific disposable set. The portable platform is a non-sterile, reusable instrument that houses the components of the LifeCradle®, including the disposable set. Because each disposable set is sterile and designed for a single use with each organ, our customers will need to purchase a new disposable set for each organ transplant that is performed using the LifeCradle®. Initially, we expect to derive much of our revenue from the sale of portable platforms. Over time, however, as use of the LifeCradle® for transplant procedures increases, we expect sales of the disposable sets will represent the majority of our revenue and will drive our revenue growth. Our ability to drive revenue growth will depend on hospitals, transplant centers and physicians adopting the LifeCradle® as a standard of care for use in organ transplant procedures.

We also have recently formed a wholly-owned subsidiary, SureScreen Medical, Inc., through which we have entered into a licensing agreement with AVM Corp. for the licensing of proprietary, patent pending technology that would enable healthcare providers to "see and treat" Human Papillomavirus (HPV), the most common sexually transmitted infection and a cause of cervical cancer, In addition to offering easy, affordable, and on-the-spot HPV diagnosis, the technology offers an important alternative to the HPV vaccine.

Currently HPV infects 233 million women worldwide; one woman dies every 2 hours from cervical cancer. Many experts advocate for HPV vaccination, but unexplained deaths in some patients has caused alarm. The Centers for Disease Control and Prevention (CDC) has examined 35 deaths that occurred among young people who received the vaccine. While no causation has been established, many patients and parents are avoiding the vaccine option.

Prominent figures, most recently two U.S. Presidential candidates, have taken firm (and opposing) public stances, further highlighting the ongoing controversy about the HPV vaccine. For other reasons, including the vaccine's cost and the inconvenience of it being administered over a number of visits, many patients don't actually complete the series. Last year only 32 percent of teenage girls nationwide received all three shots needed to prevent HPV infection. While popular, HPV vaccines do not treat existing HPV infections or HPV-associated diseases. Nor does the vaccine completely protect from all strains of HPV. Merck's Gardisil® vaccine prevents 70% of virally-caused cervical cancer but may only have limited effect against the other strains. The technology, equipment, and procedures SureScreen™ has announced are comprehensive in that a light-based exam identifies cells damaged by all known strains of HPV -- with 98% accuracy, in a single visit, and at low cost. For those who receive the vaccine, our new technology serves as a natural complement, screening for HPV-related damage that occurred in the window before the vaccine was administered. SureScreen™ will see the technology, developed by Aequorea Vision Medical, through regulatory approvals and clearances, to be followed by a broad market release.

We are a development stage enterprise as defined in FASB Accounting Standards Codification (“ASC”) Topic 915-10, Development Stage Enterprises (formerly Statement of Financial Accounting Standards, No. 7, Accounting and Reporting by Development Stage Enterprises), with a limited operating history.

-2-


ITEM 1A .	RISK FACTORS

You should carefully consider the risks described below together with all of the other information included in this report before making an investment decision with regard to our securities. The statements contained in or incorporated herein that are not historic facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by forward-looking statements. If any of the following risks actually occurs, our business, financial condition or results of operations could be harmed. In that case, you may lose all or part of your investment.

Risks Relating to Our Business

OUR MANAGEMENT HAS LIMITED EXPERIENCE IN MANAGING AND OPERATING A PUBLIC COMPANY. ANY FAILURE TO ADEQUATELY COMPLY WITH FEDERAL SECURITIES LAWS, RULES OR REGULATIONS COULD SUBJECT US TO FINES OR REGULATORY ACTIONS, WHICH MAY MATERIALLY ADVERSELY AFFECT OUR BUSINESS, RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

Our current management has limited experience managing and operating a public company and relies in many instances on the professional experience and advice of third parties including its attorneys and accountants. Failure to comply or adequately comply with any laws, rules, or regulations applicable to our business may result in fines or regulatory actions, which may materially adversely affect our business, results of operation, or financial condition and could result in delays in the development of an active and liquid trading market for our stock.

IF WE FAIL TO MAINTAIN AN EFFECTIVE SYSTEM OF INTERNAL CONTROL OVER FINANCIAL REPORTING, OUR ABILITY TO ACCURATELY AND TIMELY REPORT OUR FINANCIAL RESULTS OR PREVENT FRAUD MAY BE ADVERSELY AFFECTED AND INVESTOR CONFIDENCE AND THE MARKET PRICE OF OUR COMMON STOCK MAY BE ADVERSELY IMPACTED.

As directed by Section 404 of the Sarbanes-Oxley Act of 2002, or SOX 404, the Securities and Exchange Commission adopted rules requiring public companies to include a report of management on the company’s internal controls over financial reporting in their annual reports, including Form 10-K. Under current SEC rules, our management may conclude that our internal controls over our financial reporting are not effective. Even if our management concludes that our internal controls over financial reporting are effective, our independent registered public accounting firm may issue a report that is qualified if it is not satisfied with our controls or the level at which our controls are documented, designed, operated or reviewed, or if it interprets the relevant requirements differently from us.

THE LACK OF EXPERIENCED ACCOUNTING STAFF MAY LEAD TO MATERIAL WEAKNESS IN THE PREPARATION OF OUR FINANCIALS.

A material weakness may occur in the preparation of our financials due to insufficient resources in our accounting and finance department, resulting in (i) an ineffective review, monitoring and analysis of schedules, reconciliations and financial statement disclosures, and (ii) the misapplication of U.S. GAAP and SEC reporting requirements. Due to the effect of the lack of resources, including a lack of resources that are appropriately qualified in the areas of U.S. GAAP and SEC reporting, this could result in an adverse reaction in the financial marketplace due to a loss of investor confidence in the reliability of the Company’s financial information.

THE DEVELOPMENT OF OUR PRODUCTS MAY BE SLOWER THAN PROJECTED.

The development of our products and services and the implementation of such products in customer environments may take longer than expected. The sales cycle for contemplated products is long and the adoption rates are unknown, thus it may take longer for us to achieve meaningful revenue or meet our projections. In addition, our products will or may require regulatory review and approvals prior to any sales or distribution, including approval of the U.S. Food & Drug Administration. There can be no assurance that such approvals can be obtained, and the cost of doing so is considerable.

-3-

OUR PLANNED EXPANSION COULD BE DELAYED OR ADVERSELY AFFECTED BY, AMONG OTHER THINGS, DIFFICULTIES IN OBTAINING SUFFICIENT FINANCING, TECHNICAL DIFFICULTIES, OR HUMAN OR OTHER RESOURCE CONSTRAINTS.

Our planned expansion could be delayed or adversely affected by, among other things, difficulties in obtaining sufficient financing, technical difficulties, or human or other resource constraints. Moreover, the costs involved in these projects may exceed those originally contemplated. Costs savings and other economic benefits expected from these projects may not materialize as a result of any such project delays, cost overruns or changes in market circumstances. Failure to obtain intended economic benefits from these projects could adversely affect our business, financial condition and operating performances.

WE ENCOUNTER SUBSTANTIAL COMPETITION IN OUR BUSINESS AND ANY FAILURE TO COMPETE EFFECTIVELY COULD ADVERSELY AFFECT OUR RESULTS OF OPERATIONS.

As described in the products section, for every product we sell, we will encounter strong competitors. We anticipate that our competitors will continue to expand and seek to obtain additional market share with competitive price and performance characteristics. Aggressive expansion of our competitors or the entrance of new competitors into our markets could have a material adverse effect on our business, results of operations and financial condition.

OUR LIMITED OPERATING HISTORY MAY NOT SERVE AS AN ADEQUATE BASIS TO JUDGE OUR FUTURE PROSPECTS AND RESULTS OF OPERATIONS.

Our limited operating history may not provide a meaningful basis for evaluating our business. We entered into its current line of business in February 2011. We cannot guarantee that we will obtain or maintain profitability or that we will not incur net losses in the future. We will continue to encounter risks and difficulties that companies at a similar stage of development frequently experience, including the potential failure to:

· obtain sufficient working capital to support our expansion;

· expand our product offerings and maintain the high quality of our products;

· manage our expanding operations and continue to fill customers’ orders on time;

· maintain adequate control of our expenses allowing us to realize anticipated income growth;

· implement our product development, sales, and acquisition strategies and adapt and modify them as needed; and

· successfully integrate any future acquisitions

If we are not successful in addressing any or all of the foregoing risks, our business may be materially and adversely affected.

WE NEED TO MANAGE GROWTH IN OPERATIONS TO MAXIMIZE OUR POTENTIAL GROWTH AND ACHIEVE OUR EXPECTED REVENUES AND OUR FAILURE TO MANAGE GROWTH WILL CAUSE A DISRUPTION OF OUR OPERATIONS RESULTING IN THE FAILURE TO GENERATE REVENUES AT LEVELS WE EXPECT.

In order to maximize potential growth in our current and potential markets, we believe that we must expand our producing operations. This expansion will place a significant strain on our management and our operational, accounting, and information systems. We expect that we will need to continue to improve our financial controls, operating procedures, and management information systems. We will also need to effectively train, motivate, and manage our employees. Our failure to manage our growth could disrupt our operations and ultimately prevent us from generating the revenues we expect.

-4-

WE CANNOT ASSURE YOU THAT OUR GROWTH STRATEGY WILL BE SUCCESSFUL WHICH MAY RESULT IN A NEGATIVE IMPACT ON OUR GROWTH, FINANCIAL CONDITION, RESULTS OF OPERATIONS AND CASH FLOW.

One of our strategies is to grow through increasing our product lines. However, there are many obstacles to expand our product lines. We cannot, therefore, assure you that we will be able to successfully overcome such obstacles and establish our products in any additional markets. Our inability to implement this sustainable growth strategy successfully may have a negative impact on our growth, future financial condition, results of operations or cash flows.

IF WE NEED ADDITIONAL CAPITAL TO FUND OUR GROWING OPERATIONS, WE MAY NOT BE ABLE TO OBTAIN SUFFICIENT CAPITAL AND MAY BE FORCED TO LIMIT THE SCOPE OF OUR OPERATIONS.

If adequate additional financing is not available on reasonable terms, we may not be able to carry out our corporate strategy and we would be forced to modify our business plans accordingly. There is no assurance that additional financing will be available to us.

In connection with our growth strategies, we may experience increased capital needs and accordingly, we may not have sufficient capital to fund our future operations without additional capital investments. Our capital needs will depend on numerous factors, including (i) our profitability; (ii) the release of competitive products by our competition; (iii) the level of our investment in research and development; and (iv) the amount of our capital expenditures, including acquisitions. We cannot assure you that we will be able to obtain capital in the future to meet our needs.

In recent years, the securities markets in the United States have experienced a high level of price and volume volatility, and the market price of securities of many companies have experienced wide fluctuations that have not necessarily been related to the operations, performances, underlying asset values or prospects of such companies. For these reasons, our securities can also be expected to be subject to volatility resulting from purely market forces over which we will have no control. If we need additional funding we will, most likely, seek such funding in the United States and the market fluctuations affect on our stock price could limit our ability to obtain equity financing.

If we cannot obtain additional funding, we may be required to: (i) limit our expansion; (ii) limit our marketing efforts; and (iii) decrease or eliminate capital expenditures. Such reductions could materially adversely affect our business and our ability to compete.

Even if we do find a source of additional capital, we may not be able to negotiate terms and conditions for receiving the additional capital that are favorable to us. Any future capital investments could dilute or otherwise materially and adversely affect the holdings or rights of our existing shareholders. In addition, new equity or convertible debt securities issued by us to obtain financing could have rights, preferences and privileges senior to the Units. We cannot give you any assurance that any additional financing will be available to us, or if available, will be on terms favorable to us.

NEED FOR ADDITIONAL EMPLOYEES.

The Company’s future success also depends upon its continuing ability to attract and retain highly qualified personnel. Expansion of the Company’s business and operation will require additional managers and employees with industry experience, and the success of the Company will be highly dependent on the Company’s ability to attract and retain skilled management personnel and other employees. There can be no assurance that the Company will be able to attract or retain highly qualified personnel. Competition for skilled personnel in the construction industry is significant. This competition may make it more difficult and expensive to attract, hire and retain qualified managers and employees.

-5-

THE LOSS OF THE SERVICES OF OUR KEY EMPLOYEES COULD HARM OUR BUSINESS.

Our success depends to a significant degree on the services rendered to us by our key employees. If we fail to attract, train and retain sufficient numbers of these qualified people, our prospects, business, financial condition and results of operations will be materially and adversely affected. The loss of any key employees, including members of our senior management team, and our inability to attract highly skilled personnel with sufficient experience in our industry could harm our business.

WE ARE HIGHLY DEPENDENT ON TECHNOLOGY.

Our business and our results of operations are highly dependent on technology and our business faces many technology related risks. Infringements of our intellectual property could adversely affect our ability to compete. Our patent applications may be rejected in whole or in part in the United States or in other jurisdictions around the world. We may have to defend ourselves against claims of intellectual property infringement, which could be very expensive for us and harm our business and financial condition. We may be a party to lawsuits in the course of our business. Litigation can be expensive, lengthy, and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict. An unfavorable resolution of a particular lawsuit could have a material adverse effect on our business, operating results, or financial condition.

OUR FUTURE SUCCESS IS DEPENDENT ON INTELLECTUAL PROPERTY OWNED BY US.

The Company may not be able to protect unauthorized use of intellectual property licensed to us and to take appropriate steps to enforce our rights. Although management does not believe that our products or services infringe on the intellectual rights of others, there is no assurance that the Company may not be the target of infringement or other claims. Such claims, even if not true, could result in significant legal and other costs associated and may be a distraction to management. We plan to rely on a combination of copyright, trade secret, trademark laws and non-disclosure and other contractual provisions to protect our proprietary rights. Because the policing of intellectual and intangible rights may be difficult and the ideas and other aspects underlying our business model may not in all cases be protectable under intellectual property laws, there can be no assurance that we can prevent competitors from marketing the same or similar products and services.

DIFFICULTIES IN ESTABLISHING A NEW PRODUCT

We are an early stage company, bringing to market an advanced and unproven technology. We may not be able to raise sufficient financing to effect our business plan and deliver products and services that are accepted by customers. If we cannot find adequate capital on reasonable terms, investors will face a significant risk of losing their investments in their entirety.

WE WILL INCUR SIGNIFICANT COSTS TO ENSURE COMPLIANCE WITH UNITED STATES CORPORATE GOVERNANCE AND ACCOUNTING REQUIREMENTS.

We will incur significant costs associated with our public company reporting requirements, costs associated with newly applicable corporate governance requirements, including requirements under the Sarbanes-Oxley Act of 2002 and other rules implemented by the Securities and Exchange Commission. We expect all of these applicable rules and regulations to significantly increase our legal and financial compliance costs and to make some activities more time consuming and costly. We also expect that these applicable rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as executive officers. We are currently evaluating and monitoring developments with respect to these newly applicable rules, and we cannot predict or estimate the amount of additional costs we may incur or the timing of such costs.

-6-

Risks Relating To Our Industry

There is substantial competition in the medical device industry. Existing and new competitors may continue to improve their products and to introduce new products with competitive price and performance characteristics. Our competitors have the advantage of established relationships within the industry and they may be more highly capitalized. In addition, we cannot assure that additional competitors will not enter our existing markets, or that we will be able to compete successfully against existing or new competition.

The medical device industry is a highly regulated industry and there is no guarantee that we will be able to meet the initial regulatory requirements to market our products, or, if obtained, to continue to meet those regulatory requirements.

Risks Related To Our Securities

OUR COMMON STOCK IS QUOTED ON THE OTC BULLETIN BOARD WHICH MAY HAVE AN UNFAVORABLE IMPACT ON OUR STOCK PRICE AND LIQUIDITY.

Our Common Stock is quoted on the OTC Bulletin Board. The OTC Bulletin Board is a significantly more limited market than the New York Stock Exchange or NASDAQ system. The quotation of our shares on the OTC Bulletin Board may result in a less liquid market available for existing and potential stockholders to trade shares of our common stock, could depress the trading price of our common stock and could have a long-term adverse impact on our ability to raise capital in the future.

THERE IS LIMITED LIQUIDITY ON THE OTCBB.

When fewer shares of a security are being traded on the OTCBB, volatility of prices may increase and price movement may outpace the ability to deliver accurate quote information. Due to lower trading volumes in shares of our Common Stock, there may be a lower likelihood of one’s orders for shares of our Common Stock being executed, and current prices may differ significantly from the price one was quoted at the time of one’s order entry.

IN ORDER TO RAISE SUFFICIENT FUNDS TO EXPAND OUR OPERATIONS, WE MAY HAVE TO ISSUE ADDITIONAL SECURITIES AT PRICES WHICH MAY RESULT IN SUBSTANTIAL DILUTION TO OUR SHAREHOLDERS.

If we raise additional funds through the sale of equity or convertible debt, our current stockholders’ percentage ownership will be reduced. In addition, these transactions may dilute the value of our common shares outstanding. We may have to issue securities that may have rights, preferences and privileges senior to our common stock. We cannot provide assurance that we will be able to raise additional funds on terms acceptable to us, if at all. If future financing is not available or is not available on acceptable terms, we may not be able to fund our future needs, which would have a material adverse effect on our business plans, prospects, results of operations and financial condition.

OUR ARTICLES OF INCORPORATION PROVIDE FOR INDEMNIFICATION OF OFFICERS AND DIRECTORS AT OUR EXPENSE AND LIMIT THEIR LIABILITY WHICH MAY RESULT IN A MAJOR COST TO US AND HURT THE INTERESTS OF OUR SHAREHOLDERS BECAUSE CORPORATE RESOURCES MAY BE EXPENDED FOR THE BENEFIT OF OFFICERS AND/OR DIRECTORS.

-7-

Our articles of incorporation and applicable Delaware law provide for the indemnification of our directors, officers, employees, and agents, under certain circumstances, against attorney’s fees and other expenses incurred by them in any litigation to which they become a party arising from their association with or activities on our behalf. We will also bear the expenses of such litigation for any of our directors, officers, employees, or agents, upon such person’s written promise to repay us if it is ultimately determined that any such person shall not have been entitled to indemnification. This indemnification policy could result in substantial expenditures by us which we will be unable to recoup.

We have been advised that, in the opinion of the Securities and Exchange Commission (“SEC”), indemnification for liabilities arising under federal securities laws is against public policy as expressed in the Securities Act of 1933, as amended (the “Securities Act”), and is, therefore, unenforceable. In the event that a claim for indemnification for liabilities arising under federal securities laws, other than the payment by us of expenses incurred or paid by a director, officer or controlling person in the successful defense of any action, suit or proceeding, is asserted by a director, officer or controlling person in connection with the securities being registered, we will (unless in the opinion of our counsel, the matter has been settled by controlling precedent) submit to a court of appropriate jurisdiction, the question whether indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. The legal process relating to this matter if it were to occur is likely to be very costly and may result in us receiving negative publicity, either of which factors is likely to materially reduce the market and price for our shares, if such a market ever develops.

CURRENTLY, THERE IS A LIMITED PUBLIC MARKET FOR OUR SECURITIES, AND THERE CAN BE NO ASSURANCES THAT ANY SIGNIFICANT PUBLIC MARKET WILL EVER DEVELOP OR THAT OUR COMMON STOCK WILL CONTINUE TO BE BE QUOTED FOR TRADING AND, EVEN IF QUOTED, IT IS LIKELY TO BE SUBJECT TO SIGNIFICANT PRICE FLUCTUATIONS.

We have a trading symbol for our common stock, ALZM, which permits our shares to be quoted on the OTCBB. However, our stock has been thinly traded since approval of our quotation on the over-the-counter bulletin board by FINRA using the new trading symbol in March 2011. Consequently, there can be no assurances as to whether:

any market for our shares will develop;

the prices at which our common stock will trade; or

the extent to which investor interest in us will lead to the development of an active, liquid trading market. Active trading markets generally result in lower price volatility and more efficient execution of buy and sell orders for investors.

In addition, our common stock is unlikely to be followed by any market analysts, and there may be few institutions acting as market makers for our common stock. Either of these factors could adversely affect the liquidity and trading price of our common stock. Until our common stock is fully distributed and an orderly market develops in our common stock, if ever, the price at which it trades is likely to fluctuate significantly. Prices for our common stock will be determined in the marketplace and may be influenced by many factors, including the depth and liquidity of the market for shares of our common stock, developments affecting our business, including the impact of the factors referred to elsewhere in these risk factors, investor perception of us and general economic and market conditions. No assurances can be given that an orderly or liquid market will ever develop for the shares of our common stock.

WE ARE NOT LIKELY TO PAY CASH DIVIDENDS IN THE FORESEEABLE FUTURE.

We currently intend to retain any future earnings for use in the operation and expansion of our business. Accordingly, we do not expect to pay any cash dividends in the foreseeable future, but will review this policy as circumstances dictate.

-8-

WE MAY NOT BE ABLE TO EFFECTIVELY CONTROL AND MANAGE OUR GROWTH.

If our business and markets grow and develop as we expect, it may be necessary for us to finance and manage expansion in an orderly fashion. In addition, we may face challenges in managing expanding product offerings. Such eventualities will increase demands on our existing management and facilities. Failure to manage this growth and expansion could interrupt or adversely affect our operations and cause production backlogs, longer product development time frames and administrative inefficiencies.

WE ARE SUBJECT TO THE PENNY STOCK RULES WHICH WILL MAKE OUR SECURITIES MORE DIFFICULT TO SELL.

We are now and may be subject in the future to the SEC’s “penny stock” rules if our securities sell below $5.00 per share. Penny stocks generally are equity securities with a price of less than $5.00. The penny stock rules require broker-dealers to deliver a standardized risk disclosure document prepared by the SEC which provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer must also provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson, and monthly account statements showing the market value of each penny stock held in the customer’s account. The bid and offer quotations, and the broker-dealer and salesperson compensation information must be given to the customer orally or in writing prior to completing the transaction and must be given to the customer in writing before or with the customer’s confirmation.

In addition, the penny stock rules require that prior to a transaction, the broker dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. The penny stock rules are burdensome and may reduce purchases of any offerings and reduce the trading activity for our securities. As long as our securities are subject to the penny stock rules, the holders of such securities may find it more difficult to sell their securities.

OUR CONTROLLING SHAREHOLDER MAY TAKE ACTIONS THAT CONFLICT WITH YOUR INTERESTS.

Élan Health Services, Inc. owns approximately 36 percent of our common stock and has a non-dilution feature resulting from the acquisition of OTS. As a result, all of our officers and directors may be elected by Élan Health Services, Inc. which will be able to exercise control over all matters requiring shareholder approval, including the election of directors, amendment of our certificate of incorporation and approval of significant corporate transactions, and they will have significant control over our management and policies. The directors elected by this shareholder will be able to significantly influence decisions affecting our capital structure. This control may have the effect of delaying or preventing changes in control or changes in management, or limiting the ability of our other shareholders to approve transactions that they may deem to be in their best interest. For example, our controlling shareholders will be able to control the sale or other disposition of our operating businesses and subsidiaries to another entity.


ITEM 1B.	UNRESOLVED STAFF COMMENTS

None.


ITEM 2.	PROPERTIES

We maintain our corporate offices at 1800 NW Corporate Boulevard, Suite 201, Boca Raton, FL 33431 and also use a service office located at 1365 N. Courtenay Parkway, Suite A, Merritt Island, FL 32953 provided by a consultant to the Company. Our telephone number there is (321) 452-9091. The corporate office space is currently being provided free of charge by our Chairman and CEO, Michael Gelmon. There are currently no proposed programs for the renovation, improvement or development of the facilities currently used. Organ Transport Systems currently occupies an office at 6170 Research Road, Frisco, Texas 75033.

-9-

We do not currently have policies regarding the acquisition or sale of real estate assets primarily for possible capital gain or primarily for income. We do not presently hold any investments or interests in real estate, investments in real estate mortgages or securities of or interests in persons primarily engaged in real estate activities.


ITEM 3 .	LEGAL PROCEEDINGS

As of the date of this Report, neither we nor any of our officers or directors is involved in any litigation either as plaintiffs or defendants. As of this date, there is not any threatened or pending litigation against us or any of our officers or directors.


ITEM 4.	REMOVED AND RESERVED

PART II


ITEM 5.	MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES

The Company’s common stock has traded in the over-the-counter market on the OTC Bulletin Board system (“OTCBB”), currently under the symbol “ALZM.OB” The following table sets forth the range of high and low closing prices of the Common Stock as reported by the OTCBB for each fiscal quarter since trading commenced.


	Closing Prices
	High	Low
FISCAL 2011
First Quarter (September 1, 2010 through November 30, 2010)	$ *	$ *
Second Quarter (December 1, 2010 through February 28, 2011)	$ 0.40	$ 0.36
Third Quarter (March 1, 2011 through May 31, 2011)	$ 2.46	$ 0.55
Fourth Quarter (June 1, 2011 through August 31, 2011)	$ 0.66	$ 0.40

FISCAL 2010*
First Quarter (September 1, 2009 through November 30, 2009)	$ --	$ --
Second Quarter (December 1, 2009 through February 28, 2010)	$ --	$ --
Third Quarter (March 1, 2010 through May 31, 2010)	$ --	$ --
Fourth Quarter (June 1, 2010 through August 31, 2010)	$ --	$ --

* Prior to the closing of the acquisition of Organ Transport Systems in February 2011 and the change in the trading symbol, there was limited trading activity in the stock of the Company.

On August 31, 2011, the closing price of the Company’s Common Stock as reported by the OTCBB was $0.57 and there were approximately 65 shareholders of record.

Dividends

We have not paid any cash dividends on our common stock and do not anticipate paying any such cash dividend in the foreseeable future. Earnings, if any, will be retained to finance future growth. We may issue shares of our common stock in private or public offerings to obtain financing, capital or to acquire other businesses that can improve our performance and growth. Issuance and/or sales of substantial amounts of common stock could adversely affect prevailing market prices in our common stock.

Common Stock

As of December 2, 2011 there were approximately 71 record holders of our common stock with 173,324,482 shares issued and outstanding.

-10-


ITEM 6.	SELECTED FINANCIAL DATA

Not required.


ITEM 7.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements that include words such as “believe,” “expect,” “should,” “intend,” “may,” “anticipate,” “likely,” “contingent,” “could,” “may,” or other future-oriented statements, are forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding our business plans, strategies and objectives, and, in particular, statements referring to our expectations regarding our ability to continue as a going concern, generate increased market awareness of, and demand for, our current products, realize profitability and positive cash flow, and timely obtain required financing. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors within and beyond our control that could cause or contribute to such differences include, among others, our critical capital raising efforts in an uncertain and volatile economical environment, our ability to maintain relationship with strategic companies, our cash preservation and cost containment efforts, our ability to retain key management personnel, our relative inexperience with advertising, our competition and the potential impact of technological advancements thereon, the impact of changing economic, political, and geo-political environments on our business, as well as those factors discussed elsewhere in this Form 10-K and in “Item 1 - Our Business”.

Readers are urged to carefully review and consider the various disclosures made by us in this report and those detailed from time to time in our reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.

OVERVIEW

The Company was incorporated under the laws of the State of Delaware on September 24, 1998 with authorized common stock of 25,000,000 shares at $0.001 par value. On March 9, 2007, at the Annual General Meeting of Stockholders a Resolution was approved increasing the authorized share capital to 500,000,000 common shares with a par value of $0.001 per share.

-11-

Under the terms of the Acquisition Agreement, the Company acquired 100 percent of the issued and outstanding shares of OTS from its sole shareholder, Healthcare of Today, Inc., in exchange for the issuance of 78,255,000 common shares of the Company representing sixty (60) percent of the resulting issued and outstanding common shares of the Company on a fully diluted basis (the “Share Exchange”), which shares will thereafter be non-dilutable and will always maintain a sixty (60) percent ownership in the Company. All outstanding liabilities of the Company have been discharged, paid or converted into equity at closing and the existing mining operations of the Company were transferred at closing to Executor Capital, Inc., an unaffiliated Belize corporation, for the assumption of all such liabilities. The current officers and directors of the Company also resigned at Closing and appointed Michael Holder and Hyman White as the Directors of the Company, and Mr. Holder as President and Chief Executive Officer of the Company and Mr. White Secretary and Treasurer of the Company, effective February 18, 2011. The name of the Company also has been changed to Allezoe Medical Holdings, Inc., to reflect its new business direction, and the trading symbol for its common stock has been changed to "ALZM."

Prior to the entry into the Acquisition Agreement on January 24, 2011, there was no relationship between the Company or any of its affiliates and Healthcare of Today, Inc. ("Health Care of Today") or Organ Transport, Inc. or any of the officers, directors or affiliates of either of them. Organ Transport is now a wholly-owned subsidiary of the Company.

The Business

Current Business of OTS

OTS was incorporated in July 1999 and has devoted substantially all of its efforts to the design and development of the LifeCradle®. The LifeCradle® is comprised of two principal components: a portable platform and an organ specific disposable set. The portable platform is a non-sterile, reusable instrument that houses the components of the LifeCradle®, including the disposable set. Because each disposable set is sterile and designed for a single use with each organ, our customers will need to purchase a new disposable set for each organ transplant that is performed using the LifeCradle®. Initially, we expect to derive much of our revenue from the sale of portable platforms. Over time, however, as use of the LifeCradle® for transplant procedures increases, we expect sales of the disposable sets will represent the majority of our revenue and will drive our revenue growth. Our ability to drive revenue growth will depend on hospitals, transplant centers and physicians adopting the LifeCradle® as a standard of care for use in organ transplant procedures.

We are a development stage enterprise as defined in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 915-10, Development Stage Enterprises (formerly Statement of Financial Accounting Standards, No. 7, Accounting and Reporting by Development Stage Enterprises), with a limited operating history. Beginning in 1999, OTS adopted a fiscal year that ends on the last day in December, but this fiscal year was changed to that of the Company, August 31, as a result of the acquisition on February 18, 2011. We now operate as one reportable segment.

-12-

Our financial statements are now those of OTS as a result of the acquisition of OTS on February 18, 2011 and the disposition of our former mining operations. As of August 31, 2011, we had not generated any revenue. We have incurred net losses in each year since our inception. As of August 31, 2011 and 2010, we had a deficit accumulated during the development stage of $28.1 and $25.6 million respectively. We expect our losses to increase as we continue our development activities and expand our commercialization activities. To date, we have funded our cash requirements primarily with proceeds from the sale of equity securities and from debt financings. To the extent our cash, cash equivalents and investments, including the net proceeds from this offering, are insufficient to fund our future cash requirements, we may be required to raise additional capital. Any such required additional capital may not be available on reasonable terms, if at all. If we are unable to obtain additional capital, we may be required to reduce the scope of, delay or eliminate some or all of, our planned development and commercialization activities, which could materially harm our business.

Plan of Operation

We are a development stage company which plans to enter into the business of providing hospitals, transplant centers and physicians with advanced organ transportation technology, allowing hospitals, transplant centers and physicians to use this technology to make organ preservation and transportation more efficient and effective. If we obtain FDA clearance of the LifeCradle®, we intend to market our products in the United States through a direct sales force supported by clinical specialists.

We also plan to acquire additional related or complementary companies and business to add to our cash flow as well as to enhance the development and marketing of the Life Cradle®

Our Product

The LifeCradle® technology is planned to (i) increase the number and quality of currently transplantable organs (generally provided from brain dead donors), (ii) expand the traditional pool of donor organs to include organs from deceased cardiac donors in addition to brain dead donors, (iii) treat and improve the health of currently non-transplantable organs, and (iv) expand beyond transplantation to externally treat organs of patients prior to replacing them in the patient’s body – all while reducing the costs associated with preservation, hospital stay, and ischemic time related patient complications. Research for all four steps has been conducted and/or proposed by leading transplant programs around the world in collaboration with OTS.

The Company believes its technology can roughly double the size of the transplant industry by improving the condition of organs and significantly extending the post-procurement life of donor organs (e.g. 4 times longer for donor hearts) which could potentially enable the transplantation of up to 80% of documented hearts currently not transplanted. The Company has completed in excess of 225 preservation experiments (rat, swine, canine and human hearts) with its technology. In proof of concept experiments in swine hearts, we have demonstrated perfusion times up to 24 hours followed by successful transplantation. Superior results include far less apoptosis (cell death), tissue lactate build up, and levels of the CK-MB isoenzyme (heart muscle damage), as well as active oxygen consumption and stable pH. Studies presented at the 2009 International Society of Heart & Lung Transplantation in Paris with discarded human hearts using the LifeCradle® in the real donor operating room setting, have verified the ease of use in the current procurement process. Twelve-hour preservation periods with these discarded human hearts in the LifeCradle® have shown that the hearts are still consuming oxygen and that tissue lactate levels are significantly lower at the end of the preservation periods than with the cold, static storage controls currently used. These results are consistent with the findings in the earlier animal transplant studies. The Company’s initial product, The LifeCradle® HR Cardiac Perfusion System (the “LifeCradle® HR”), perfuses and feeds a heart via a circulating, oxygenated, hypothermic, proprietary nutrient solution with the intention of better preserving and maintaining the organ beyond current standards of care. The LifeCradle® HR does this by (i) providing stable temperature control, (ii) maintaining aerobic metabolism through the delivery of oxygen and nutrients, (iii) providing real-time metabolic and physiological data during perfusion, and (iv)fitting seamlessly into the procurement environment, requiring negligible resource commitment.

-13-

With its LifeCradle® HR device, OTS plans to (i) decrease the current travel time restrictions associated with the prevailing organ transportation process, (ii) provide the time necessary to evaluate the organ’s health instead of preemptively rejecting an organ simply due to a quick assessment of the donor’s medical or social history, (iii) resuscitate organs that are temporarily in poor condition (too fatigued), (iv) reduce the probability of organ damage prior to transplantation and complications following procurement, and (v) medically treat and enhance previously non-transplantable organs. All of these benefits could improve transplant outcomes, reduce costs and expand the pool of transplantable organs and thus transplants. In 2006, 41,000 available organs went unused while 96,000 patients were on the transplant waiting list at the end of the year. Almost 110,479 patients are waiting today.

While our initial product is designed for heart preservation in transplantation, we plan to adapt our technology for additional organs such as the liver, kidney, lungs, pancreas, intestines and limbs. The Company is also developing proprietary perfusion solutions to be used in the LifeCradle® devices.

Competitive Advantages

We believe there are several competitive advantages with our system over competitive systems. Our LifeCradle® transports donor hearts while pumping a proprietary solution through the organ, keeping it at optimal levels for transplantation. The LifeCradle® keeps the donor organ at an optimum level by keeping the organ at ideal temperatures and by continuously monitoring during transportation. The only comparative system is a “warm blood” device that has been introduced to the market but has failed to be proven effective. The only other competitive technology is an “igloo” cooler full of ice that is used to transport the donor heart.

At this point, however, we cannot provide any assurance or guarantee that we will be successful and capitalize upon the believed competitive advantages described above.

Employees

As a result of the acquisition of OTS and the disposition of the former mining operations, we now have four employees, all of whom work for OTS. OTS has utilized a significant number of outside vendors and consultants to facilitate its product development, research and regulatory affairs.

Liquidity and Capital Resources

We have historically met our capital requirements through either private placement of equity or private borrowings. Our cash balance increased $20,673 from $17,647 at August 31, 2010 to $38,320 at August 31, 2011. During 2011, our primary sources of cash were cash provided by borrowings under notes payable issuances. Our primary uses of cash were for operating activities and expenditures for the acquisition of patents.

2011 and 2010 Operating, Investing, and Financing Activities

Operating activities in 2011 and 2010 used $475,288 and $100,350 of cash flow, respectively. Cash flow from operating activities is related to both the level of our profitability and changes in working capital and other assets and liabilities. Operating cash outflows are largely attributable to recurring expenditures for labor and other activities. For the years ended August 31, 2011 and 2010, we reported net losses of $2,534,520 and $3,501,650, respectively.

Changes in the components of our working capital impact cash flow from operating activities. During 2011 and 2010, accrued interest on notes payable increased $273,245 and $118,176, respectively, contributing favorably to our net cash flows from operating activities. Changes in accounts payable and accrued expenses, and other current and non-current liabilities also impact our cash flow from operating activities. During 2011 and 2010, our accounts payable and accrued expenses increased $125,847 and $245,349, respectively, contributing favorably to our net cash provided by operating activities. During 2011 and 2010, our accrued salaries increased $536,854 and $682,501, respectively, contributing favorably to our net cash flows from operating activities.

-14-

Liquidity and Capital Resources (continued)

Investing activities in 2011 and 2010 used $43,225 and $48,821 in cash, respectively. Investments in patents are classified as investing activities. During 2011 and 2010, we invested $43,010 and $48,821 in patents, respectively. Investing activities also include expenditures for the purchase of property and equipment.

Financing activities provided $539,186 and $166,818 of cash during 2011 and 2010, respectively.

On February 24, 2011, we borrowed $25,000 from Orchid Island Capital, LLC and issued a convertible debenture in that amount due in August 2011 at 9 percent interest. The debenture is convertible into shares of our common stock at a price discounted 30 percent from the ten day average market price at the time of conversion.

Additionally, we received loan proceeds of $300,000 in March of 2011 from Crystal Falls Investments, LLC, an unrelated third party, and issued three identical convertible debentures for $100,000 each dated as of March 30, 2011 due September 30, 2011 at 9 percent interest. The notes are all convertible into common stock at a price equal to 80 percent of the five lowest volume weighted average prices for our common stock for the ten trading days prior to the notice of conversion. On July 9, 2011, Crystal Falls Investments, LLC issued a notice of conversion of the principal amount of all three notes, with the accrued interest of $7,323 paid through the issue of a new convertible promissory note in that amount at July 9, 2011, due January 8, 2012, on the same terms as the converted notes.

During 2010, we issued 84,000 shares of our common stock at prices ranging from $.66 to $1.88 per share. Additionally, warrants were exercised for the purchase of our common stock at $.33 per share. The net proceeds from the two issuances aggregated $149,788. The net proceeds were used for general corporate purposes including improving our overall liquidity.

See ITEM 8. “FINANCIAL STATEMENTS, Note 8 – “Notes Payable” for additional information regarding our outstanding debt.

Year 2012 Cash Requirements and Potential Sources of Liquidity

In our opinion, available funds will satisfy our capital requirements for the next several months while we are in the process of negotiating additional funding to implement our FDA clearance process and bring the Life Cradle® to market. We expect to do so in 2012. There can be no assurance that we will be successful in raising additional funds to meet our capital needs.

Recurring Fair Value Measurements

In accordance with accounting principles generally accepted in the United States of America, certain assets and liabilities are required to be recorded at fair value on a recurring basis.

Off-Balance Sheet Arrangements

None

-15-

Current Economic Environment

The U.S. economy is currently in a recession, which could be long-term. Consumer confidence continued to deteriorate and unemployment figures continued to increase during 2011. However, in recent months, certain economic indicators have shown modest improvements. The generally deteriorating economic situation, together with the limited availability of debt and equity capital, including bank financing, will likely have a disproportionate impact on all micro-cap companies. As a result, we may not be able to execute our business plan due to our inability to raise sufficient capital and/or be able to develop a customer base for our planned products.

Contractual obligations

Currently, we have no employment agreements or other contractual undertakings with any of our officers, directors or employees, other than promissory notes issued in payment of accrued salaries.

The following is a summary of notes payable at August 31, 2011 and 2010:


Description	August 31, 2011	August 31, 2010
NTEC, Inc.
Note payable to NTEC, Inc. The note accrues interest at 7% per annum and matures on August 31, 2012.	$ 235,629	$ 129,350
The Realtime Group
Related party note payable to The Realtime Group, president Marshall Wenrich served as OTS’ Director of Engineering. The note accrues interest at 7% per annum and matures on December 31, 2011.	131,433	122,834
Musculoskeletal Transplant Foundation
Note payable to Musculoskeletal Transplant Foundation (MTF). The note accrues interest at the WSJ prime rate plus 2% and matures on December 31, 2011.	907,664	822,217
University of Texas Southwestern Medical Center
Note payable to the University of Texas Southwestern Medical Center. The note accrues interest at 7% per annum and matures on the December 31, 2011.	349,162	326,320
Employees and consultants
Notes payable to related parties – employees and consultants. The notes accrue interest at 7% per annum and mature December 30, 2011.	109,402	102,768
Convertible debentures - officers
Convertible notes payable to related parties – officers by OTS. The notes accrue interest at 12% per annum, mature December 15, 2012, and are convertible one year after issuance into shares of Company common stock at a price discounted from average trading price. $1,408,579 less discount at $909,507 for conversion.	499,072	-

-16-


Ambrose and Keith
Note payable to Ambrose and Keith. The note accrues interest at 9% per annum and mature April 30, 2011 and is convertible into shares of the Company’s common stock at a price discounted from average trading price.	25,000	-
Asher Enterprises, Inc.
Note payable to Asher Enterprises, Inc. The note accrues interest at 8% per annum and mature April 11, 2012 and is convertible 180 days after issuance into shares of the Company’s common stock at a price discounted from average trading price. $53,000 Note less discount of $35,917 for conversion.	17,083	-
Asher Enterprises, Inc.
Note payable to Asher Enterprises, Inc. The note accrues interest at 8% per annum and mature May 18, 2012 and is convertible 180 days after issuance into shares of the Company’s common stock at a price discounted from average trading price. $44,000 Note less discount of $33,320 for conversion.	6,680	-
Crystal Falls Investments, LLC.
Convertible notes payable to Crystal Falls. The notes accrue interest at 9% per annum and mature January 31, 2012 and are convertible into shares of Allezoe common stock at a price discounted from the average trading price. $100,000 Note less discount of $59,185 for conversion.	40,815	-
Ambrose and Keith
Demand loan to Ambrose and Keith. The note does not accrue interest and matured April 30, 2011.	5,000	-

Total	2,326,940	1,503,489
Less: current portion	1,827,868	129,350
Long-term debt	$ 499,072	$ 1,374,139

Our subsidiary, Organ Transport Systems, Inc., leases office and lab space in a two story, 50,000 square foot building located in Frisco, Texas under a license agreement which terminated on October 31, 2010. The license agreement provides the Company with five offices and lab space, and full access to building common areas including conference rooms, break room / kitchen, reception area and common lab areas. The agreement also covers telephone, wired and wireless internet access, and utilities. The required monthly payment under the license agreement is $4,267. The agreement automatically renews on a month to month basis at the previous agreed upon terms until either party notifies the other in writing of its intention to terminate the license agreement 30 days prior to the termination date.

-17-

We now maintain our corporate offices in space made available at no charge by our Chief Executive Officer, located in Boca Raton, Florida.

Results of Operations

As a result of the reverse merger with Organ Transport Services, Inc. on February 18, 2011, the former mining development activities of the Company have been terminated and all of the related assets and liabilities have been disposed of. Our operations and financial statements have been restated retroactively as the results of operations of Organ Transport Services, Inc., as the successor entity. There have been no material changes in the operations or assets of Organ Transport Systems, Inc. since the end of the fiscal year August 31, 2010, except that the financial statements of Organ Transport, Inc. have been restated to August 31, to accommodate the change in fiscal year to that of the Company.

Results of Operations for the Years Ended August 31, 2011 and 2010.

For the years ended August 31, 2011 and 2010, the Company had no revenues. Since inception, the Company has yet to earn revenues and has incurred cumulative net losses of $28,096,219. For the years ended August 31, 2011 and 2010, the Company had net losses of $2,534,520 and $3,501,650, respectively. Our activities have been attributed primarily to start up and business development.

For the years ended August 31, 2011 and 2010, we incurred operating expenses of $1,608,551 and $3,382,479, respectively. The decreases relate primarily to officer payroll, directors and advisor fees, and contract labor.

Off-Balance Sheet Arrangements

We currently do not have any off-balance sheet arrangements.

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. We believe that the following critical policies affect our more significant judgments and estimates used in preparation of our financial statements.

The Company has incurred deferred offering costs in connection with raising additional capital through the sale of its common stock. These costs are capitalized and charged against additional paid-in capital when common stock is issued. If there is no issuance of common stock, the costs incurred are charged to operations.

Research and development costs are charged to operations when incurred and are included in operating expenses.

-18-

Recent Accounting Pronouncements:

In September 2011, the FASB issued an amendment to Topic 350, Intangibles—Goodwill and Other, which simplifies how entities test goodwill for impairment. Previous guidance under Topic 350 required an entity to test goodwill for impairment using a two-step process on at least an annual basis. First, the fair value of a reporting unit was calculated and compared to its carrying amount, including goodwill. Second, if the fair value of a reporting unit was less than its carrying amount, the amount of impairment loss, if any, was required to be measured. Under the amendments in this update, an entity has the option to first assess qualitative factors to determine whether the existence of events or circumstances leads the entity to determine that it is more likely than not that its fair value is less than its carrying amount. If after assessing the totality of events or circumstances, an entity determines that it is not more likely than not that the fair value of the reporting unit is less than its carrying amount, then the two-step impairment test is unnecessary. If the entity concludes otherwise, then it is required to test goodwill for impairment under the two-step process as described under paragraphs 350-20-35-4 and 350-20-35-9 under Topic 350. The amendments are effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011 and early adoption is permitted. The Company is currently evaluating whether early adoption is necessary.


ITEM 7A.	Quantitative and Qualitative Disclosures About Market Risk

Not applicable.

-19-


ITEM 8.	FINANCIAL STATEMENTS

Allezoe Medical Holdings, Inc.

(A Development Stage Company)

Consolidated Financial Statements

August 31, 2011 and 2010

CONTENTS


	Page(s)

Report of Independent Registered Certified Public Accounting Firm	21

Consolidated Balance Sheets - As of August 31, 2011 and 2010	22

Consolidated Statements of Operations -	23
For the years ended August 31, 2011 and 2010
and the period from July 13, 1999 (inception)
through August 31, 2011

Consolidated Statement of Stockholders’ Equity (Deficit)	24
For the years ended August 31, 2011 and 2010
and the period from July 13, 1999 (inception)
through August 31, 2011

Consolidated Statements of Cash Flows -	25
For the years ended August 31, 2011 and 2010
and the period from July 13, 1999 (inception)
through August 31, 2011

Notes to Consolidated Financial Statements	26

-20-

REPORT OF INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders

Allezoe Medical Holdings, Inc.

We have audited the accompanying consolidated balance sheets of Allezoe Medical Holdings, Inc. and subsidiary (a development stage company) as of August 31, 2011 and 2010 and the related consolidated statements of operations, stockholders’ equity, and cash flows for the years then ended and for the period from July 13, 1999, inception, to August 31, 2011. Allezoe Medical Holdings, Inc.’s management is responsible for these consolidated financial statements. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Allezoe Medical Holdings, Inc. and subsidiary as of August 31, 2011 and 2010, and the results of their operations and their cash flows for the years then ended and for the period from July 13, 1999, inception, to August 31, 2011, in conformity with accounting principles generally accepted in the United States of America.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company is in the development stage and has no established source of revenue. These conditions raise substantial doubt about its ability to continue as a going concern. Management’s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ Moss, Krusick & Associates, LLC

Winter Park, Florida

December 14, 2011

-21-


Allezoe Medical Holdings, Inc.
(A Development Stage Company)
CONSOLIDATED BALANCE SHEETS

			August 31, 2011	August 31, 2010

ASSETS

CURRENT ASSETS
	Cash		$ 38,320	$ 17,647
	Prepaid expenses		12,396	6,181

		Total current assets	50,716	23,828

Property, plant and equipment (net of accumulated
	depreciation of $76,557 and $73,233 respectively)		2,558	5,667
Deferred loan costs, net of accumulated amortization of $800 and $0			4,700	-
Patents			363,561	320,551

		Total assets	$ 421,535	$ 350,046

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

CURRENT LIABILITIES
	Accounts payable and accrued expenses		$ 585,240	$ 556,926
	Accrued salaries		393,821	1,257,717
	Notes payable net of debt discount of $128,422 and $0		1,827,868	129,350
	Accrued interest		216,389	88,242

		Total current liabilities	3,023,318	2,032,235

Long-term notes payable , net of debt discount of $909,507 and $0			499,072	1,374,139

		Total liabilities	3,522,390	3,406,374

STOCKHOLDERS' EQUITY (DEFICIT)
	Common stock, $0.001 par value; 500,000,000
		shares authorized. 140,080,039 and 18,717,740 shares
		issued and outstanding	140,080	18,718
	Additional paid in capital		26,535,284	22,486,653
	Deferred equity		(1,680,000)	-
	Deficit accumulated during the development stage		(28,096,219)	(25,561,699)

		Total stockholders' equity (deficit)	(3,100,855)	(3,056,328)

		Total liabilities and stockholders' equity	$ 421,535	$ 350,046

See accompanying notes to consolidated financial statements.

-22-


Allezoe Medical Holdings, Inc.
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF OPERATIONS

		For the Year Ended August 31, 2011	For the Year Ended August 31, 2010	For the Period from July 13, 1999 (Inception) to August 31, 2011

REVENUES		$ -	$ -	$ -

GENERAL AND ADMINISTRATIVE EXPENSES
	Payroll and payroll taxes	1,178,409	2,154,510	13,130,805
	Research and development	20,312	-	4,601,342
	Professional fees	249,423	164,630	3,183,282
	Directors fees	-	608,534	2,447,968
	Travel and entertainment	6,335	13,167	837,601
	Advisor fees	-	262,500	478,501
	Rent	60,723	75,672	407,806
	Organizational costs	-	-	287,344
	Insurance	56,425	23,553	240,977
	Office expense	2,739	7,870	181,334
	Management contract	-	-	160,350
	Telephone and internet	6,652	4,333	147,588
	Contract labor	-	58,277	137,553
	Miscellaneous	18,165	1,027	118,090
	Depreciation and amortization expense	3,324	6,436	76,557
	Dues and subscriptions	937	1,970	49,539
	Repairs and maintenance	5,107	-	29,059
	Bad debt expense	-	-	11,996
	Contributions	-	-	9,700

	Loss from operations	(1,608,551)	(3,382,479)	(26,537,392)

OTHER INCOME (EXPENSE)
	Finance cost	(133,494)	-	(133,494)
	Interest, net	(792,475)	(119,171)	(1,425,333)

	Net loss	$ (2,534,520)	$ (3,501,650)	$ (28,096,219)

Net loss per share (basic and diluted)		$ (0.03)	$ (0.07)	$ (0.47)

Weighted average number of shares outstanding during the period-basis and diluted		94,733,387	52,170,000	59,510,063

See accompanying notes to consolidated financial statements.

-23-


Allezoe Medical Holdings, Inc.
(A Development Stage Company)
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)
For the Periods from Inception, July 13, 1999, to August 31, 2011
					Deficit
					Accumulated	Total
			Additional		During the	Stockholders'
	Common Stock		Paid In		Development	Equity
	Shares	Par Value	Capital	Deferred Equity	Stage	(Deficit)
Balance - July 13, 1999 (inception)	-	$ -	$ -	$ -	$ -	$ -
Common stock issued to founders for services, $.001 per share, 1999 - 2004	6,280,530	6,281	-	-	-	6,281
Converted notes payable to common stock, $.25 - $1.00 per share, 2000 - 2002	801,890	802	365,279	-	-	366,081
Common stock issued for cash, $.10 - $.62 per share, 2000 - 2001	1,240,000	1,240	428,760	-	-	430,000
Common stock issued for services, $.40 - $1.50 per share, 2000 - 2008	413,520	413	501,867	-	-	502,280
Converted notes payable to common stock, $1.00 per share, 2005	193,620	194	193,426	-	-	193,620
Common stock issued for cash, $1.00 - $1.75 per share, 2002 - 2008	8,284,820	8,285	9,887,591	-	-	9,895,876
Common stock issued for warrants exercised, $.10 - $.75 per share, 2006 - 2008	1,361,680	1,361	138,057	-	-	139,418
Cancel stock to issue warrants	(15,290)	(15)	-	-	-	(15)
Stock option warrants issued for services, 2000 - 2009	-	-	8,365,651	-	-	8,365,651
Net loss for the period from July 13, 1999 (inception) to August 31, 2009	-	-	-	-	(22,060,049)	(22,060,049)
Balance - August 31, 2009	18,560,770	18,561	19,880,631	-	(22,060,049)	(2,160,857)
Common stock issued for cash, $.66 - $1.88 per share	84,000	84	125,845	-	-	125,929
Conversion of notes payable to stock option warrants	-	-	107,077	-	-	107,077
Warrants exercised, $.33 per share	72,970	73	23,786	-	-	23,859
Stock option warrants issued for services			2,349,314	-	-	2,349,314
Net loss for the year ended August 31, 2010	-	-	-	-	(3,501,650)	(3,501,650)
Balance - August 31, 2010	18,717,740	18,718	22,486,653	-	(25,561,699)	(3,056,328)
Recapitalization - OTS acquisition February 18, 2011	111,707,260	111,707	(111,707)	-	-	-
Common stock issued for services, $0.42 per share	5,000,000	5,000	2,095,000	(1,680,000)	-	420,000
Converted notes payable to common stock, $0.36per share	927,666	928	458,454	-	-	459,382
Issuance of notes payable-beneficial conversion feature	-	-	1,554,412	-	-	1,554,412
Common stock issued for services, $0.7242 per share	77,624	77	56,122	-	-	56,199
Common stock issued at par, $0.001 per share	3,649,749	3,650	(3,650)	-	-	-
Net loss for the year ended August 31, 2011	-	-	-	-	(2,534,520)	(2,534,520)
Balance - August 31, 2011	140,080,039	$ 140,080	$26,535,284	$(1,680,000)	$(28,096,219)	$ (3,100,855)

See accompanying notes to consolidated financial statements.

-24-


Allezoe Medical Holdings, Inc.
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF CASH FLOWS
					For the Year Ended August 31, 2011		For the Year Ended August 31, 2010		For the Period from July 13, 1999 (Inception) to August 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES
	Net loss				$ (2,534,520)		$ (3,501,650)		$ (28,096,219)
	Adjustments to reconcile net loss to net
		cash used by operations:
		Depreciation expense			3,324		6,436		76,557
		Stock based compensation expense			476,200		2,349,314		11,699,728
			Amortization of debt discount			649,977		-		649,977
	Changes in certain operating assets and liabilities:
		Interest accrued on notes payable			273,245		118,176		683,438
		Increase in prepaid expenses			(6,215)		-		(12,396)
		Increase in accounts payable
				and accrued expenses	125,847		245,349		1,640,806
		Decrease in bank overdraft			-		(476)		-
		Increase in accrued salaries			536,854		682,501		1,794,571

Net cash used by operating activities					(475,288)		(100,350)		(11,563,538)

CASH FLOWS FROM INVESTING ACTIVITIES
	Purchase of property and equipment				(215)		-		(79,115)
	Investment in patents				(43,010)		(48,821)		(363,561)

Net cash used by investing activities					(43,225)		(48,821)		(442,676)

CASH FLOWS FROM FINANCING ACTIVITIES
	Proceeds from issuance of common stock				-		149,788		10,615,067
	Proceeds from notes payable				539,186		17,030		1,957,699
	Payments of notes payable				-		-		(528,232)

Net cash provided by financing activities					539,186		166,818		12,044,534

Net increase (decrease) in cash					20,673		17,647		38,320

Cash and equivalents, beginning of period					17,647		-		-

Cash and equivalents, end of period					$ 38,320		$ 17,647		$ 38,320
Supplemental cash flow information:
	Cash paid for interest				$ -		$ -		$ 4,500
	Cash paid for income taxes				$ -		$ -		$ -

	Significant non-cash activities
		Notes payable converted to warrants			$ -		$ 107,077		$ 107,077
		Notes payable converted to common stock			$ 458,495		$ -		$ 1,016,271
		Liabilities converted to notes payable			$ 1,498,283		$ 98,268		$ 2,486,316
		Accrued interest converted to notes payable			$ 145,098		$ 137,722		$ 467,049
		Common stock issue at par			$ 3,650		$ 131,740		$ 3,650

See accompanying notes to consolidated financial statements.

-25-

ALLEZOE MEDICAL HOLDINGS, INC.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

August 31, 2011

Note 1 Nature of Operations and Summary of Significant Accounting Policies

Allezoe Medical Holdings, Inc., formerly Stanford Management, Ltd. (the “Company”), was incorporated under the laws of the State of Delaware on September 28, 1998 with the authorized common stock of 25,000,000 shares at $0.001 par value. On March 9, 2007, at the Annual General Meeting of Stockholders a Resolution was approved increasing the authorized share capital to 500,000,000 common shares with a par value of $0.001 per share.

The Company was organized for the purpose of acquiring and developing mineral properties. On February 18, 2011, all of the mineral properties and related development and exploration activities were disposed of as part of a series of transactions resulting in the acquisition of Organ Transport Systems, Inc. “OTS”. On January 24, 2011, the Company acquired all of the outstanding shares of Organ Transport Systems, Inc., a Nevada corporation and simultaneously disposed of the assets relating to its former activities in mining exploration, along with all related liabilities. Consequently, Organ Transport Systems, Inc. is considered to be the surviving entity and the financial results presented in this Report through January 24, 2011 are solely those of Organ Transport Systems, Inc. This acquisition has been reflected retroactively in the historic financial information presented in this Report.

OTS is a development stage company. It was organized under the laws of the State of Nevada on July 13, 1999 and is a medical technology company based in Frisco, Texas. OTS has developed human organ preservation technologies designed to revolutionize the organ transplantation industry by dramatically improving the quality and increasing the availability of vital organs. Its strategic goal is to be the worldwide leader of technologically advanced products and services for the entire organ preservation and enhancement market.

Nature of Operations

The Company’s assets at August 31, 2011 consisted of fixed assets and patents related to new organ transportation technology. The Company has developed a business plan that consists of providing new organ transportation technology to a target market. The Company’s strategy is to become the worldwide leader in a growing market for technologically advanced organ and tissue preservation and enhancement products and services. While OTS’ initial product, the LifeCradle® HR, is designed for the portable perfusion of the heart, the Company plans to offer a complete line of LifeCradle® products for all solid human organs including the heart, liver, kidney, lungs, pancreas, intestines and tissues such as limbs. The Company plans to also offer perfusion solutions for use in its devices, as well as static storage solutions as a replacement for the current‚ “picnic-cooler” technology.

Principles of Consolidation

The consolidated financial statements presented herein include the accounts of the Company and its wholly-owned subsidiary, OTS. These financial statements reflect the financial position and results of operations, cash flows, and changes in equity of OTS from inception (July 13, 1999) through February 18, 2011, at which time the Company began reporting consolidated results.

Development Stage

The Company's financial statements are presented as those of a development stage enterprise. Activities during the development stage include company formation, equity issued for patents and technology, and fixed assets and further implementation of the business plan. The Company has not generated any revenues since inception.

-26-

ALLEZOE MEDICAL HOLDINGS, INC.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

August 31, 2011

Risks and Uncertainties

The Company operates in an industry that is subject to rapid technological change. The Company's operations will be subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks associated with a development stage company, including the potential risk of business failure.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. A significant estimate in 2011 and 2010 included a 100% valuation allowance for deferred tax assets arising from net operating losses incurred since inception.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ materially from estimates.

Cash and Cash Equivalents

The Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents. The Company had no cash equivalents at August 31, 2011 and 2010, respectively.

The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. There were no balances that exceeded the federally insured limit at August 31, 2011 and 2010, respectively.

Earnings per Share

In accordance with Financial Accounting Standards Board “FASB” Accounting Standards Codification “ASC” Topic 260, “Earnings per Share,” Basic earnings per share (“EPS”) is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period, excluding the effects of any potentially dilutive securities. Diluted EPS gives effect to all dilutive potential of shares of common stock outstanding during the period including stock options or warrants, using the treasury stock method (by using the average stock price for the period to determine the number of shares assumed to be purchased from the exercise of stock options or warrants), and convertible debt or convertible preferred stock, using the if-converted method. Diluted EPS excludes all dilutive potential of shares of common stock if their effect is anti-dilutive. The computation of basic and diluted loss per share for the period from July 13, 1999 (inception) to August 31, 2011, is equivalent since the Company has had continuing losses. The Company also has no common stock equivalents.

-27-

ALLEZOE MEDICAL HOLDINGS, INC.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

August 31, 2011

Accounting for Stock-Based Compensation

The Company adopted the provisions of FASB ASC 718-20, Stock Compensation – Awards Classified as Equity, which require companies to expense the estimated fair value of employee stock options and similar awards based on the fair value of the award on the date of grant. The cost is recognized over the period during which an employee is required to provide service in exchange for the award, usually the vesting period. The Company’s stock-based compensation plans and assumptions used in determining stock-based compensation expense common stock are computed using the treasury stock method which assumes that the increase in the number of shares is reduced by the number of shares which could have been repurchased by the Company with the proceeds from the exercise of the options and warrants (which were assumed to have been made at the average market price of the common shares during the reporting period). Diluted loss per common share is the same as basic loss per share as the effect of potentially dilutive securities are anti-dilutive. Weighted average common shares outstanding prior to February 18, 2011 have been adjusted based upon a ratio of post merger to pre merger shares.

Non-Employee Stock Based Compensation

Share-based payment awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the share-based payment, whichever is more readily determinable.

Intangible Asset

The cost of patent assets has been capitalized and is not being amortized as revenues relating to the asset have not been generated. The Company will test for impairment of this asset on an annual basis by comparing the carrying amount to its estimated fair value.

Property and Equipment

Property and equipment are stated at cost. Expenditures for major betterments and additions are charged to the property accounts, while replacements, maintenance, and repairs that do not improve or extend the lives of the respective assets will be charged to expense. Depreciation is computed using the straight-line method over the estimated useful lives of five years.

Research and Development Costs

Costs incurred in the research and development phase of the Company’s products are expensed as incurred. Research and development expenses include direct costs for salaries, employee benefits, subcontractors, facility related expenses, and stock-based compensation related to employees involved in the Company’s research and development.

Income Taxes

The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is recorded and deducted from deferred tax assets when the deferred tax assets are not expected to be realized based on currently available evidence. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

-28-

ALLEZOE MEDICAL HOLDINGS, INC.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

August 31, 2011

Income Taxes (continued)

Management has analyzed its various federal and state filing positions and believes that its income tax filing positions and deductions are well documented and supported. Additionally, management believes that no accruals for tax liabilities are necessary. Therefore, no reserves for uncertain income tax positions have been recorded.

Fair Value of Financial Instruments

The carrying amounts of the Company’s short-term financial instruments, including accounts payable and accrued liabilities, approximate fair value due to the relatively short period to maturity for these instruments.

Fair Value Measurements

The Company follows accounting guidance relating to fair value measurements. This guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows:

Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.

Level 2 – Inputs other than quoted prices included within Level 1 that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.

Level 3 – Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement date.

At August 31, 2011, the Company has no instruments that require additional disclosure. The carrying amounts of the Company’s short-term financial instruments, including accounts payable and accrued liabilities, approximate fair value due to the relatively short period to maturity for these instruments.

The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the unobservable inputs.

Recurring Fair Value Measurements

In accordance with accounting principles generally accepted in the United States of America, certain assets and liabilities are required to be recorded at fair value on a recurring basis.

-29-

ALLEZOE MEDICAL HOLDINGS, INC.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

August 31, 2011

Recently Issued Accounting Pronouncements

The Company continually assesses any new accounting pronouncements to determine their applicability to the Company. Where it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequence of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s financials properly reflect the change.

Note 2. GOING CONCERN

As reflected in the accompanying financial statements, the Company has not yet emerged from the development stage, has a net loss of $2,534,520 and net cash used in operations of $475,288 for the year ended August 31, 2011; and negative working capital of $2,972,602 and an accumulated deficit of $28,096,219 at August 31, 2011.

The accompanying consolidated financial statements of the Company have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company is a development stage company and has suffered recurring losses and has no established source of revenue. Its ability to continue as a going concern is dependent upon achieving profitable operations and generating positive cash flows.

There can be no assurances that the Company will be able to achieve profitable operations or obtain additional funding. These factors create substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of the uncertainty.

Management intends to raise financing through private or public equity financing or other means and interests that it deems necessary to provide the Company with the ability to continue in existence. Upon FDA approval, the Company expects to begin actual manufacturing and sales operations. The Company is currently negotiating larger financing to initiate the FDA5-10K process which will be completed within 5-10 months.

-30-

ALLEZOE MEDICAL HOLDINGS, INC.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

August 31, 2011

NOTE 3. PROPERTY AND EQUIPMENT

A summary of property and equipment as of August 31, 2011 and August 31, 2010 is as follows:


	August 31, 2011	August 31, 2010
Electronic equipment	$ 73,788	$ 73,788
Furniture and equipment	5,112	5,112
Software	215	-
	79,115	78,900
Less accumulated depreciation	(76,557)	(73,233)
	$ 2,558	$ 5,667

NOTE 4. INCOME TAXES

The Company accounts for income taxes in accordance with accounting standards for Accounting for Income Taxes which require the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and tax credit carry-forwards. Additionally, the standards require the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets.

As of the acquisition date, February 18, 2011, Organ Transport Systems, Inc. had net operating losses for Federal income tax purposes totaling approximately $15,205,761 which expire in 2030, when it was acquired by the Company. The following is a schedule of deferred tax assets as of August 31, 2011, and August 31, 2010:


		August 31, 2011		August 31, 2010
Net operating loss	$	17,274,178	$	14,739,658
Future tax benefit at 34%		5,873,221		5,011,484
Less: Valuation allowance		(5,873,221)		(5,011,484)
Net deferred tax asset	$	--	$	--

The valuation allowance changed by approximately $861,737 during the year ended August 31, 2011.

Under Sections 382 and 269 (the ‘shell corporation’ rule) of the Internal Revenue Code, following an “ownership change,” special limitations (“Section 382 Limitations”) apply to the use by a corporation of its net operating loss, or NOL, carry-forwards arising before the ownership change and various other carry-forwards of tax attributes (referred to collectively as the ‘Applicable Tax Attributes’). The Company had NOL carry-forwards due to historical losses of Stanford of approximately $368,374 at November 30, 2010, and OTS had net operating loss carry-forwards of $14,739,698 at August 30, 2010 and $17,274,178 at August 31, 2011. As a result of the acquisition of OTS and the disposition of the former mining operations, the Company experienced an ownership change, and Section 382 Limitations will apply to the Applicable Tax Attributes of the Company.

The Company has adopted the provisions of FASB ASC 740-10-25. As a result of its implementation, the Company performed a comprehensive review of its uncertain tax positions in accordance with recognition and measurement standards established by FASB ASC 740-10-25. In this regard, an uncertain tax position represents the Company’s expected treatment of a tax position taken in a prepared and filed tax return, or expected to be taken in a tax return, that has not been reflected in measuring income tax expense for financial reporting purposes. The Company does not expect any reasonably possible material changes to the estimated amount of liability associated with uncertain tax positions through August 31, 2011. The Company’s continuing policy is to recognize accrued interest and penalties related to income tax matters in income tax expense.

-31-

ALLEZOE MEDICAL HOLDINGS, INC.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

August 31, 2011

Note 5: SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES

As of August 31, 2011, Healthcare of Today, Inc. had acquired 60% of the common capital stock issued, on a non-diluting basis, as part of the transfer of Organ Transport Systems, Inc. to the Company. Healthcare of Today, Inc. also provides financial, accounting, legal, administrative and similar services to the Company at a monthly fixed fee of $10,000, commencing March 1, 2011.


NOTE 6.	CAPITAL STOCK

The Company is authorized to issue 500,000,000 shares of common stock, par value $0.001 per share. During the year ended August 31, 2011, the Company issued 78,255,000 shares of common stock to Healthcare of Today, Inc. in exchange for the acquisition of all of the outstanding stock of Organ Transport Systems, Inc., representing 60 percent of the resulting 130,425,000 shares of the issued and outstanding common stock. As part of the acquisition agreement and closing, the Company also agreed that the shares issued to Healthcare of Today, Inc. would be non-dilutive and would always represent 60 percent of the common shares outstanding. In the event that additional common shares are issued to another party, then additional common shares also will be issued to Healthcare of Today, Inc. so that its resulting percentage ownership of the then outstanding common shares will remain at 60 percent.

NOTE 7. LEASE COMMITMENT

The Company leases office and lab space in a two story, 50,000 square foot building located in Frisco, Texas under a license agreement which terminated on October 31, 2010. The license agreement provides the Company with five offices and lab space, and full access to building common areas including conference rooms, break room / kitchen, reception area and common lab areas. The agreement also covers telephone, wired and wireless internet access, and utilities. The required monthly payment under the license agreement is $4,267. The agreement automatically renewed on a month to month basis at the previous agreed upon terms until either party notifies the other in writing of its intention to terminate the license agreement 30 days prior to the termination date.

-32-

ALLEZOE MEDICAL HOLDINGS, INC.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

August 31, 2011

NOTE 8. NOTES PAYABLE (continued)

The following is a summary of notes payable at August 31, 2011 and August 31, 2010:


Description	August 31, 2011	August 31, 2010
NTEC, Inc.
Note payable to NTEC, Inc. The note accrues interest at 7% per annum and matures on August 31, 2012.	$ 235,629	$ 129,350
The Realtime Group
Related party note payable to The Realtime Group, president Marshall Wenrich served as OTS’ Director of Engineering. The note accrues interest at 7% per annum and matures on December 31, 2011.	131,433	122,834
Musculoskeletal Transplant Foundation
Note payable to Musculoskeletal Transplant Foundation (MTF). The note accrues interest at the WSJ prime rate plus 2% and matures on December 31, 2011.	907,664	822,217
University of Texas Southwestern Medical Center
Note payable to the University of Texas Southwestern Medical Center. The note accrues interest at 7% per annum and matures on the December 31, 2011.	349,162	326,320
Employees and consultants
Notes payable to related parties – employees and consultants. The notes accrue interest at 7% per annum and mature December 30, 2011.	109,402	102,768
Convertible debentures - officers
Convertible notes payable to related parties – officers by OTS. The notes accrue interest at 12% per annum, mature December 15, 2012, and are convertible one year after issuance into shares of Company common stock at a price discounted from average trading price. $1,408,579 less discount at $909,507 for conversion.	499,072	-

-33-

ALLEZOE MEDICAL HOLDINGS, INC.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

August 31, 2011

NOTE 8. NOTES PAYABLE (continued)


Ambrose and Keith
Note payable to Ambrose and Keith. The note accrues interest at 9% per annum and mature April 30, 2011 and is convertible into shares of the Company’s common stock at a price discounted from average trading price.	25,000	-
Asher Enterprises, Inc.
Note payable to Asher Enterprises, Inc. The note accrues interest at 8% per annum and mature April 11, 2012 and is convertible 180 days after issuance into shares of the Company’s common stock at a price discounted from average trading price. $53,000 Note less discount of $35,917 for conversion.	17,083	-
Asher Enterprises, Inc.
Note payable to Asher Enterprises, Inc. The note accrues interest at 8% per annum and mature May 18, 2012 and is convertible 180 days after issuance into shares of the Company’s common stock at a price discounted from average trading price. $44,000 Note less discount of $33,320 for conversion.	6,680	-
Crystal Falls Investments, LLC.
Convertible notes payable to Crystal Falls. The notes accrue interest at 9% per annum and mature January 31, 2012 and are convertible into shares of Allezoe common stock at a price discounted from the average trading price. $100,000 Note less discount of $59,185 for conversion.	40,815	-
Ambrose and Keith
Demand loan to Ambrose and Keith. The note does not accrue interest and matured April 30, 2011.	5,000	-

Total	2,326,940	1,503,489
Less: current portion	1,827,868	129,350
Long-term debt	$ 499,072	$ 1,374,139

-34-

ALLEZOE MEDICAL HOLDINGS, INC.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

August 31, 2011

NOTE 8. NOTES PAYABLE (continued)

Notes payable consist of borrowings under convertible debenture arrangements. In July 2011, the Company entered into an arrangement with a creditor in which the Company borrowed $53,000 with interest payable at 8% per annum with a maturity date of January 31, 2012. The indebtedness including interest is convertible into common stock at 58% of the average lowest three (3) trading prices during the ten (10) trading day period ending on the latest complete trading day prior to conversion. In August 2011, the Company entered into an arrangement with a creditor in which the Company borrowed $40,000 with interest payable at 8% per annum with a maturity date of January 31, 2012. The indebtedness including interest is convertible into common stock at 58% of the average lowest three (3) trading prices during the ten (10) trading day period ending on the latest complete trading day prior to conversion. In July 2011, the Company entered into an arrangement with a creditor in which the Company borrowed $100,000 with interest payable at 9% per annum with a maturity date of January 31, 2012. The indebtedness including interest is convertible into common stock at $.29 per share. The Company accounted for the borrowings under these arrangements in accordance with ASC 470-20 Debt with Conversions and Other Options. The fair value of the beneficial conversion feature is calculated using the intrinsic value method at the time of issuance or commitment date. The company records a debt discount for the calculated value, which is amortized over the debt term.

NOTE 9. SUBSEQUENT EVENTS

In November 2011, the Company entered into an arrangement with a creditor in which the Company borrowed $50,000 with interest payable at 12% per annum with a maturity date of November 4, 2012. The indebtedness including interest is convertible into common stock at 50% of the average lowest price during the ten (10) trading day period ending on the latest complete trading day prior to conversion.

In November 2011, the Company entered into an arrangement with a creditor in which the Company borrowed $260,000 with interest payable at 12% per annum with a maturity date of November 4, 2012. The indebtedness including interest is convertible into common stock at 50% of the average lowest price during the ten (10) trading day period ending on the latest complete trading day prior to conversion. This was an assignment of part of the convertible notes payable to related parties – officers by OTS (See Note 8) where $261,453 was assigned to a creditor for $260,000. In November 2011, the Company converted $100,000 of the note into 7,497,585 shares of common stock.

-35-


ITEM 9.	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.


ITEM 9A,	CONTROLS AND PROCEDURES

The Company’s Chief Executive Officer and consulting principal accounting officer have evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the fiscal period ending August 31, 2011 covered by this Annual Report on Form 10-K. Based upon such evaluation, the Chief Executive Officer and consulting principal accounting officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were not effective as required under Rules 13a-15(e) and 15d-15(e) under the Exchange Act.

Management’s Annual Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) of the Company. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.

The Company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.

Management, under the supervision of the Company’s Chief Executive Officer and consulting principal accounting officer, conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that the Company’s internal control over financial reporting was not effective as of August 31, 2011 under the criteria set forth in the Internal Control—Integrated Framework.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has determined that material weaknesses exist due to the lack of an independent Audit Committee Chair, as well as a lack of segregation of duties, inadequate staffing with our accounting department, lack of consistent accounting policies and procedures, inadequate monitoring of controls, and lack of staff with SEC reporting experience all resulting from the Company’s limited resources.

This annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to rules of the SEC that permit us to provide only management’s report in this Annual Report on Form 10-K.

-36-

Changes in Internal Control Over Financial Reporting

No change in the Company’s internal control over financial reporting occurred during the fourth quarter of the year ended August 31, 2011, that materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.


ITEM 9B	OTHER INFORMATION

None

PART III


ITEM 10.	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Set forth below is certain information concerning the directors and executive officers of the Company as of August 31, 2011:


Name:	Age:	Position:
Michael Gelmon¹	46	President, Chief Executive Officer and Chairman
Michael Choo²	46	Director
Michael Holder³	49	Former Director, President and CEO of Organ Transport Systems, Inc.
Carole Pinell⁴	39	Director
Hyman White⁵	68	Director, Secretary, Treasurer
Jancy Gregorio⁶	32	Former Chief Executive Officer and President, former director
Reynan Ballan⁷	33	Former Chief Financial Officer, Secretary and Treasurer, and former director

¹ Mr. Gelmon was named a director on May 31, 2011 and, Chairman and CEO on June 24, 2011.

² Mr. Choo was named a director on May 31, 2011.

³ Mr. Holder served as a director from February 18, 2011 to November 22, 2011 when he resigned for personal

reasons. He also served as Chairman and CEO from February 18, 2011 to June 24, 2011.

⁴ Ms Pinell was named as a director on May 31, 2011..

⁵ Mr. White was named a director, Secretary and Treasurer on February 18, 2011, as a result of the acquisition of

Organ Transport Systems, Inc. He also serves as a director and Vice President of Organ Transport Systems, Inc.

⁶Mr. Gregorio resigned as an officer and director effective February 18, 2011, as a result of the acquisition of Organ

Transport Systems, Inc.

⁷ Mr. Ballan resigned as an officer and director effective February 18, 2011, as a result of the acquisition of Organ

Transport Systems, Inc.

-37-

Biographies

MICHAEL GELMON, 46, an experienced CEO and Director of several publicly traded companies, has been involved in consulting and turn- rounds or work outs for various public and private companies. As part of the work outs, he has been actively involved with management in cutting costs, increasing sales as well as compliance issues, including consulting and assisting investment groups in structuring and restructuring debt in several private and public companies; advising various investor and investment groups as lawyers conducting due diligence on target companies; and consulting and advising on management restructuring.

He is also founder and a partner of Gelmon Brothers Real Estate Consultants which has developed and consulted on commercial real estate developments in excess of $100 million; was a founder of Proteus Currency Fund, a Cayman Island based Hedge Fund involved in the Forex marketplace utilizing Dynex Corporation trading in Monaco and Jacobsen Asset Management in London; and, as a founding-shareholder, Director, as well as Head of Acquisitions and Real Estate for Domino's Pizza of Canada Ltd., the Domino's Pizza Master Franchisor in Canada, he was an integral part of the team that was responsible for turning around the Domino’s operations in Canada in the 1990s, growing the Domino's chain to 200 stores located in every region of Canada with system-wide sales of approximately CAD $80,000,000 per annum.

Mr. Gelmon received his Law Degree from the University of London, King’s College.

MICHAEL O. CHOO, 46, President & Chief Executive Officer of Bellflower Medical Center, Los Angeles, CA. Previously served as Principal, Managing Partner & President & Chief Executive Officer of Integra Healthcare, Inc., Principal, Managing Partner, & Chairman of The Board of Directors of Doctors’ Hospital of Shreveport, and Principal, Managing Partner & Senior Vice President of Operations for Ethicus Healthcare Management, LLC. Mr. Choo was also previously the Senior Vice President of Promise Healthcare, Inc. and Chief Executive Officer of Promise Specialty Hospital of Shreveport, a 146 bed JCAHO long-term acute care, acute rehabilitation, gerontologic and adult psych turnaround hospital located in Shreveport, Louisiana. As second in command of the Company, he had corporate oversight of the Company’s 14 other facilities from the standpoint of corporate recruitment, new business development, and operational turnaround. Before his departure from Promise Healthcare, Inc., he brought together over 120+ collective years of corporate operational experience, leadership, structure, “team concept” and organization to the Promise Healthcare Executive team. Mr. Choo has over 29 years of experience in healthcare with expertise in Operational Executive Management, Hospital Turnarounds, Hospital Acquisitions, and Ground Floor Start-ups. He has vast experience in the clinical setting as well as the operational and organizational development & structure of hospitals and healthcare organizations to comply with state & federal regulatory agency guidelines. Mr. Choo is finishing his Masters degree in Business Administration from California Coast University, and served in executive positions with various hospitals and companies managing hospitals. He held a previous position as the Chief Executive Officer of HealthSouth in Reno a 63 Acute Rehabilitation Freestanding Hospital in Reno, NV acting as Team Leader for the HealthSouth Surgical center, and HealthSouth Sports Clinic in Carson City, NV. He also has been the Vice President of NPSI with responsibility for 4 major hospitals in the Los Angeles and San Diego area, and Regional Chief Operations Officer of ARMS with responsibilities for 5 hospital turnarounds and 2 ground floor start-ups. Mr. Choo brings experience from the acute care industry, LTAC industry, Behavioral Health Industry, and Acute Rehabilitation Industry to the organization.

-38-

CAROLINE PINELL, 39, is an attorney and medical doctor and currently serves as a high level healthcare operations consultant to various clients, including Hospitals, Independent Physician Associations, Physician Groups and Networks, Medical Practices, Attorneys, and various Medicare and Medicaid Health Plans. She was formerly President and Chief Executive Officer of ATRIO Health Plans, a Medicare Advantage (MA-PD) Plan located in Oregon. It services three counties including Douglas, Coos, and Klamath Counties with expansion plans in place for Washington County. The Plan covers approximately 4500 lives with significant growth expected over the next three years. The Provider Network included 99% of all providers in each of the counties it currently services. From 2006 to 2008, she served as Executive Vice President, Director of Physician Relations, Business Development and Managed Care for HCA-Bayshore Medical Center in Pasadena, Texas, and previously has served in management capacities with several large physician associations and provider networks.

Dr. Pinell studied medicine at the University of Texas Health Science Center and holds a JD degree from South Texas College of Law in Houston, Texas.

MICHAEL B. HOLDER is an experienced executive with over 25 years of demonstrated success in operational, fund-raising, and transactional capacities. Mr. Holder is currently the Chairman and Chief Executive Office of Organ Transport Systems, Inc. Mr. Holder is also a Founder, Director and has served as acting CFO of Servergy Inc., a computer hardware company. Mr. Holder previously was a Vice President with and managed the technology solutions business for Premier Inc., an $18 billion hospital group purchasing organization and supplier. During Mr. Holder’s career, he has served as an executive with both another leading healthcare company, BeaconEye Inc., where he completed an IPO and a strategic sale of the company, and with the Sam Walton family private equity fund, Heartland Capital Partners. Mr. Holder has led corporate development activities for AMR Corporation. Mr. Holder received his M.B.A. from the Wharton School of Business, his B.S. in Business Administration from the University of North Carolina, and previously earned a CPA designation in Texas.

HYMAN P. WHITE is the founder of Organ Transport Systems, Inc. and served as CEO until 2004 at which time he assumed his current position as Executive Vice President-Business Development, Secretary and Treasurer.. Prior to OTS, his career includes almost 30 years of experience in the medical technology and device marketplace primarily with Baxter, C.R Bard, Motorola and TechLease. Mr. White served in and was honorably discharged from the United States Air Force. Mr. White earned his B.B.A. in Business and Marketing from the University of

North Texas.

COMMITTEES

The Company has established committees of the Board of Directors, and adopted appropriate committee charters. The current Committees of the Board, and their members, are:

Audit Committee:

Michael Choo, Chair

Caroline Pinell

Compensation Committee:

Michael Choo, Chair

Caroline Pinell

Governing and Nominating Committee:

Caroline Pinell (Chair)

Michael Choo

Hyman White

-39-

CODE OF ETHICS

We have adopted a code of ethics meeting the requirements of Section 406 of the Sarbanes-Oxley Act of 2002. We believe our code of ethics is reasonably designed to deter wrong doing and promote honest and ethical conduct; provide full, fair, accurate, timely and understandable disclosure in public reports; comply with applicable laws; ensure prompt internal reporting of violations; and provide accountability for adherence to the provisions of the code of ethic.


ITEM 11.	EXECUTIVE C OM PENSATION

The following table sets forth information concerning the aggregate compensation paid or to be paid by the Company to its executive officers.

SUMMARY COMPENSATION TABLE


Name and Principal Position	Year	Salary	Bonus	Stock Awards	Option Awards	Non-equity Incentive Plan Compensation	Nonqualified Deferred Compensation	All Other Compensation	Total
		($)	($)	($)	($)	($)	($)	($)	($)
Michael Gelmon¹, Chairman of the Board	2011	60,000	0	42,000	0	0	0	0	102,000
Jancy Gregorio² Former Chairman of the Board	2011	0	0	0	0	0	0	0	0
	2010	0	0	0	0	0	0	0	0
Reynan Ballan³ Former CFO, Secretary and Treasurer	2011	0	0	0	0	0	0	0	0
	2010	0	0	0	0	0	0	0	0
Michael Holder⁴ Former Chairman; President of OTS	2011	250,000	-	-	-	-	-	-	250,000
	2010	156,500	-	-	-	-	-	-	156,500
Hyman White⁵ Secretary, Treasurer; VP of OTS	2011	100,000	-	-	-	-	-	-	100,000
	2010	112,750	-	-	336,712	-	-	-	449,462

¹Mr. Gelmon receives a base salary of $10,000 per month as Chairman and CEO, commencing July 1, 2011. He was also awarded a grant of 500,000 shares of common stock, vesting annually over 5 years at 100,000 shares per year as of July 1 of each year. The July 1, 2011 grant of 100,000 shares was valued at $42,000, based on the closing price of $0.42 for the common stock on July 1, 2011

² Mr. Gregorio resigned effective February 18, 2011.

³Mr. Ballan resigned effective February 18, 2011.

⁴Mr. Holder received no compensation while serving as a director and officer of the Company from February 18, 2011 to November 22, 2011. He serves as Chairman and President of Organ Transport Systems, Inc. (OTS), a wholly-owned subsidiary of the Company, and is entitled to a salary of $250,000 annually under an employment agreement with OTS. He was paid $73,141 and $39,250 in 2011 and 2010 respectively, and $93,526and $210,750 in compensation was accrued in each of 2011 and 2010.

-40-

⁵Mr. White serves as a Vice President of Organ Transport Systems, Inc. (OTS), a wholly-owned subsidiary of the Company, and is entitled to a salary of $100,000 annually under an employment agreement with OTS. He was paid $36,085 and $10,000 in 2011 and 2010 respectively, and $63,915and $140,000 in compensation was accrued in each of 2011 and 2010.

In addition to the amounts paid or accrued for officers and directors, as noted above, the Company also pays a consulting fee of $10,000 per month to CFOs to Go, Inc. under a consulting agreement, for legal, financial and accounting services, including the provision of Mr. John Burke as principal accounting officer of the Company. Mr. Burke is not compensated directly by the Company for his services and is not an elected officer of the Company.

DIRECTOR COMPENSATION

Directors receive no compensation for serving on the Board.

ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following table sets forth certain information as of August 31, 2011, with respect to the beneficial ownership of our common stock by each beneficial owner of more than 5% of the outstanding shares of common stock of the Company, each director, each executive officer named in the “Summary Compensation Table” and all executive officers and directors of the Company as a group, and sets forth the number of shares of common stock owned by each such person and group. Unless otherwise indicated, the owners have sole voting and investment power with respect to their respective shares.


Name of Beneficial Owner	Number of Shares Beneficially Owned		Percentage of Outstanding Common Stock Owned¹
Michael Gelmon, CEO	555,560¹		3.9%

Michael Choo, Director	--		--
Carole Pinell, Director	--		--
Michael Holder, Former CEO, CEO of Organ Transport Systems	--		--
Hyman White	--		--

All Directors and executive officers as a group (5 person)⁽²⁾	555,560¹		-

Élan Health Services, Inc.⁽³⁾		51,509,735	33.6%
Lin-Han Century Corp.⁽⁴⁾		13,000,000	8.8%

(1)

Based on a total of 140,080,039 common shares outstanding at August 31, 2011.

(2)

Mr. Gelmon was awarded a total of 5,000,000 shares of common stock at the time he was retained as Chairman and CEO of the Company, with the shares vesting over 5 years on a proportionate basis. As of August 31, 2011, one-fifth of the shares had vested and the balance have been issued but are held in escrow for releases on an annual basis each July 1. On the original issue, Mr. Gelmon requested that a portion of the shares be issued to other named parties, as to which he disclaims any beneficial interest.

(3)

Élan Health Services currently holds 51,744,517 common shares as of November 8, 2011, and is issued additional shares equal to 60 percent of the amount of shares issued to third parties by the Company, as part of the terms of the acquisition of Organ Transport Systems, Inc.

(4)

Lin-Han Century Corp. is the majority shareholder of Élan Health Services, Inc.

-41-

ITEM 13.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

None


ITEM 14.	PRINCIPAL ACCOUNTANT FEES AND SERVICES

Audit Fees

During the years ended, August 31, 2011 and 2010, we were billed by our then independent registered public accounting firm, Moss, Krusick and Associates, LLC approximately $51,300 and $0 for audit and review fees associated with our 10-K and 10-Q.

Tax Fees

During the years ended, August 31, 2011 and 2010, our independent registered public accounting firm, Moss, Krusick and Associates, LLC, did not perform any tax services for the Company.

All Other Fees

During the years ended, August 31, 2011 and 2010, our independent registered public accounting firm, Moss, Krusick and Associates, LLC, did not perform any other work.

Board of Directors Pre-Approval Process, Policies and Procedures

Our principal auditors have performed their audit procedures in accordance with pre-approved policies and procedures established by our Board of Directors. Our principal auditors have informed our Board of Directors of the scope and nature of each service provided. With respect to the provisions of services other than audit, review, or attest services, our principal accountants brought such services to the attention of our Board of Directors prior to commencing such services.

-42-


ITEM 15.		EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

Regulation Number	Exhibit
3.1	Certificate of Incorporation, as amended ⁽¹⁾
3.2	Certificate of Amendment⁽¹⁾
3.3	Bylaws ⁽¹⁾
	Articles of Amendment dated July 20, 2010.⁽¹⁾


31.1 31	Rule 13a-14(a) Certifications of Chief Executive Officer and Principal Accounting Officer





32.1 32	Certifications Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of Chief Executive Officer and Principal Accounting Officer


⁽¹⁾	Previously filed

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	ALLEZOE MEDICAL HOLDINGS, INC.

Dated: December 14, 2011	By:	/s/ Michael Gelmon
		Chief Executive Officer and Chairman of the Board (Principal Executive Officer)

Dated: December 14, 2011	By:	/s/ John Burke
		Principal Accounting Officer

__/s/ Michael Gelmon________________________

December 14, 2011

Michael Gelmon, Director

__/s/ Michael Choo ________________________

December 14, 2011

Michael Choo, Director

__/s/ Hyman White ________________________

December 14, 2011

Hyman White, Director

__/s/ Carole Pinell ________________________

December 14, 2011

Carole Pinell, Director

-43-

EX-31 2 exhibit311.htm PRINCIPAL EXECUTIVE OFFICER CERTIFICATION Converted by EDGARwiz

Exhibit 31.1

PRINCIPAL EXECUTIVE OFFICER CERTIFICATION

I, Michael Gelmon, certify that:


(1)	I have reviewed this annual report on Form 10-K of Allezoe Medical Holdings, Inc.


(2)	Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

(3)	Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this annual report;


(4)	The issuer’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small business issuer and we have:


	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

	(b)	Evaluated the effectiveness of the issuer’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon based such evaluation; and

	(c)	Disclosed in this report any change in the issuer’s internal control over financial reporting that occurred during the small business issuer’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the small business issuer’s internal control over financial reporting;


(5)	The issuer’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer’s auditors and the audit committee of the issuer’s board of directors (or persons performing the equivalent function):


	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer’s ability to record, process, summarize and report financial information; and


	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer’s internal controls over financial reporting.

Dated: December 14 , 2011

By:

/s/ Michael Gelmon

Michael Gelmon

Chief Executive Officer

EX-31 3 exhibit312.htm PRINCIPAL FINANCIAL OFFICER CERTIFICATION Converted by EDGARwiz

Exhibit 31.2

PRINCIPAL ACCOUNTING OFFICER CERTIFICATION

I, John Burke, certify that:


(1)	I have reviewed this annual report on Form 10-K of Allezoe Medical Holdings, Inc.;


(2)	Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;


(3)	Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this annual report;


(4)	The issuer’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small business issuer and we have:


	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;


	(b)	Evaluated the effectiveness of the issuer’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon based such evaluation; and


	(c)	Disclosed in this report any change in the issuer’s internal control over financial reporting that occurred during the small business issuer’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the small business issuer’s internal control over financial reporting;


(5)	The issuer’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer’s auditors and the audit committee of the issuer’s board of directors (or persons performing the equivalent function):


	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer’s ability to record, process, summarize and report financial information; and


	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer’s internal controls over financial reporting.

Dated: December 14 , 2011

By:

/s/ John Burke

John Burke

Consulting Principal Accouinting Officer

EX-32 4 exhibit32.htm CERTIFICATION Converted by EDGARwiz

Exhibit 32

CERTIFICATION

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, each of the undersigned officers of Allezoe Medical Holdings, Inc., (the “Company”), does hereby certify, to each such officer’s knowledge, that:

(1) The annual report on form 10-K of the Company for the annual period ended August 31, 2011 (“the Report”) fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


Dated: December 14 , 2011	By:	/s/ Michael Gelmon
		Michael Gelmon Chief Executive Officer
Dated: December 14 , 2011	By:	/s/ John Burke
		John Burke Consulting Principal Accounting Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 5 alzm.ob-20110831.xml XBRL INSTANCE DOCUMENT 10-K 2011-08-31 false Allezoe Medical Holdings Inc 0001080602 --08-31 173324482 79845622 Smaller Reporting Company No No No 2011 FY

38320

17647

12396

6181

50716

23828

2558

5667

4700

363561

320551

370819

326218

421535

350046

585240

556926

393821

1257717

1827868

129350

216389

88242

3023318

2032235

499072

1374139

3522390

3406374

140080

18718

26535284

22486653

-1680000

-28096219

-25561699

-3100855

-3056328

421535

350046

500000000

140080039

18717740

140080039

18717740

0.001

1178409

2154510

13130805

20312

4601342

249423

164630

3183282

608534

2447968

6335

13167

837601

262500

478501

60723

75672

407806

287344

56425

23553

240977

160350

6652

4333

147588

58277

137553

18165

1027

118090

3324

6436

76557

937

1970

49539

5107

29059

11996

9700

1608551

3382479

26537392

-1608551

-3382479

-26537392

-133494

-792475

-119171

-1425333

-2534520

-3501650

-28096219

-2534520

-3501650

-28096219

-0.03

-0.07

-0.47

59510063

52170000

6281

6280530

9525

10316351

9524820

413

501867

502280

413520

996

558705

559701

995510

1346

138057

139403

1346390

8365651

-22060049

18560770

18561

19880631

-22060049

-2160857

125845

125929

84000

107077

2349314

23786

23859

72970

-3501650

18717740

18718

22486653

-25561699

111707

-111707

111707260

8727

2095000

-1680000

423727

8727373

928

510926

511854

1554412

927666

-2534520

140080039

140080

26535284

-1680000

-28096219

6281

6280530

10325876

9524820

-2534520

-3501650

-28096219

3324

6436

76557

476200

2349314

11699728

649977

-528232

-6215

-12396

125847

245349

1640806

-476

536854

682501

1794571

-475288

-100350

-11563538

-215

-79115

-43010

-48821

-363561

-43225

-48821

-442676

149788

10615067

539186

17030

1957699

539186

166818

12044534

20673

17647

38320

17647

38320

4500

107077

458495

1016271

2953365

235990

3650

131740

3650

Nature of Operations   The Companys assets at August 31, 2011 consisted of fixed assets and patents related to new organ transportation technology. The Company has developed a business plan that consists of providing new organ transportation technology to a target market. The Companys strategy is to become the worldwide leader in a growing market for technologically advanced organ and tissue preservation and enhancement products and services. While OTS initial product, the LifeCradle® HR, is designed for the portable perfusion of the heart, the Company plans to offer a complete line of LifeCradle® products for all solid human organs including the heart, liver, kidney, lungs, pancreas, intestines and tissues such as limbs. The Company plans to also offer perfusion solutions for use in its devices, as well as static storage solutions as a replacement for the current picnic-cooler technology.

Allezoe Medical Holdings, Inc., formerly Stanford Management, Ltd. (the Company), was incorporated under the laws of the State of Delaware on September 28, 1998 with the authorized common stock of 25,000,000 shares at $0.001 par value.  On March 9, 2007, at the Annual General Meeting of Stockholders a Resolution was approved increasing the authorized share capital to 500,000,000 common shares with a par value of $0.001 per share.   The Company was organized for the purpose of acquiring and developing mineral properties.  On February 18, 2011, all of the mineral properties and related development and exploration activities were disposed of as part of a series of transactions resulting in the acquisition of Organ Transport Systems, Inc. OTS. On January 24, 2011, the Company acquired all of the outstanding shares of Organ Transport Systems, Inc., a Nevada corporation and simultaneously disposed of the assets relating to its former activities in mining exploration, along with all related liabilities. Consequently, Organ Transport Systems, Inc. is considered to be the surviving entity and the financial results presented in this Report through January 24, 2011 are solely those of Organ Transport Systems, Inc. This acquisition has been reflected retroactively in the historic financial information presented in this Report.  OTS is a development stage company. It was organized under the laws of the State of Nevada on July 13, 1999 and is a medical technology company based in Frisco, Texas. OTS has developed human organ preservation technologies designed to revolutionize the organ transplantation industry by dramatically improving the quality and increasing the availability of vital organs. Its strategic goal is to be the worldwide leader of technologically advanced products and services for the entire organ preservation and enhancement market.

Principles of Consolidation   The consolidated financial statements presented herein include the accounts of the Company and its wholly-owned subsidiary, OTS. These financial statements reflect the financial position and results of operations, cash flows, and changes in equity of OTS from inception (July 13, 1999) through February 18, 2011, at which time the Company began reporting consolidated results.

Development Stage   The Company's financial statements are presented as those of a development stage enterprise. Activities during the development stage include company formation, equity issued for patents and technology, and fixed assets and further implementation of the business plan. The Company has not generated any revenues since inception.

Use of Estimates   The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. A significant estimate in 2011 and 2010 included a 100% valuation allowance for deferred tax assets arising from net operating losses incurred since inception.   Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ materially from estimates

Risks and Uncertainties   The Company operates in an industry that is subject to rapid technological change. The Company's operations will be subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks associated with a development stage company, including the potential risk of business failure.

Cash and Cash Equivalents   The Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents.  The Company had no cash equivalents at August 31, 2011 and 2010, respectively.   The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits.  There were no balances that exceeded the federally insured limit at August 31, 2011 and 2010, respectively.

Earnings per Share   In accordance with Financial Accounting Standards Board FASB Accounting Standards Codification ASC Topic 260, Earnings per Share,  Basic earnings per share (EPS) is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period, excluding the effects of any potentially dilutive securities. Diluted EPS gives effect to all dilutive potential of shares of common stock outstanding during the period including stock options or warrants, using the treasury stock method (by using the average stock price for the period to determine the number of shares assumed to be purchased from the exercise of stock options or warrants), and convertible debt or convertible preferred stock, using the if-converted method. Diluted EPS excludes all dilutive potential of shares of common stock if their effect is anti-dilutive. The computation of basic and diluted loss per share for the period from July 13, 1999 (inception) to August 31, 2011, is equivalent since the Company has had continuing losses. The Company also has no common stock equivalents.

Accounting for Stock-Based Compensation   The Company adopted the provisions of FASB ASC 718-20, Stock Compensation Awards Classified as Equity, which require companies to expense the estimated fair value of employee stock options and similar awards based on the fair value of the award on the date of grant. The cost is recognized over the period during which an employee is required to provide service in exchange for the award, usually the vesting period. The Companys stock-based compensation plans and assumptions used in determining stock-based compensation expense common stock are computed using the treasury stock method which assumes that the increase in the number of shares is reduced by the number of shares which could have been repurchased by the Company with the proceeds from the exercise of the options and warrants (which were assumed to have been made at the average market price of the common shares during the reporting period). Diluted loss per common share is the same as basic loss per share as the effect of potentially dilutive securities are anti-dilutive. Weighted average common shares outstanding prior to February 18, 2011 have been adjusted based upon a ratio of post merger to pre merger shares.   Non-Employee Stock Based Compensation   Share-based payment awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the share-based payment, whichever is more readily determinable.

Intangible Asset   The cost of patent assets has been capitalized and is not being amortized as revenues relating to the asset have not been generated. The Company will test for impairment of this asset on an annual basis by comparing the carrying amount to its estimated fair value.

A summary of property and equipment as of August 31, 2011 and August 31, 2010 is as follows: <table width="595" style="MARGIN:auto auto auto 4.65pt; WIDTH:446.6pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:12.75pt"> <td width="355" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:266.25pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="111" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:82.9pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> August 31, 2011</td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="115" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:86.35pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> August 31, 2010</td></tr> <tr style="HEIGHT:12.75pt"> <td width="355" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:266.25pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Electronic equipment</td> <td width="111" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:82.9pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">  $              73,788 </td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="115" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:86.35pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">  $                73,788 </td></tr> <tr style="HEIGHT:12.75pt"> <td width="355" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:266.25pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Furniture and equipment</td> <td width="111" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:82.9pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">               5,112 </td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="115" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:86.35pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">                    5,112 </td></tr> <tr style="HEIGHT:12.75pt"> <td width="355" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:266.25pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Software</td> <td width="111" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:82.9pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">                  215 </td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="115" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:86.35pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">                            - </td></tr> <tr style="HEIGHT:12.75pt"> <td width="355" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:266.25pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="111" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:82.9pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">             79,115 </td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="115" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:86.35pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">                  78,900 </td></tr> <tr style="HEIGHT:12.75pt"> <td width="355" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:266.25pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Less accumulated depreciation</td> <td width="111" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:82.9pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">           (76,557)</td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="115" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:86.35pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">                 (73,233)</td></tr> <tr style="HEIGHT:13.5pt"> <td width="355" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:266.25pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="111" style="BORDER-BOTTOM:windowtext 2.25pt double; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:82.9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">  $                2,558 </td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="115" style="BORDER-BOTTOM:windowtext 2.25pt double; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:86.35pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">  $                  5,667 </td></tr></table>

Research and Development Costs   Costs incurred in the research and development phase of the Companys products are expensed as incurred. Research and development expenses include direct costs for salaries, employee benefits, subcontractors, facility related expenses, and stock-based compensation related to employees involved in the Companys research and development.

The Company accounts for income taxes in accordance with accounting standards for Accounting for Income Taxes which require the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and tax credit carry-forwards. Additionally, the standards require the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets.   As of the acquisition date, February 18, 2011, Organ Transport Systems, Inc. had net operating losses for Federal income tax purposes totaling approximately $15,205,761 which expire in 2030, when it was acquired by the Company. The following is a schedule of deferred tax assets as of August 31, 2011, and August 31, 2010:   <table style="MARGIN:auto auto auto 41.4pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr> <td width="204" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:153pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top">  </td> <td width="22" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:16.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top">  </td> <td width="144" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.5in; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> August 31, 2011</td> <td width="22" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:16.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top">  </td> <td width="156" style="BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:117pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> August 31, 2010</td></tr> <tr> <td width="204" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:153pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> Net operating loss </td> <td width="22" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:16.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> $</td> <td width="144" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.5in; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> 17,274,178</td> <td width="22" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:16.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> $</td> <td width="156" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:117pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <div style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:medium none; PADDING-BOTTOM:1pt; PADDING-LEFT:0in; PADDING-RIGHT:0in; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:medium none; PADDING-TOP:1pt"> <p style="BORDER-BOTTOM:medium none; TEXT-ALIGN:right; BORDER-LEFT:medium none; PADDING-BOTTOM:0in; MARGIN:0in 0in 0pt; PADDING-LEFT:0in; PADDING-RIGHT:0in; BORDER-TOP:medium none; BORDER-RIGHT:medium none; PADDING-TOP:0in" align="right">14,739,658</div></td></tr> <tr> <td width="204" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:153pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> Future tax benefit at 34%                      </td> <td width="22" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:16.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top">  </td> <td width="144" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.5in; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> 5,873,221</td> <td width="22" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:16.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top">  </td> <td width="156" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:117pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> 5,011,484</td></tr> <tr> <td width="204" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:153pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> Less: Valuation allowance</td> <td width="22" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:16.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top">  </td> <td width="144" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.5in; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top">    (5,873,221)</td> <td width="22" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:16.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top">  </td> <td width="156" style="BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:117pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> (5,011,484)</td></tr> <tr> <td width="204" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:153pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> Net deferred tax asset</td> <td width="22" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:16.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> $</td> <td width="144" style="BORDER-BOTTOM:windowtext 1.5pt double; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.5in; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> --</td> <td width="22" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:16.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> $</td> <td width="156" style="BORDER-BOTTOM:windowtext 1.5pt double; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:117pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> --</td></tr></table>   The valuation allowance changed by approximately $861,737 during the year ended August 31, 2011.   Under Sections 382 and 269 (the shell corporation rule) of the Internal Revenue Code, following an ownership change, special limitations (Section 382 Limitations) apply to the use by a corporation of its net operating loss, or NOL, carry-forwards arising before the ownership change and various other carry-forwards of tax attributes (referred to collectively as the Applicable Tax Attributes). The Company had NOL carry-forwards due to historical losses of Stanford of approximately $368,374 at November 30, 2010, and OTS had net operating loss carry-forwards of $14,739,698 at August 30, 2010 and $17,274,178 at August 31, 2011.  As a result of the acquisition of OTS and the disposition of the former mining operations, the Company experienced an ownership change, and Section 382 Limitations will apply to the Applicable Tax Attributes of the Company.   The Company has adopted the provisions of FASB ASC 740-10-25. As a result of its implementation, the Company performed a comprehensive review of its uncertain tax positions in accordance with recognition and measurement standards established by FASB ASC 740-10-25. In this regard, an uncertain tax position represents the Companys expected treatment of a tax position taken in a prepared and filed tax return, or expected to be taken in a tax return, that has not been reflected in measuring income tax expense for financial reporting purposes. The Company does not expect any reasonably possible material changes to the estimated amount of liability associated with uncertain tax positions through August 31, 2011. The Companys continuing policy is to recognize accrued interest and penalties related to income tax matters in income tax expense.

Fair Value of Financial Instruments   The carrying amounts of the Companys short-term financial instruments, including accounts payable and accrued liabilities, approximate fair value due to the relatively short period to maturity for these instruments.   Fair Value Measurements   The Company follows accounting guidance relating to fair value measurements. This guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows:   Level 1  Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.   Level 2  Inputs other than quoted prices included within Level 1 that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.   Level 3  Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement date.   At August 31, 2011, the Company has no instruments that require additional disclosure. The carrying amounts of the Companys short-term financial instruments, including accounts payable and accrued liabilities, approximate fair value due to the relatively short period to maturity for these instruments.   The asset or liabilitys fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the unobservable inputs.   Recurring Fair Value Measurements   In accordance with accounting principles generally accepted in the United States of America, certain assets and liabilities are required to be recorded at fair value on a recurring basis.

Recently Issued Accounting Pronouncements   In September 2011, the FASB issued an amendment to Topic 350, IntangiblesGoodwill and Other, which simplifies how entities test goodwill for impairment. Previous guidance under Topic 350 required an entity to test goodwill for impairment using a two-step process on at least an annual basis. First, the fair value of a reporting unit was calculated and compared to its carrying amount, including goodwill. Second, if the fair value of a reporting unit was less than its carrying amount, the amount of impairment loss, if any, was required to be measured. Under the amendments in this update, an entity has the option to first assess qualitative factors to determine whether the existence of events or circumstances leads the entity to determine that it is more likely than not that its fair value is less than its carrying amount. If after assessing the totality of events or circumstances, an entity determines that it is not more likely than not that the fair value of the reporting unit is less than its carrying amount, then the two-step impairment test is unnecessary. If the entity concludes otherwise, then it is required to test goodwill for impairment under the two-step process as described under paragraphs 350-20-35-4 and 350-20-35-9 under Topic 350. The amendments are effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011 and early adoption is permitted. The Company is currently evaluating whether early adoption is necessary.   The Company continually assesses any new accounting pronouncements to determine their applicability to the Company. Where it is determined that a new accounting pronouncement affects the Companys financial reporting, the Company undertakes a study to determine the consequence of the change to its financial statements and assures that there are proper controls in place to ascertain that the Companys financials properly reflect the change.

As reflected in the accompanying financial statements, the Company has not yet emerged from the development stage, has a net loss of $2,534,520 and net cash used in operations of $475,288 for the year ended August 31, 2011; and negative working capital of $2,972,602 and an accumulated deficit of $28,096,219 at August 31, 2011.   The accompanying consolidated financial statements of the Company have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.  The Company is a development stage company and has suffered recurring losses and has no established source of revenue.  Its ability to continue as a going concern is dependent upon achieving profitable operations and generating positive cash flows.   There can be no assurances that the Company will be able to achieve profitable operations or obtain additional funding.  These factors create substantial doubt about the Companys ability to continue as a going concern.  The consolidated financial statements do not include any adjustments that might result from the outcome of the uncertainty.   Management intends to raise financing through private or public equity financing or other means and interests that it deems necessary to provide the Company with the ability to continue in existence. Upon FDA approval, the Company expects to begin actual manufacturing and sales operations. The Company is currently negotiating larger financing to initiate the FDA5-10K process which will be completed within 5-10 months.

As of August 31, 2011, Healthcare of Today, Inc. had acquired 60% of the common capital stock issued, on a non-diluting basis, as part of the transfer of Organ Transport Systems, Inc. to the Company.  Healthcare of Today, Inc. also provides financial, accounting, legal, administrative and similar services to the Company at a monthly fixed fee of $10,000, commencing March 1, 2011.

The Company leases office and lab space in a two story, 50,000 square foot building located in Frisco, Texas under a license agreement which terminated on October 31, 2010. The license agreement provides the Company with five offices and lab space, and full access to building common areas including conference rooms, break room / kitchen, reception area and common lab areas. The agreement also covers telephone, wired and wireless internet access, and utilities. The required monthly payment under the license agreement is $4,267. The agreement automatically renewed on a month to month basis at the previous agreed upon terms until either party notifies the other in writing of its intention to terminate the license agreement 30 days prior to the termination date.

The following is a summary of notes payable at August 31, 2011 and August 31, 2010:     <table width="654" style="MARGIN:auto auto auto 4.65pt; WIDTH:490.75pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:0.25in"> <td width="409" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:306.75pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Description</td> <td width="117" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:87.6pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> August 31, 2011</td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> August 31, 2010</td></tr> <tr style="HEIGHT:22pt"> <td width="409" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:306.75pt; PADDING-RIGHT:5.4pt; HEIGHT:22pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> NTEC, Inc.</td> <td width="117" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:87.6pt; PADDING-RIGHT:5.4pt; HEIGHT:22pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:22pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:22pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:29.25pt"> <td width="409" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:306.75pt; PADDING-RIGHT:5.4pt; HEIGHT:29.25pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Note payable to NTEC, Inc. The note accrues interest at 7% per annum and matures on August 31, 2012. </td> <td width="117" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:87.6pt; PADDING-RIGHT:5.4pt; HEIGHT:29.25pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">  $       235,629 </td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:29.25pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:29.25pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">  $            129,350 </td></tr> <tr style="HEIGHT:17.1pt"> <td width="409" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:306.75pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> The Realtime Group</td> <td width="117" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:87.6pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:51pt"> <td width="409" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:306.75pt; PADDING-RIGHT:5.4pt; HEIGHT:51pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Related party note payable to The Realtime Group, president Marshall Wenrich served as OTS Director of Engineering. The note accrues interest at 7% per annum and matures on December 31, 2011.</td> <td width="117" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:87.6pt; PADDING-RIGHT:5.4pt; HEIGHT:51pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">           131,433 </td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:51pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:51pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">          122,834 </td></tr> <tr style="HEIGHT:17.1pt"> <td width="409" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:306.75pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Musculoskeletal Transplant Foundation</td> <td width="117" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:87.6pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:39.75pt"> <td width="409" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:306.75pt; PADDING-RIGHT:5.4pt; HEIGHT:39.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Note payable to Musculoskeletal Transplant Foundation (MTF). The note accrues interest at the WSJ prime rate plus 2% and matures on December 31, 2011.</td> <td width="117" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:87.6pt; PADDING-RIGHT:5.4pt; HEIGHT:39.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">           907,664 </td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:39.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:39.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">                822,217 </td></tr> <tr style="HEIGHT:21.15pt"> <td width="409" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:306.75pt; PADDING-RIGHT:5.4pt; HEIGHT:21.15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> University of Texas Southwestern Medical Center</td> <td width="117" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:87.6pt; PADDING-RIGHT:5.4pt; HEIGHT:21.15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:21.15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:21.15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:38.25pt"> <td width="409" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:306.75pt; PADDING-RIGHT:5.4pt; HEIGHT:38.25pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Note payable to the University of Texas Southwestern Medical Center. The note accrues interest at 7% per annum and matures on the December 31, 2011.</td> <td width="117" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:87.6pt; PADDING-RIGHT:5.4pt; HEIGHT:38.25pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">           349,162 </td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:38.25pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:38.25pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">                326,320 </td></tr> <tr style="HEIGHT:17.1pt"> <td width="409" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:306.75pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Employees and consultants</td> <td width="117" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:87.6pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:0.3in"> <td width="409" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:306.75pt; PADDING-RIGHT:5.4pt; HEIGHT:0.3in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> Notes payable to related parties employees and consultants. The notes accrue interest at 7% per annum and mature December 30, 2011. </td> <td width="117" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:87.6pt; PADDING-RIGHT:5.4pt; HEIGHT:0.3in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">            109,402</td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:0.3in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:0.3in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">                102,768 </td></tr> <tr style="HEIGHT:0.25in"> <td width="409" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:306.75pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Convertible debentures - officers</td> <td width="117" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:87.6pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:63pt"> <td width="409" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:306.75pt; PADDING-RIGHT:5.4pt; HEIGHT:63pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Convertible notes payable to related parties officers by OTS. The notes accrue interest at 12% per annum, mature December 15, 2012, and are convertible one year after issuance into shares of Company common stock at a price discounted from average trading price. $1,408,579 less discount at $909,507 for conversion.</td> <td width="117" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:87.6pt; PADDING-RIGHT:5.4pt; HEIGHT:63pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">        499,072 </td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:63pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:63pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">                            - </td></tr></table>   <table width="628" style="MARGIN:auto auto auto 4.65pt; WIDTH:470.65pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:12.75pt"> <td width="397" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:297.75pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Ambrose and Keith</td> <td width="102" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:76.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:51pt"> <td width="397" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:297.75pt; PADDING-RIGHT:5.4pt; HEIGHT:51pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Note payable to Ambrose and Keith. The note accrues interest at 9% per annum and mature April 30, 2011 and is convertible into shares of the Companys common stock at a price discounted from average trading price.</td> <td width="102" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:76.5pt; PADDING-RIGHT:5.4pt; HEIGHT:51pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">             25,000 </td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:51pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:51pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">                            - </td></tr> <tr style="HEIGHT:20.25pt"> <td width="397" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:297.75pt; PADDING-RIGHT:5.4pt; HEIGHT:20.25pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Asher Enterprises, Inc.</td> <td width="102" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:76.5pt; PADDING-RIGHT:5.4pt; HEIGHT:20.25pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:20.25pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:20.25pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:51pt"> <td width="397" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:297.75pt; PADDING-RIGHT:5.4pt; HEIGHT:51pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Note payable to Asher Enterprises, Inc. The note accrues interest at 8% per annum and mature April 11, 2012 and is convertible 180 days after issuance into shares of the Companys common stock at a price discounted from average trading price. $53,000 Note less discount of $35,917 for conversion.</td> <td width="102" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:76.5pt; PADDING-RIGHT:5.4pt; HEIGHT:51pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">             17,083 </td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:51pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:51pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">                            - </td></tr> <tr style="HEIGHT:0.3in"> <td width="397" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:297.75pt; PADDING-RIGHT:5.4pt; HEIGHT:0.3in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Asher Enterprises, Inc.</td> <td width="102" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:76.5pt; PADDING-RIGHT:5.4pt; HEIGHT:0.3in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:0.3in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:0.3in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:59.85pt"> <td width="397" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:297.75pt; PADDING-RIGHT:5.4pt; HEIGHT:59.85pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Note payable to Asher Enterprises, Inc. The note accrues interest at 8% per annum and mature May 18, 2012 and is convertible 180 days after issuance into shares of the Companys common stock at a price discounted from average trading price. $44,000 Note less discount of $33,320 for conversion.</td> <td width="102" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:76.5pt; PADDING-RIGHT:5.4pt; HEIGHT:59.85pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">             6,680 </td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:59.85pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:59.85pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">                            - </td></tr> <tr style="HEIGHT:19.35pt"> <td width="397" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:297.75pt; PADDING-RIGHT:5.4pt; HEIGHT:19.35pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Crystal Falls Investments, LLC.</td> <td width="102" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:76.5pt; PADDING-RIGHT:5.4pt; HEIGHT:19.35pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:19.35pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:19.35pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:51pt"> <td width="397" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:297.75pt; PADDING-RIGHT:5.4pt; HEIGHT:51pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Convertible notes payable to Crystal Falls. The notes accrue interest at 9% per annum and mature January 31, 2012 and are convertible into shares of Allezoe common stock at a price discounted from the average trading price. $100,000 Note less discount of $59,185 for conversion.</td> <td width="102" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:76.5pt; PADDING-RIGHT:5.4pt; HEIGHT:51pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">           40,815 </td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:51pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:51pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> -</td></tr> <tr style="HEIGHT:0.25in"> <td width="397" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:297.75pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Ambrose and Keith</td> <td width="102" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:76.5pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:25.5pt"> <td width="397" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:297.75pt; PADDING-RIGHT:5.4pt; HEIGHT:25.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Demand loan to Ambrose and Keith. The note does not accrue interest and matured April 30, 2011.</td> <td width="102" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:76.5pt; PADDING-RIGHT:5.4pt; HEIGHT:25.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">               5,000 </td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:25.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:25.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">                            - </td></tr> <tr style="HEIGHT:12.75pt"> <td width="397" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:297.75pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="102" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:76.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:12.75pt"> <td width="397" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:297.75pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Total</td> <td width="102" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:76.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">        2,326,940 </td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">             1,503,489 </td></tr> <tr style="HEIGHT:12.75pt"> <td width="397" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:297.75pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Less: current portion</td> <td width="102" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:76.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">        1,827,868 </td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">                129,350 </td></tr> <tr style="HEIGHT:13.5pt"> <td width="397" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:297.75pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> Long-term debt</td> <td width="102" style="BORDER-BOTTOM:windowtext 2.25pt double; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:76.5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">  $       499,072 </td> <td width="15" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.1pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="114" style="BORDER-BOTTOM:windowtext 2.25pt double; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:85.3pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom">  $         1,374,139 </td></tr></table>   Notes payable consist of borrowings under convertible debenture arrangements. In July 2011, the Company entered into an arrangement with a creditor in which the Company borrowed $53,000 with interest payable at 8% per annum with a maturity date of January 31, 2012. The indebtedness including interest is convertible into common stock at 58% of the average lowest three (3) trading prices during the ten (10) trading day period ending on the latest complete trading day prior to conversion. In August 2011, the Company entered into an arrangement with a creditor in which the Company borrowed $40,000 with interest payable at 8% per annum with a maturity date of January 31, 2012. The indebtedness including interest is convertible into common stock at 58% of the average lowest three (3) trading prices during the ten (10) trading day period ending on the latest complete trading day prior to conversion. In July 2011, the Company entered into an arrangement with a creditor in which the Company borrowed $100,000 with interest payable at 9% per annum with a maturity date of January 31, 2012. The indebtedness including interest is convertible into common stock at $.29 per share. The Company accounted for the borrowings under these arrangements in accordance with ASC 470-20 Debt with Conversions and Other Options. The fair value of the beneficial conversion feature is calculated using the intrinsic value method at the time of issuance or commitment date. The company records a debt discount for the calculated value, which is amortized over the debt term.

In November 2011, the Company entered into an arrangement with a creditor in which the Company borrowed $50,000 with interest payable at 12% per annum with a maturity date of November 4, 2012. The indebtedness including interest is convertible into common stock at 50% of the average lowest price during the ten (10) trading day period ending on the latest complete trading day prior to conversion.   In November 2011, the Company entered into an arrangement with a creditor in which the Company borrowed $260,000 with interest payable at 12% per annum with a maturity date of November 4, 2012. The indebtedness including interest is convertible into common stock at 50% of the average lowest price during the ten (10) trading day period ending on the latest complete trading day prior to conversion. This was an assignment of part of the convertible notes payable to related parties officers by OTS (See Note 8) where $261,453 was assigned to a creditor for $260,000. In November 2011, the Company converted $100,000 of the note into 7,497,585 shares of common stock.

273245

118176

683438

2739

7870

181334

0001080602 2010-09-01 2011-08-31 0001080602 2011-08-31 0001080602 2010-08-31 0001080602 2009-09-01 2010-08-31 0001080602 1999-07-13 2011-08-31 0001080602 1999-07-13 2009-08-31 0001080602 us-gaap:CommonStockMember 1999-07-13 2009-08-31 0001080602 us-gaap:AdditionalPaidInCapitalMember 1999-07-13 2009-08-31 0001080602 us-gaap:DeferredCompensationShareBasedPaymentsMember 1999-07-13 2009-08-31 0001080602 us-gaap:AccumulatedOtherComprehensiveIncomeMember 1999-07-13 2009-08-31 0001080602 us-gaap:CommonStockMember 2009-08-31 0001080602 us-gaap:AdditionalPaidInCapitalMember 2009-08-31 0001080602 us-gaap:DeferredCompensationShareBasedPaymentsMember 2009-08-31 0001080602 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2009-08-31 0001080602 2009-08-31 0001080602 us-gaap:CommonStockMember 2009-09-01 2010-08-31 0001080602 us-gaap:AdditionalPaidInCapitalMember 2009-09-01 2010-08-31 0001080602 us-gaap:DeferredCompensationShareBasedPaymentsMember 2009-09-01 2010-08-31 0001080602 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2009-09-01 2010-08-31 0001080602 us-gaap:CommonStockMember 2010-08-31 0001080602 us-gaap:AdditionalPaidInCapitalMember 2010-08-31 0001080602 us-gaap:DeferredCompensationShareBasedPaymentsMember 2010-08-31 0001080602 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2010-08-31 0001080602 us-gaap:CommonStockMember 2010-09-01 2011-08-31 0001080602 us-gaap:AdditionalPaidInCapitalMember 2010-09-01 2011-08-31 0001080602 us-gaap:DeferredCompensationShareBasedPaymentsMember 2010-09-01 2011-08-31 0001080602 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2010-09-01 2011-08-31 0001080602 us-gaap:CommonStockMember 2011-08-31 0001080602 us-gaap:AdditionalPaidInCapitalMember 2011-08-31 0001080602 us-gaap:DeferredCompensationShareBasedPaymentsMember 2011-08-31 0001080602 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-08-31 0001080602 1999-07-12 iso4217:USD shares iso4217:USD shares Net of accumulated depreciation of $76,557and $73,233 Net of accumulated amortization of $800 and $0 Net of debt discount of $128,422 and $0 Net of debt discount of $909,507 and $0 $0.001 par value, 500,000,000 shares authorized, 140,080,039 and 18,717,740 shares issued and outstanding Stock option warrants issued for services, 2000 - 2009 Stock option warrants issued for services Discount on notes payable EX-101.SCH 6 alzm.ob-20110831.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000030 - Statement - CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) link:presentationLink link:definitionLink link:calculationLink 200000 - Disclosure - Organization, Consolidation and Presentation of Financial Statements link:presentationLink link:definitionLink link:calculationLink 250000 - Disclosure - Accounting Changes and Error Corrections link:presentationLink link:definitionLink link:calculationLink 831000 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 370000 - Disclosure - Intangible Assets, Goodwill and Other link:presentationLink link:definitionLink link:calculationLink 815000 - Disclosure - Fair Value Measures and Disclosures link:presentationLink link:definitionLink link:calculationLink 300000 - Disclosure - Cash and Cash Equivalents link:presentationLink link:definitionLink link:calculationLink 760000 - Disclosure - Research and Development link:presentationLink link:definitionLink link:calculationLink 500000 - Disclosure - Equity link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 360000 - Disclosure - Property, Plant, and Equipment link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 290000 - Disclosure - Accounting Policies link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 275000 - Disclosure - Risks and Uncertainties link:presentationLink link:definitionLink link:calculationLink 845000 - Disclosure - Related Party Disclosures link:presentationLink link:definitionLink link:calculationLink 000060 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 460000 - Disclosure - Debt link:presentationLink link:definitionLink link:calculationLink 870000 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 770000 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 alzm.ob-20110831_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 alzm.ob-20110831_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 alzm.ob-20110831_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Concentration Risk Disclosure [Text Block] Nature of Operations [Text Block] Common stock issued at par NET CASH PROVIDED BY INVESTING ACTIVITIES Accounts payable and accrued expenses Accounts payable and accrued expenses Increase in prepaid expenses Stock issued during period, Shares, conversion of notes Weighted average number of shares outstanding during the period - basic and diluted Loss from operations Bad debt expense Directors fees General & Administrative Common stock, par value Long-term notes payable Subsequent Events Leases of Lessee Disclosure [Text Block] Compensation Related Costs, Policy [Policy Text Block] Accrued interest payable Additional Paid-in Capital Entity Voluntary Filers Income Tax Disclosure [Text Block] Consolidation, Policy [Policy Text Block] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Net Income (loss) Net Income (loss) Stock issued during period, Value, conversion of notes Shares authorized Total Current Liabilities Total Assets Entity Registrant Name Property, Plant and Equipment Disclosure [Text Block] Liabilities converted to notes payable Amortization of debt discount Net Income (Loss) Total Liabilities and Stockholders' Equity (Deficit) Common Stock Accrued interest Document Period End Date Stock issued during period, Shares, warrants Contributions General and administrative Office expense Travel and entertainment Amendment Flag Leases Fair Value Measures and Disclosures Intangible Assets, Goodwill and Other Proceeds from notes payable NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES Statement of Cash Flows Research and development Total Stockholders' Equity (Deficit) Stockholders' Equity Stockholders' Equity Additional paid in capital Accounts payable and accrued liabilities Current Fiscal Year End Date Related Party Transactions Disclosure [Text Block] Stock issued during period, Shares Statement of Stockholders' Equity Insurance Payroll and payroll taxes Current Liabilities Property, plant, and equipment Total Current Assets Shareholders' Equity: Entity Current Reporting Status Related Party Disclosures Common Stockholders' Equity Going Concern Note Conversion of notes payable to stock Other liabilities Other liabilities Depreciation Adjustments to reconcile net income (loss) to net cash provided by (used in) continuing operations: Adjustments to paid in capital Organizational costs Total Liabilities Assets {1} Assets Entity Central Index Key Fair Value Disclosures [Text Block] Income Taxes Accounting Changes and Error Corrections Development Stage Enterprises NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES Stock issued during period, Value, services Stock issued during period, Shares, founder shares Repairs and maintenance Dues and subscriptions Professional fees Document Fiscal Year Focus Income taxes, net Increase (Decrease) in cash and cash equivalents NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES Stock issued during period, Shares, services Deferred Equity Other income (expense) Contract labor Income (Loss) from Continuing Operations before Taxes Stockholders' Equity: Patents Organization, Consolidation and Presentation of Financial Statements Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance Stock issued during period, Value, founder shares Total Expenses Total Noncurrent Assets Entity Filer Category Equity Debt Property, Plant, and Equipment Significant Accounting Policies [Text Block] Accounting Changes and Error Corrections [Text Block] Supplemental disclosures of non-cash investing and financing activities: Issuance of Common Stock Investment in patents Revenues Shares issued Shares issued, Shares issued, Deficit accumulated during the development stage Deferred loan costs Cash Current Assets Statement [Line Items] Document and Entity Information Cash and Cash Equivalents Disclosure [Text Block] Risks and Uncertainties Supplemental disclosuers of cash flow information: Weighted average number of common shares outstanding Net loss per common share (basic and diluted) Income taxes Income (loss) before income taxes Interest, net Finance cost Rent Stockholder's Equity (Deficit) Accrued salaries Liabilities & Stockholders' Equity Prepaid expenses Statement of Financial Position Entity Common Stock, Shares Outstanding Subsequent Events [Text Block] Debt Disclosure [Text Block] Accounting Policies NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES: Stock based compensation expense Depreciation and amortization expense Telephone and internet Advisor fees Income Statement Shares outstanding Document Fiscal Period Focus Research, Development, and Computer Software Disclosure [Text Block] Cash and Cash Equivalents Use of Estimates, Policy [Policy Text Block] NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES: Stock issued during period, Value Common Stock {1} Common Stock Statement, Equity Components [Axis] Earnings Per Share: Net income (loss) qualified Notes payable Entity Well-known Seasoned Issuer Interest Interest Payments of notes payable Purchase of property and equipment Accrued liabilities Accrued liabilities Accumulated Other Comprehensive Income (Loss) Management contract Entity Public Float Research and Development Goodwill and Intangible Assets Disclosure [Text Block] Notes payable converted to warrants Stock issued during period, Value, warrants Equity Component Deferred equity Document Type EX-101.PRE 10 alzm.ob-20110831_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 R9.htm IDEA: XBRL DOCUMENT

Risks and Uncertainties

12 Months Ended

Aug. 31, 2011

Risks and Uncertainties

Concentration Risk Disclosure [Text Block]

Risks and Uncertainties

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 21, 22, 24

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6442-108592

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13531-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6327-108592

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

+ Details

EXCEL 13 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\R.3!C8S'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=OF%T:6]N7T-O;G-O;&ED871I;VY?86YD M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I%>&-E M;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E!R;W!E#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O M#I%>&-E;%=O#I%>&-E;%=O5]$:7-C;&]S M=7)E#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U M8G-E<75E;G1?179E;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0 M#I%>&-E;%=O7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA2!296=I'0^075G(#,Q+`T*"0DR,#$Q/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^9F%L2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,#`P,3`X,#8P,CQS<&%N/CPO'0^+2TP."TS,3QS<&%N M/CPO2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^3F\\2!7 M96QL+6MN;W=N(%-E87-O;F5D($ES'0^3F\\7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$2`H1&5F:6-I="D\+W1D/@T*("`@("`@ M("`\=&0@8VQAF5D M+"`Q-#`L,#@P+#`S.2!A;F0@,3@L-S$W+#3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R.3!C M8S'0O:'1M;#L@8VAA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7)O;&P@86YD('!A>7)O;&P@=&%X97,\ M+W1D/@T*("`@("`@("`\=&0@8VQAF%T:6]N86P@8V]S=',\+W1D/@T* M("`@("`@("`\=&0@8VQA'!E;G-E'!E;G-E*3PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#4S M-"PU,C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\R.3!C8S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!A="!*=6PN M(#$R+"`Q.3DY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\2!A="!!=66%B;&4\+W1D/@T*("`@("`@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6%B;&4@86YD(&%C8W)U960@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@ M8VQA6%B;&4@8V]N=F5R=&5D('1O('=A'0^,S8U,#QS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/"$M M+65G>"TM/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE. M.C!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63HG5&EM M97,@3F5W(%)O;6%N)RPGF5D('-H87)E(&-A<&ET86P@=&\@-3`P+#`P M,"PP,#`@8V]M;6]N('-H87)E6QE/3-$ M)T9/3E0M1D%-24Q9.B=4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B=4:6UE2`Q."P@,C`Q,2P@86QL(&]F('1H92!M:6YE M2!A8W%U:7)E9"!A;&P@;V8@=&AE(&]U='-T86YD:6YG('-H M87)E2`R-"P@,C`Q,2!A6QE/3-$)T9/3E0M1D%-24Q9.B=4:6UE2!A;F0@:6YC2!A9'9A M;F-E9"!P'0^/"$M+65G>"TM/CQP('-T>6QE M/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T)SX\ M8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63HG5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)U1% M6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63HG5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I M;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63HG5&EM97,@ M3F5W(%)O;6%N)RPG2!P;&%N2!P;&%N6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63HG5&EM97,@3F5W M(%)O;6%N)RPG2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/"$M+65G>"TM/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@ M34%21TE..C!I;B`P:6X@,'!T)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63HG5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63HG5&EM97,@3F5W M(%)O;6%N)RPG2!A;F0@:71S('=H;VQL>2UO=VYE9"!S=6)S:61I87)Y+"!/5%,N(%1H97-E M(&9I;F%N8VEA;"!S=&%T96UE;G1S(')E9FQE8W0@=&AE(&9I;F%N8VEA;"!P M;W-I=&EO;B!A;F0@6QE/3-$)T9/3E0M1D%-24Q9.B=4 M:6UE6QE/3-$)T9/ M3E0M1D%-24Q9.B=4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B=4:6UE6QE/3-$)U1%6%0M04Q)1TXZ:G5S M=&EF>3L@34%21TE..C!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63HG5&EM97,@3F5W(%)O;6%N)RPG6QE M/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63HG5&EM97,@3F5W(%)O;6%N)RPG M&5R8VES92!S:6=N M:69I8V%N="!J=61G;65N="X@270@:7,@870@;&5A2!P M;W-S:6)L92!T:&%T('1H92!E&ES=&5D(&%T('1H92!D871E(&]F('1H92!F:6YA;F-I86P@2P@=&AE(&%C='5A;"!R97-U;'1S(&-O=6QD(&1I M9F9E6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^/&9O;G0@2=S(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%R92!P2P@86YD(&9I>&5D(&%S6QE/3-$)T9/3E0M1D%-24Q9.B=4:6UE M6QE/3-$)U1% M6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63HG5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I M;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63HG5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9 M.B=4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B=4:6UE2!W:6QL(&)E(&%B;&4@=&\@ M86-H:65V92!P28C,30V.W,@ M86)I;&ET>2!T;R!C;VYT:6YU92!A6QE/3-$)T9/3E0M1D%-24Q9.B=4:6UE M6QE/3-$ M)T9/3E0M1D%-24Q9.B=4:6UE2!F:6YA;F-I;F<@;W(@;W1H97(@;65A;G,@86YD(&EN=&5R97-T2!T;R!P6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^ M/&9O;G0@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!) M6QE/3-$)T9/3E0M1D%-24Q9.B=4:6UE M6QE/3-$)U1%6%0M M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63HG5&EM97,@3F5W(%)O;6%N)RPG6EN M9R!A;6]U;G0N($EF(&%F=&5R(&%S2!D971E2!I2X\+V9O;G0^/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=. M.FIU6QE/3-$)T9/3E0M1D%-24Q9.B=4:6UE2!T;R!D971E28C,30V.W,@9FEN86YC:6%L2!R969L96-T('1H92!C M:&%N9V4N(#PO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\R.3!C8S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^/"$M+65G>"TM/CQP('-T M>6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^/&(^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B=4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF M>3L@34%21TE..C!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63HG5&EM97,@3F5W(%)O;6%N)RPG3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R.3!C M8S'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`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`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0@0FQO8VM= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM96=X+2T^/'`@ M6QE/3-$)T9/3E0M1D%-24Q9.B=4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ:G5S M=&EF>3L@34%21TE..C!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63HG5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/ M3E0M1D%-24Q9.B=4:6UE2X@ M/"]F;VYT/CPO<#X@/'`@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A2P@4&QA;G0L(&%N9"!%<75I<&UE;G0\8G(^/"]S=')O;F<^/"]T:#X- M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\(2TM96=X+2T^/'`@2!O9B!P2!A;F0@97%U:7!M96YT(&%S(&]F($%U9W5S M="`S,2P@,C`Q,2!A;F0@075G=7-T(#,Q+"`R,#$P(&ES(&%S(&9O;&QO=W,Z M/"]F;VYT/CPO<#X@/'1A8FQE('=I9'1H/3-$-3DU('-T>6QE/3-$)TU!4D=) M3CIA=71O(&%U=&\@875T;R`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`[('!A9&1I;F6QE/3-$)U1%6%0M04Q)1TXZ7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0@0FQO M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM96=X+2T^ M/'`@6QE/3-$)T9/3E0M1D%-24Q9.B=4:6UE6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@ M34%21TE..C!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63HG5&EM97,@3F5W(%)O;6%N)RPG6EN9R!A;6]U;G0@=&\@:71S(&5S=&EM871E9"!F86ER M('9A;'5E+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\R.3!C8S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0@0FQO8VM=/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM96=X+2T^/'`@6%B;&4@870@075G=7-T(#,Q+"`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`Q."P@,C`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`[('!A M9&1I;F6QE/3-$)T9/3E0M1D%-24Q9.B=4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63HG5&EM97,@3F5W(%)O;6%N)RPG M6%B;&4@8V]N2!B;W)R;W=E9"`D-3,L,#`P('=I M=&@@:6YT97)E2!P97)I;V0@96YD:6YG(&]N('1H92!L871E6%B;&4@870@."4@<&5R(&%N;G5M M('=I=&@@82!M871U2!D871E(&]F($IA;G5A2!B M;W)R;W=E9"`D,3`P+#`P,"!W:71H(&EN=&5R97-T('!A>6%B;&4@870@.24@ M<&5R(&%N;G5M('=I=&@@82!M871U2!D871E(&]F($IA;G5A2!A8V-O=6YT960@9F]R('1H92!B;W)R;W=I;F=S M('5N9&5R('1H97-E(&%R3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R.3!C8S'0O M:'1M;#L@8VAA6QE/3-$ M)T9/3E0M1D%-24Q9.B=4:6UE6QE/3-$)TU!4D=)3CHP M:6X@,&EN(#!P="<^/&9O;G0@65E(&)E;F5F:71S+"!S=6)C M;VYT'!E;G-E65E28C,30V.W,@3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\R.3!C8S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R"!$:7-C;&]S M=7)E(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/"$M+65G>"TM/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@ M34%21TE..C!I;B`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`P:6X@,'!T)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63HG5&EM97,@3F5W(%)O;6%N)RPG6QE M/3-$)T9/3E0M1D%-24Q9.B=4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B=4:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(V8P9C!F,#L@0D]21$52+4Q%1E0Z(V8P9C!F,#L@4$%$1$E.1RU"3U14 M3TTZ,&EN.R!"04-+1U)/54Y$+4-/3$]2.G1R86YS<&%R96YT.R!0041$24Y' M+4Q%1E0Z-2XT<'0[(%=)1%1(.C$N-6EN.R!0041$24Y'+5))1TA4.C4N-'!T M.R!"3U)$15(M5$]0.B-F,&8P9C`[($)/4D1%4BU224=(5#HC9C!F,&8P.R!0 M041$24Y'+51/4#HP:6XG('9A;&EG;CTS1'1O<#X@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B=4:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(V8P9C!F,#L@0D]21$52+4Q%1E0Z(V8P9C!F,#L@4$%$1$E.1RU"3U14 M3TTZ,&EN.R!"04-+1U)/54Y$+4-/3$]2.G1R86YS<&%R96YT.R!0041$24Y' M+4Q%1E0Z-2XT<'0[(%=)1%1(.C$V+CAP=#L@4$%$1$E.1RU224=(5#HU+C1P M=#L@0D]21$52+51/4#HC9C!F,&8P.R!"3U)$15(M4DE'2%0Z(V8P9C!F,#L@ M4$%$1$E.1RU43U`Z,&EN)R!V86QI9VX],T1T;W`^(#QP('-T>6QE/3-$)U1% M6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63HG5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)U1%6%0M M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63HG5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B=4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B=4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B=4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%2 M1TE..C!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63HG M5&EM97,@3F5W(%)O;6%N)RPG"!A6QE/3-$)T9/3E0M1D%-24Q9 M.B=4:6UE6QE/3-$)T9/ M3E0M1D%-24Q9.B=4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B=4:6UE6QE/3-$)T9/3E0M1D%-24Q9 M.B=4:6UE6QE/3-$)TU! M4D=)3CHP:6X@,&EN(#!P="<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B=4 M:6UE2!A M<'!R;WAI;6%T96QY("0X-C$L-S,W(&1U65A2!A(&-O2!A&EM M871E;'D@)#,V."PS-S0@870@3F]V96UB97(@,S`L(#(P,3`L(&%N9"!/5%,@ M:&%D(&YE="!O<&5R871I;F<@;&]S2UF;W)W87)D6QE M/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63HG5&EM97,@3F5W(%)O;6%N)RPG M2!P97)F;W)M960@82!C;VUP"!P;W-I=&EO;G,@:6X@86-C;W)D86YC92!W M:71H(')E8V]G;FET:6]N(&%N9"!M96%S=7)E;65N="!S=&%N9&%R9',@97-T M86)L:7-H960@8GD@1D%30B!!4T,@-S0P+3$P+3(U+B!);B!T:&ES(')E9V%R M9"P@86X@=6YC97)T86EN('1A>"!P;W-I=&EO;B!R97!R97-E;G1S('1H92!# M;VUP86YY)B,Q-#8['!E8W1E9"!T2!R96%S;VYA8FQY M('!O"!E>'!E;G-E+CPO9F]N M=#X\+W`^/&9O;G0@7,^/"]B6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R M.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B=4:6UE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$ M)T9/3E0M1D%-24Q9.B=4:6UE6QE/3-$)T9/3E0M M1D%-24Q9.B=4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`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`P:6X@,'!T)SX\=3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63HG5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$5$585"U$14-/4D%424]. M.FYO;F4^)FYB6QE/3-$)T9/3E0M1D%-24Q9.B=4:6UE6QE/3-$)T9/ M3E0M1D%-24Q9.B=4:6UE2!H87,@;F\@:6YS=')U;65N=',@=&AA="!R97%U:7)E(&%D9&ET M:6]N86P@9&ES8VQO&EM:7IE('1H92!U M6QE/3-$)T9/3E0M M1D%-24Q9.B=4:6UE XML 14 R8.htm IDEA: XBRL DOCUMENT

Accounting Changes and Error Corrections

12 Months Ended

Aug. 31, 2011

Accounting Changes and Error Corrections

Accounting Changes and Error Corrections [Text Block]

Recently Issued Accounting Pronouncements

- Definition

The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.

+ References+ Details

XML 15 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (USD $)

Aug. 31, 2011

Aug. 31, 2010

Current Assets

Cash

$ 38,320

$ 17,647

Prepaid expenses

12,396

6,181

Total Current Assets

50,716

23,828

Property, plant, and equipment

2,558

^[1]

5,667

Deferred loan costs

4,700

^[2]

Patents

363,561

320,551

Total Noncurrent Assets

370,819

326,218

Total Assets

421,535

350,046

Current Liabilities

Accounts payable and accrued liabilities

585,240

556,926

Accrued salaries

393,821

1,257,717

Notes payable

1,827,868

^[3]

129,350

Accrued interest

216,389

88,242

Total Current Liabilities

3,023,318

2,032,235

Long-term notes payable

499,072

^[4]

1,374,139

Total Liabilities

3,522,390

3,406,374

Stockholder's Equity (Deficit)

Common Stock

140,080

^[5]

18,718

Additional paid in capital

26,535,284

22,486,653

Deferred equity

(1,680,000)

Deficit accumulated during the development stage

(28,096,219)

(25,561,699)

Total Stockholders' Equity (Deficit)

(3,100,855)

(3,056,328)

Total Liabilities and Stockholders' Equity (Deficit)

$ 421,535

$ 350,046

[1]	Net of accumulated depreciation of $76,557and $73,233
[2]	Net of accumulated amortization of $800 and $0
[3]	Net of debt discount of $128,422 and $0
[4]	Net of debt discount of $909,507 and $0
[5]	$0.001 par value, 500,000,000 shares authorized, 140,080,039 and 18,717,740 shares issued and outstanding

ZIP 16 0001080602-11-000017-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001080602-11-000017-xbrl.zip M4$L#!!0````(`$.)CC]3&54="D@``.L^`P`4`!P`86QZ;2YO8BTR,#$Q,#@S M,2YX;6Q55`D``[X>Z4Z^'NE.=7@+``$$)0X```0Y`0``Y%UM;^-&DOY\!]Q_ MX.(.\2Y@V:JJJ[JZNTA]__>GA2<]D#!R`__C@7R$#B3B3P+']67P3)6Y,I"B8QH\X)(?2 MV'G`/KW@-%@LDYB$TH7O!P\X!H3H$'Z9'!W"9\OGT)W-8^FOIW^3%(2LD8)D M61J-*,[3?>A)0,R//CC$_7@PC^/EA^-C^N>CB$R.9L'#,7QP3&\9(7FDR@>K MRZ>N]W+Y^,N_OQY=_9A>A:R7:UX^?WQ\/$I%!N$,+D+JL>M',>6^EO84N;FK M']7UM?+Q/[]^N9W,R0*/-N[R7/_W;??)MFT?IY^N+]VX,L^'?GR/HU?)\*G; M@'\2C688+U_NF.+H/KUZ]<$6`X++-44VJT"R*UA.3L%'JVN-X^S#`_#I?WU/ ME?D0I2:[(5,IM<.'^'E)/AY$[F+I4=;IW^8AF7X\P-ZWQ5%P/UI[[^@I<@ZD MXU04^/[#63!)%L2/[T""-`G\F#S%-_3&,QDA&\F_K9S^@XQ&/W]_7+QE0\XU M"=W`^>0[9SBN%I@9S0*CY<7F)+S('\-'#OWXW,.S2KE3[$4D$YF[Z474)S]V MX^<;,G.C.,1^?(D7U4S'GD>^!43Z2AQW@CWII\"C@1W1(,R`MHDLX)T"C1![ M%[Y#GGXFSY6`""(#6YZ)#P%J\R" ML-I]MX`!UTHW9!F$,34.S>'8?V:!8S4$OH#,[\_<>X]D(Q$^__0T\1(Z/7\.`N?1 M];PVJ[PRG0U% MWD@YE7@MM(+ECZ[J192FLDLTT!'2-K)S7O9D$D`5$UWC9TR]Z3OPES`ASA<7 MW[N>&[NDC5:ZI2L:$U(\,&)YE:1$W;`5HQLO^O$M]G#8SC2J#3.9G*/`2FR- M5E+4*+IIRB8?W&40D[4I*M(]>UGC'"];BFD93%BQTGC9\&ENP_CGP(%<1F!] M%?-`E4SWLJ%:=BX[LA);HVU7S+(43>$#8T9Q^Q)/18JJLHEP4VH7T))R#ZF* MPN;%.M#`G]V1<,$YA+==WKQ;K2@"R[V"P(;$*,R[>6R89:)=S8 M<5RZ$0X+;%C=7?BG>.G&N$W9J1A0@R@68_L2V9WQ2Z)=T2P#.#3#7]?I=%\) M%K;IH0!=U<3/+4PPD@T+H6WKCTWQ(EAPKT)JX1^(%Z0+N=L8S\@G.ATL0S$<;8RD6LJ$ZMEFZ77D,J=9VZX]@W6[(AMV? M6FDDSP//(6'4?JBJE+_.3(Z;8KN@EAA'1;JALGLP-:A,^H:Z6HCFQ<52'80X M/GP+K$9\-G;XQTD\#T+W&W':G2/H:/7?UOFCB"&*2\E"JSV7[,-TL[NE(;)) M&[$E$BNT-5KYE&V:[&JW!JS[@5&9?L4SHM:XS30M@V4\?HW#JY`>P!`G+62N M29C>RP1=Y*S_R&<%=(20O'5XE8'U0JYD(N]&[@8F$3^I+*,+1R\5E<1:6&,$ MD)\BU-8JK1'H"DI6V^IPAY]@\,5S$K:WDRR;EH:82'H5V@*KVF(P>VFZC`1A M5=M.5F45DH1>"W9#(H+#R1PF+*9TJ3]ZJK$K+.!EA?5?!8H8/@U&:^]H"M-KDJ6U"[ M*IRXEX'OKK;55DXX,&`=H6J#DZKVE:)IIIW? M(N9G=1=B""!ZODGOB+'K"TEGALJN.RI!Q-"IB2)59L]V!^!3[3)+-0VVWN$G M=+L,_"@(A845(Z\-3LT$;B@Z$@=6,TN8EL[:M`SL"\$1/;FZ`0MCK_M(1R8[ M+6R5W@V_VL:F;N0VU<7CUY@=F18RFA!(:ZK/Q">A`/,SHVN+W"ZXW/618-R: M9&^9JJ;Q@]\0^'M$ET\7?I2$M$&CO;%U0U-TM@S;D-T%NR:7J#J[X2T8NVZ& M1;9I\H/?DO#!G9"OV,LS`S4.Y*M*FIP7MD/^6_MK>XO0I!O;DK!1"!)6:=:VF M&H-1J7:,:>BZV9Q+&B^P\`T*?FSO'ELMYH4MXCMSJ`D.VRPFR3Y(U%3XMLX> MG7"Q>.F6[NP&74:,'XIR6X-RESS"$&M*3!OI-B?JKZ$;DZOI]&JZ;GHX(_'>D&O]H1MHJ8$H+ZE^VW=ZR:Z)ZSGSB[SHEOC5AM<52U%,^T><&L2E:&K MIFHKG,`7_B18D"]!%)V'P8)ZQO43F#16]5;@=S#]:,/V]6@"R57[9[3AH$') M53MQM.G%ANRN\3.=GJ*K:?;8#US9<;4]DE55LYF*N`RB,P_N3-8;@QKOM++$ M:V.[ZU0_TU7G"-.&@:NS0R,GN2UJ3;S`;"J;LG#4.E-KBI[;=:F&K8N1'\DT M"$EV7=I`<`8_1+$[Z>`.(*CI[!.\'6@,H4Y=7M21;.AO1YVZ3+K1VBM6G_1S M.AB%5(8%F6WQN#.H(#SNOJ(C,>A@+>7VJF21A%O\SM'%-BZ4GQ2K@JT+XJ\XUU&JFRH.N>TU2OE?M-]O];N M+\%S\U[517GB'5,Z#&;-4GA#KW>JHI-X[X1[3MO]&[S'1-TL(-?KK?P#ZF)2 MMB:K?+&XG<1@.O`.?QW)%MNNO\B6B3B7LWNI:+_UQ5ZJW&/5L8_Z;AFS MMHDX]S.$*)2EK08:=5V4VWKNK0[=:.U*0]%UR]XJVG,UL[=Z]UGC[*O2>Q"K M&WGM%Z`OJ.B15:U%U9,2&((Z]YZW:B&=2>&Z)B9WI(5V'?2BX+XK6#.XBOM:U+F,.'5M'N[6484US7> MOIH1SJ%[?A!OEA:1.E(49""D<37_,Q3KENZ@4SV[0:L_([` M;8IL<>@"*F.!INA8S@ICTFD$-'KY/.?H*VZQB_H^@*:;.;9E(4/MF8V@U9IH M&XG)DSU0VP*;/FQ>W'6K0176OI)[!*ER:+/?2K-7'3AY%;C#0]$MC?,$=\L(*_WE$O6,T[EQ3=5HK999]ZP9KD@MP#:?O7=M,N)[PAE=YC*]@0B6%? MU-M12'7O,>%/$F^K=Z9E%8%,9+8X,=T;1?\4?6"#51S[J._NQZR8?A*1B6?O MFF7ZK5?V5M$_3PO8<+7-OBH]D$)#')^U2D5OZ9A,0&Y25,U69>W=Z?\G/C46 MFL/>DA7Z.37.FW/CU+@Z>0X37L)Z!/DSIMEGKV!7XOS)S[3VJR%X5ZN^X5SS MYOMHZP+>TCDWCUOQ;=<-V""NE=Q7#NQ+.^-P"Z]!%7D_3;2[63@-J52/H=+N M-:$#=GUU#C_A'/:BZZO[H&_R9M<&+3<<`Z3LR^F[]?IT2-#BT/>C`4M0*A33 M$\4Y(*Q".A/55-.T+E MN]HN7O>4_EM_!^X0,;L+508/@Y9MB_QQ;)G*OKX^L5U$*\C6>?JN]D&GEF$^ MD@T+O14=WU,W<'4NT!1U@&#JT*[8+"NH'.^WP.5WF,_\'!UP>[5 MVUE0=>\VY$\4ME+!>ZOHG^M!>)29Z"VHMX1T1? MO3,-CY,,7=65C3?E"&8C]B!(M*E:I9.-[X0?H,VH^A5V_7UE=>-#Y5JB/7Z[ M<(LO_=SRP+FJZ);)N27:]W(QM&LK&E-(,O$_R#1^BW#/VU>-!IHVYYL:16@?ZXT4` M"[YOZ0=74[HE=>9&DR#QX^N0+-QDT7Z<&!IP949O+90X8MQO(1B04[5GNQD+ MUF$A`3^?D>S?"_\"D&'JBJ_Q,X;E/*S5A#2?\@`)9<;MR<&9UJ*AS'],L,D-YF:]BED>2!BK#K[LB5&-#V5%9;_:LB.M\22-WVCE M[[L0.QV,<6:"=70D(4J?=R"8[I@N`S\20)K M=C\>1Q&)H['O?''QO>NENZK])60^\-XUJ%F/:&:ET?=$B>K!T[\;8.R%L"1E M[NG0[Z$:N7X/'C2A]&K659:BLU]5.CB]FD1AVIIN=N$'WC[%T1Q6P@^N0YP? MGW^!NAS&R9*$4.7YL_$D=A\Z^AC""NH.9GG`#]H#UYH4`']7"T\K[XYK724@ MZX:JJ]TM>[W:JKT+TFVYD(``)Z'7DBQ%=-E08JNZ6B!QM+CKN@$YU?C3M.7V MQMI:RF-_1L]-L\M/LZ3?)9!5)->M;K9!BB=:-Y%;EE*9%@ENG)"ZOA9%'*=J#\N:;;(5Q8#$:BHR9,@Z,DP1U"Z#F*P7 M>%TJ;%MFWP%7AM"91HW'3*26C"2A+&K<8^MF[BT27#Q*8O+<]<&9@M)KT4W\ MF#U0K7&E85AR?=$Y#-4:?RM(H_L]GS0>L$?KYC%X.@R?P:GIN5/]JVEX[%(+ M(Y982:L`VBFIU(7*GI'B'U#-B+T>B+A.^W&MZ2BW<'J5F<^)=`JZ(>DJK]-7 M/!6^6B$OMR5D7>7##9GN0G[%8`,7>W0W$KQQ$9-%A^E3TRW-9E8GI1#=B=29 M0384=DNN`9-;=^:[4W>"_7AUX5V(_0BG%LQZDF@W=`035YB>P=Z0"7$?2-6X M+(L+Q=95U2A:K#6#H90IZY_0;?;+W@7JPG:BI^7Z)7E1-J@].FDFS*B]3@"+@4B?:3WN$GNH!P'8'G M:`6Q'5";''2+0VUR6%6%RC]-<5M7]`S%;6"^*>$R?>SN:KK:O*?MN57YYCLO M/OG+:$1F3Z/1=[/XA/Z^E*+XV2,?O_LC">*3NT__O!N-OUQ\OOQ`'PETI\\G MTM?QS>>+RP_(]:7T_V6<7;N6<+_^80K0.6GG5Y=WH_/QUXLO__KP'5X&TKFP_W'I[\?B*E'-3B6QLD,R$NJ?"@I2)9ID$5N%$,A`F-OZC[!#^N+?4=: M0MC"BD$*2?IH@10'D@],@W"&?2FF!<8R"..LHS(FD[D?>,'L^4AB:$AS'$%V M>"!>L*3"I?LD!2Q.>)`H(2S%.)Q!7E[@\'<2 MY\!9&T0@)29PCQO1V^X)S<"`3Z3'(/2<1ZB,)(]@J(\D<"669F'P2&ED8J5I M$+X"0YWE><\2=A[HA.^L:%*+Q2[M8`-+_T[\.;V4'G%1%6D:SDQ, M+W,G)#J2?IV['I&N[FY?60,3-X:TN;[E,.7[Q9V2TQ`['EE=:6HGTD\WAU0S MAT10"0*EE"]@.ALH$3@UHF7I(.<<80' MY7AX*/WN.CYYAE\3?Q8=0@AF>T'@79@.Z:D(B9B1!N,ZF;?-B[Q;^DCHGHAW, M7A"!_#LHK7[TZ/'/\'76X-8?>Q[Y%A#I*W%HZI9^"CP:?3#$H1`_.J1C=D%" MR.A@*1]^<:2OV(=Q3FUV*'V)G2/IKW1,OX[@P@1CG?SM4'K$:60'(>3<=+I, M?#J;T!L]_!BM\V[J#?K+&G1C>?I#3B) MYT'H?@.)V2.94OI,)A6AZ(<((?J_E#Z+F,[Q_X>.$)(AI/ER/> MJF+LG$2'2I"E,+9*22!HHM3+.&W_H:.'SG*KRC$MQ-QL1,(P6])7)$#-5#*P MS\E]F.#P69*MK,P]3"?B5?QMRDF1UC7N"C&=R]+*[?_;^](FMVUET<_G5;W_ MP%?'*=M5E$;[8CNN&L^23.+M><8W'U,4"4D\I@@%)&>L\^MO=P/<)&J93:(D MU,E)-!()H!N]H[OQ<^IQH2RY])3NC@$I.VZ`RR;C&>`":@WI(UIU^!#.F(;A MT(X.(H_8R?4E3\D1UY$YN[QO4L0$]9BJF,],D8B;VWBVQ0)LK=^EI@ M__^P?-K^1BO>_JR1*PD,?9&4)G@4@H7CDTFF)-"Z[0":@C7?6@Y:R5+DQ\9^ MX$Y@FRV?\2@`I9*E$MITZ6`1P9&4Y&1V2264I3$@$B!6?"1#A$C+'+Z2$A)` MB`G72[->JP9:!NR?"(C8`UMR-5VY@?3`0*Y+'V\@_2(P$VYA*3B]'V(=.IF= M\,,P-BP400?2W\$".$G8,.(W1C.%8\&CT7AA2PS4!*`_&.`'](-D_=7+O,%A MLPR#GN6`,1]6,?28C;,+%@I.&,2!%9/!>V"V@O6:KMM%+3^1.[9L[0>G7C#" M)=)@DLAS+L@4I`0K)P"!*4:,O$#@G*IQ%<[)[S46CN(/0/(?$>Q'O4FF39\( MB>::*(,LX]*KR0PJFL0MN118=F<:8+%:0-FXSGQ,(>-:Y1WOU%]G&<\8"%RP M6V6Z`!12`&0"#>`UJ4B#ZSNPG4"V`^!B82'!2,_?G5"<0IDX_X#!%//'O/5S M:[F>Y,L98N263!_I!B(^D[@$D.>((V4&&0Y17[$= M`E/S)&QB&GC69`P]?H?!+'C,!BDWDH85DZUUT.H`A3(4?(+`@!>.0[[*J:O7 MB153Y%B`2AR[X$>'K@HGQW`/&(I:0;8$JH,<>M6"UTO958)PKMU%HK:O46M? M(+M,07>RQQZEE5:2T!T-42QRT#M)A1U8FXF/4F0? MLX35JD8FD=>A9B`D$Q;?B25G;.XF_H@9BR97]HU#`RX^AR,'+#&5I4Q;.+0; M1H*Z,[EX=#.)K;!8*N>.WQ9/ZGP>&B,*_1'@\"W8RLRG@P:4CZF0/#CW:/,( M_0I1FQ/)WP/V97@!`,/.'K`4_BXY(P%4"V$MA-<)X2FV[1")9"H4PK!88!D4 MC"@.*=[UO0JFHI1/Y/O:*(Q04$G;$\7M-'68!*-(7P`N;7R:@\[UQ/H!,CMA M2Y29(#ZCR50&:2DEP1H.8Y-36G`XR22Q;S/B-A-VDQ'KQ+/%!Y'G85443%[R MCIS%42&3O)&;54DJ^%:PG)12$F&M(M?8$R6GB%)S=$J5!J"PC"#-'4W0@LB7 M<3H8"#[48H6%*1P@NWZA8QD50/#`PJ8$2M15<9],([1^)C"#;,0YR%']S=9+4@J+W9% MXQ"USRQ,+Q(3X%5&"3B8;B.,"0OD MX_]*C,PE/4K'-@V$@>WD>7BFD!DL*WY!._\@,HYR9)QFJ24"T$Q'Q3]R:S%! M[(Q0XG$A@W[4B9H&IPQ4CFU303:JU(ZEQTSF7'K-N$Z0R8D/.[1< M#R1-M8#C%L-H:^74!B5ZQR3=$'3:1_J008(6;UJ\;2K>8ILHH%2%L3L:@_GA MN4!,:"2!I(O4R4(D0)0%J7B88!:DBM"'8\$8V$)^.,;#9[`-@_B4E"+\+*7- MPI2@?)#+,7R^\%Y1;GSL^J!@"Z9,914R3(KN*V39;<<\FHG[7]1J:!># MC>[&>F].,Q%E#&;*/U:'[$QYNTHEJ??C M4[DZQ:/>@][O01;E56:KA.U@J=&PJ0V0;T>>6E:G25B*3N[`J#I\L^'"$IBR M%E">+K4_7^4/:76]<\"N?`J?"HG MUQ\R51R%[YR!+$6FH$!,^NKI]5GFS1L^=6VCT0$1A*AP$[S3LXN49:;O%@E) MVAL:Y(,5P,`L.X!,1G^5&?YK)JGVMBBS=,BJ>\2-*]*?H<#;G/9N$F@G92D5DHEC/>$4RV"6# MT5CJ$SM)E&^*N6VWX.XE-\A5C7/\$A8!4!HC^#&(PV54'N2E+Z7N%@R=YL+F M*P]6K33COJFG56`=++<[2^!%"8%I1$F*7(A!O@CTIGQZPL(Q#/(*L!=ETN@D MZN0CH&A5L#DS*\#A,`RA8:4:Q=02-,>E$1CD3S)<4XN3HF&$TS@VB>\L6_IK ME4J27M0'\PY"?"3[W53$<7`:*0NP.ZRH)^%7"6Y^?^1.L^#^&^-2P-(5\>9B M+!7>J<2#2"M$TG5R^#(@YI!G%W(11-\ID\QAFO"53^A\E03L7R-ZYRP+JDQ, MC6T5XP_'^:-GM,SE<4F4'@SD3ZBICDT>4^?ASGD`QVJN;&9XS(5OTTM)OLD\ M\C,>A,'39ER6%\\9585$3A5.E0\D%;*HT1$/;4)MZFE:#J2`TR M--!,,L#@,;KU7J4!-HYLOYF[ETA9(.T:F%%WTG#R0&\!6\L\)'DK7WSXI,[8 M5.048[9TPB8OW<@>D3D8*LV4TK')U.,SQN;4G"I>`;-&&):<7J;AR9H#?LIPZ40:$A,CRT[6YR2$BZ6S9&8#% MJ>V4Q/E3':/%&HJ6@[HV(DL(OU*M9)/S[J7M`9#U);39*QY5$?5\DD"DBA-B MDR.Q=HJ&B'Y"$4.I$M;=C"1^30 M\J1P#'967%*3VD?JS:2"+ZY+G:IVHL4&%%559.@JMI^,5W)&BEUD3+)T[@G> M)Z(@C`T_U85!6GYJ]+SUO"+)X75J7B663?9E*KK`@B=K@DM2!M&<$60%5=@N0,`D")-\\6(-BJ:8C:&08<<.H M3!F&1@&(84IX`9T&,G.6*%<,LARO6[>ACY;SZW[CW,%#_U/?F;]2X9B.L%/8 M#0)>"U`M0-=7P072O*.:BSB#-:DU5]U+R)-19<-QUH,A#7%^5=C_Y,G_/`;;=F'W%,FMX'SU:R@+:OF#: M?KC)`'>'SHAEISM"A,S5CK&`E`,_%IW-YK^K47`7-3BF7P=O5K&B[`!WYSKA M6$':[K?EAR*$61$>"B3_:E4[[2D\^=?5^='&3-=A%D:K$?OMS'CQ>5-^N77T_/SJ\^_ MQ0\#Z<"#IV=__O;MR_?/YQ6YT[)5@(4MSM(W:)QVM95BJ]'I5!N$O?B9;P2* M>B@/6+*>FR]?%]8HWUM8)#X**U0@WV8KI@<\#/ED3N.$SC+$U>OUM8B[O9Z=E=RZ.\E%DB0M;139GXK5ZO MULM!*6NY;3W:=L5MG6JS)"+KD-FMMI[=Y$>1TI!6BUNAL=(9CA?8`$-P'Y-8 M8DOQ@=)Z`RV_/3K0BOVY/?07A8E16_UD=)MFM]=;ED>JS8L=F1=;9'-M41P! MGS^.][6MHVT=FO0R$KY+%<^YP)@V=[08W.!`8E=RKFW6ZPUMXF@39_=XT[R] MZT\;2P-M]&BC1Z;N\&&(=X$\GY6CCVZT6$P*O;<@`QOUMC:'2F8.Z0,E+00. M[9-1T796.7A+AV*T2-IZ>+D/GI8V-,IF:.BXBV;D9V?]GMFOU;3R+RWQER[( M\A'[QEFV'5%C7KKK<2H8-O\JK/'7D18&[+^A2=.L'J9%0W#M6FS<2_$W""S#X='`8V51_MM`XZ$* MCK+FVS7`@#B>5-M2"()[V0];%P0;V1!:$AR<)%B2E]+I=.\7,I$?L8#X@6[^ MGK7;N$]]>JZP_1L+F"7L<>9V0&P>+5M\B3C!XYC:;\08H43>[%VMU+]DQ9[H M9ARZ&<=;(I+T8CC5XDYD:2I[A\P4F]7-W3U-N%$-_J:".Y&M[G95'?FH3T<\ M0]7XMFSLY":]^-96QQ78!;(J@`]&4X6]_GX\$R M+2<9KWP`@]U8/Y]>^.T%)>?:@\:WI%-#%T(,WI2H+H":Z\.>N=8R2#JIXXMS M?6LE@HT;&B??&E3R##7?C/L]%][0.'M9`,P`%`Z<6I5W$!7=@HJT?RDO;,G(!FQ5#TNE[K[8 M>@I[.$U!G?VDQDW>S'A1;YN-6MOL=NJ*^X%YD)#I$M=F#7OL`7\"-]Q9@01` M+/1UE8VG9#\R=K-I;&))PU&A'RZ:21B)T+HP:2W)CK5:)1IMSO5GM[N MY]SN>FL]=^_H,+->;>/KI=K[$@4=G[5%EY8"ZR@!+X=E8D-2D`_OH71H=];2 M`9E"VQ4,]6[IR&'O!,.#FHEI&_$@C(;/"Z[D`\]_M9K8JWU_H6U$K0IPGGK7 M;'1;9KW;TWRO^?XQUM\VTWMV9O4Y[NVC1-^$.6XTP8M4V`).8'@M"U^'++Y>UH'`G+8R9'J]?2@>6C%018+__&^)_%M#>M!HY@]W4N M@M8)Z\NFC5>)?@@6JA4-,MKEG^,W;=#EM?VWW.Q?,;LDQ\?T4NBI*5? M)0<""_N*BE?ML>6/9"'@7$%AKU,WN\VNX40"9YAR8GP>",+A+3S(H\#@\(28'P1QA=Y2 M&`IW$(6PHZ]$XD9Q`PM"$;I;9$DK,/);<0I0N3;5G-[`(*?)(.F6O)8UO7'K M`2P[!ECF5^%$5,8^=H.0"QC1BZN187G7H>7#@U3-/BV>RV,+WE,[]E MDP'`AZ7&6(P@*X"_W%PO*74N0,2+.)6JW\,A8Q&C!J3Q7J1YKME'$BE4$)T\ MQ2)FP8+("XOJM^$K7"2U#!AC5X\`N";YB?H9<#$!P":NCVM74`!]F=G2:>I5 M(%SLAN`@82^0,\VPA%+!2`*6RM'HTJV=:V]R#\%;.IESL,(TSW%`?PZ?4M,6 M^!X8Z!9H#W<==O+R]/J#<7I]9G1;M4J]5FFTJ\86#),N")*;:HP58A2SK8),U`0L&L M,&W)D1LFM'Y@EP-8-B":HP!MP'/,\0R,!%@8#B5^"`4K0$LKL18S#I`!2[!]:QFA+LZP)']^OI M;Q>5#]\N3O^L?+BX_/+MXHWEW5FS(#_4R2#UDV((C\Z,3MM/K6HLP=6FY M`O,4,JVH@L/OKX=04WH&]6>Y3&3-E1^$(J+>2XLHUDWVM+62MU;(&">?;"); MDRUOHA>,08E50(9,,JK-33VH"W0`6#CE.-PP*67=`3FL@E[V.ZA57UGH>; M2R%`/Z5F[IX*S;V0-P08@!F= MO)+Z6N@<9EX:NTQ@=\Z9]%.F(!)!$H+5+?THUY]&(9GC:?`W9/;8=_^)X)$H MD':WFCH[,!CK*'<%8X:'G3^IT9N"ZAZ-W/9BX[9%D='.(/R(6V@4U&[L;DDK MD+Z;M?R[WJZ]-?X_?`=,`8R$?4U?1;[EX/XRY[6,E*`)`@:'^,'B!JX.,"S% M3%5#1/@NVT:5^#*($7(S9DA2S9D@0-&02A-K[;JG@)TN'/F:"Z:5S[/!'ZDEXJ[N5M+Y M'0]Z5918GFSH"-C^D,'!TO=-H=C*TEYQO$"ZZ+&!1$D+12$"$)[R2A$N'P)? M'H_CY,NB`HN,>] M9/M*QU%3US::[1K>_!,"]V`. M5YRAVZZ__8US1^9_8KXL>KFFNL$GP+0_L+Y@_6-^9V"864:4T6@;Q:]1#!I\ M%%=(:^PKIOUAOG%R>!11;G>RCE0PPE)I4)EUNF)4L-G(F3'".UX)0C;%-$8* M6:/X1`O2HK0N^,>/P!F24M2X=$40FO/V*&7MI;EPD:\N);(MSXYD*ABB`G,9 M+26^,7]QSD'+.EGQJJN88,M]AV(#&\[J(104=2R!( M<_I&F8-4NA?Q^0"?2IN:@YA0^KZ#*,E*I2*-ZBYL%U(!+!Z3,.7YQ.V*^QH@JF<&&"% MW7/DE"DUI,-)5X"\@0GFN=/]9C.),DQ65+_G7!-W#5ZKQA4@;@A3**CB"A-Y MNQ4&?Y8N-XNJ9)5!=IFXJN5+7:0+Z5OG*&,=`$08TD9)6")#',1+N+F^SY!- M+#$CD#,X!CJEL+8*?-^Y`5.#RNFSU+2:-1/J6F!.("28P!;N`,:1SP%+62-A M3<GV%U$=XD.')]RK27]'$.""1I6V_+B`]-`8^BN>@H'G%IR(D; MALAOV7-X^(6N]B0=S=0A.`P>,\GB0.F.':K[=01Z.DL"*D%9.A@D;=!!@!]\ MF"SGD>3LM3DAR$!B6*HH(SFWS=V=]Y<,4!/W)F\ZZIAJY61`ZLA*2U/?"U+( M\W%/8E?,7Z<+^\+(69#A#-$0@$R)E0%])8N4E()=>F\G(`U=@T1\8B!54"7# M%`N:`+V">Z31IK`K-)X5),GE<\??A7`%:C!OEKM*4ZZONJS+;.K)W,L_R7DV M'UT0LPYL9^H#_<9Q'([I\?YG'K)CN)[V-,A7-<@J*5MN&5TQ6T`<1;'W$,1X M:,#O8I1BPA@J#*-R,*S_:ICM9LML-V2M%_YD6\%8AA)A M46GI%3W=ZK;-1J^7G/?I&Z8A]IFB_"R5A_CP( MR/>6R7*@I-"(0DDCKH9#\2$=H=B?(SD"+AT%LZ31F;L<.!/+PMN^`[3NU4_9 MV)9B3Q\,**P!XI&0`?4!.FF@W0JK(.=L(FN1(PT[OIX:YD?F#"*ZW]G)1,=4 M56C\A,]S16`!+$4J%R$K?@M7+34UMF,Y)?R[GKYY'!2ORI;B@Q?8(N0N+8T47XJLR'`75\LLK>E;T9Q`DSZP:@#(#!"]I2%N%*! MXLE2RO0KH@)@%W+@8MF9P`*[5611AMDD+OXL88*UM2OUVI])C$6J]E@`H0[U M6)@F*^+#Q@2`'>?T\E&<+VW@6^5\L6^R$/BK)<+9#?9LDO9/4%#Y>20^&9YX MSN<[_0Y&8SBVT0.'GV^X8\WP9,&N4J,-:FV!1ENG]DOBYO,)4&#B[@0A(E"> M5IC2:/6Y7W%<+PJ3(U`3E1.8M4G/#&JB!?8@-4$B1#(!`C,3.S$-#SPY_,K!;)$@%-*M([9W)R[PL(%9(Y0\ MG%^,0:$88D8C-;-6JYF$+2:9_Q.FS1AK?+N4WN]!O_D8!+/` MJOXRQ%[KC!TIM6?%LT<(@5T!MUONJV<-C&"*P279G^&.(QD+H)HV;9L1_!,A M-0TY-FF(7,^1[HIMJ8#&I0"TF8^[#(.S?NI(&?Z&B$S`&?$F]QW1(0D"#22Y7C)H<8 M,QUT_B4:48?2(3%V;[3 M^$"41G*D(XD[C'0`ZS682Y8.2KL9VM#RR)4L8_H!R.<.B^K0+%+]6-#&BD_G M$F)9`D^S9H!\"V1M7BR0XI=PC*-,0O$7TY8GK-!^/0BLG3XNZ'&4W&G M-(K8!-%D@E8VT"`0*#./-J^E'D@V[1+)#'`+ZZ4@E+6\=K]F^]ODM79U^=T:FM>>AM=J MZWE-?LQ>S5*DUAN-["2'HM01*JW2WWZ^N3B3<;CGT^C;V_I-E/@6-O[0U%D) M4+:!,MLBF6V@O[:+LPTE>1^4ZD$*T.C^@NG4E-(]D56Y6%[.J-HC;UV=BMT*J1V>EM41L0[/G)%P M:6N&CL2^8>((C&K\)G@T/1;38RLD<&A*M!1(VSL=NFVL;2;;VPA)']]%8T4%^KV3P6SW@+I'=P M*EVSZX[9%5S=AMEKMK2K6P;C#WXPCV')ABRU\+`+YR6/?,=Z MWJRKZ MX\)BL%!B-7[1#NW,ZU$9RD;G<:/>?3*ON`&\=I!FD@),FTEOO_LN5B:K!K&REON: M1^$8[['`CE&?F$-7\9W)6\Z/Q'[9#H$W<;/7->J=Q-"[R5JCOX%2U9MHR M,>U#V+S1,9L-G2-=BG.;?3"1+B93C\^8ZC*&36,C#YO4%MRH=YAV2BG./?=- MO98":7NG7WIES?HZG\?0[:TT;TX[,J:WVS56L, MG'L/#F^8W4[OR=Q?W9/RP-W?,^[?,C"%T#QRV`"02]'[BNJ]+8[Y%S\'] M4[$E0-H>ZMCM8FTS4=]I'F*_?PR>.M8`QF&%Y\!I/N-[(N,+F M@A^L[B-NR(L/\/().[,L[JL+*>4MQGC;"MW%#A-P(QA;=*@\--([:NE:!GDU M"UU2,A5X]X6#MU9$?AC?I6G!!'A7'U"5(V_!<_':I!=U\(1Z9KO;E]=6QZ_A M4"_ZX">U:UVZ)U,N,7"Y?S0GU[OAF2-U`8Q6OV_6ND=S,+T%XCHX@T$SY![[ MY#N+!53N%P60']$F*+%1TUBRR\6`+KL>I-$K$``;70_2K:F_%>-M\7J0>F.# MFL9FOTS&1J/?W205H:%K&N6DIY.!X(&\O^U/O&/K@39!K5$B(NAVJB4A@4,S MIM/RZ:%*K4?9C3:=+/MD412=&G@9X`_8%&F]@'04L>-3]8'MG(VV'$`Y-EY<#:WNG MSK>.-NW*'[U\7W#EB^7]:G^^M]*?KZNKPHK\^7JO9CC6+%B3)O$L?K[QHMTD M#XMPD,^;@#E?--MFO_Y4:1-[I_FT;U%JW\*H=\U:3_=]U^:$YN#]Y.!R?GK" MZ,`&E:C[:#CNJ*:H=);CD4<&RE"/MV]:O`PXVSLUOF6D;1@3Z%=[!QGY58!I M^?Z\D8%/U@Q\_[+&!5JME7&!)O5D.M:XP*X81#L6FYKP';/3.YZ\@:W0X\%9 M%9J-R\[&Y?STA/&!>K_:/$@;4@&F;/9T=A,VR&(0]/LY<#:WFGVK:--9Q%H.;^J(4-.":SIN;"L,N`/RX\L,8O[ M[C<*>R[,!0=./8_]E[.-HP$83%C:7Z%66Q42:/?->J]]M"$!?=!8%D?":-7, M7KU]-,Z_3@O0:0'/S:V5ISL07]]^B'P[SP:=&_3?Q99Z[4_1E=Q3O7 M=_A=R'Z&!D@D(^">ZY1$:^R*N/;8%BW!`=!15:5OA42?0$?OB,LWJFK37+Y_ M7+[[3T]YT*Q[S3VG>-H[;[4<:-LW55@.K.V=OUK2_FQ:)AZ\RWK#0\L[E@CD MSK;]2,U,HV'BY<3]UM&X@EK_E5C_:<9\!"O7S7:M:;9Z?>UQE9::2V==?&1! M\,:P(X&(-:9PJ7MD+CV^;>S@.9\NI9F>`?&9=CPNQMR`<\8=V/7'N<&D.N!$>+.M/16DC\80S#?5T>-3:F%;C@S'"MD M"-Y\T9S,402Y`H82C&G?D2NC;,K]KOQ!5S'BP!V_/\O!/7:B[=G?YN=^=%M=&G M!5"IJAPWAL*RDY)4Q![\LB"CX,L@+Y,0(?BB<*A'%D%T>GUFM+JU2J-FG,.* MY9=GR58$E(S\)<267E^F&+I5E;E#RQ5H.40LIB"0@FSHVJ[E9;;2&#)9F(L` M6YX=R3O7HR`F(H`<""IP;378A(5CH!\KE"0&\AW'3_IZ4>'L9.)2=PC:`[D< M6^%%,`0/5DU>7EI\&V,ILP::SU04`LNS)AB;_B_\PF\E^N08Z#,NR[M^=Q(% ME9%E3=\@\LYA-H\'`.X-F&,?/-C']__W__SK7?S,=30(V#\1K/SB%O0H1 MAA;<-S;\]>4YT&6_5O^[7J_UFO67[W&V_U>IL-'/2B6>?0^5*[#T9T#L9`"X M?5Z5N(:KZXU-V#I9:^O)A6YMF=!5Y>;;D+`'9KD=K$FZ-:YI=#3;;&"8W(QA MK7=60-@.`O!N"=FP,'#PPWB!]JHV%X))_8,ON/`3T>Z_ZVWPS_D0%"A,90QF MQI>;:^/5-1AAU$JB]QIV#Y"%&U4W6^VF7`2M`,;"[4^W&I5=O*%D2ZT@(;74 MK#VD@*`:)=J*KMGJ=\UVKYUIFI'=GO7:<:GFR^G'*Q]`L`)VSN1_K_Q3JHQR M/KK6P/5<1->I[Y`U\@7VTPIAKS*_@>'C2AWZ_?K\Y2JE"IK==B>6%_SZ\NKS MY_5N9P_!ZO=KW7ISV6YU>LU6L_=, M8-%3%S^GS`\>25']=(6Y01\VW>J=[O:ZM2>=;O4.`%TUFZU5$ZK!#-=9M&CA M]W^]`S$`BH,^_^N=Z^"?0Q>='7L,"NS7E^,PG+XY.;F[NZL&S*Z.^.W)V=6? M+]^#A()A:IU:X]U)^IH<\R0SZ#LI\-4$00C2]ASD[GL0@;5*K5^IU=^=I-_* MIT`YQ,_4*[5>I5G'(9WDB7[1!.<*5"RP]S$,3?W0>"6AD@ MJ#T<@CEVV37)(;VM);G:PTENCEUW"VZ]WP=8NY5Z\[DX+`87MGA?P,7M?QIP M_Y:F%UE>SPN!PI76 M/CO%NU8H9=P5K2/*L1_Y$W:M!%:JXN<^_Y_;#*TQ]F"3M'K9^RW4NFB?-N]* MJZIG3N'2VF>7>-<*I8R[HG5$2?:#DCL:.STA2K(@&IM"@.G2M'Q,EY;/3IB% M]7[OW8"W&O7N&_CEW4G\)0V`+^7?)EX)Y@:0E15KW_T>.%^9H!'4`(Y["[`K MV/"YS]$$4]RY(KKU:_R7FFGN11KLG/E\XOI%PQ6L.!YI_JUW)^DJ,U!YKO_C MS9#S$$M-/L(?QD_Z*IQ-8=E^E9P+T\+2,E5+D8GC5JM>8(_G^"# M"B_TCL?MW)CP-RXJ'G(L,-?]WXJ+_OXJ.&Q]./OJ`2V<^@[RW!29XC,+_XY% MB)LLR+,&S$M8=;.WX9V7QLF#5QB+WDM`KF^S,QZ$P4:+6_?B(]=%G1.^RAJG M]8LI?/J1*\#V3C=,3.ZWDI5O/7)%&/UJEK[QR)6<.EC@2%KYAB\Q MHC(W,V,I\U]N.$ZKP"]E$???)7U_6J[7X2;PK_+':84?PU-?#=)MFH]E\=Y(#X-E@JC\93*H_4`I3KU:C[D@O:ML"IO$H8/(= MD1"">J-GMAJ-+4/1?&(H0$J8[5IWRU"T'@;%BUJU5JMC\X^X`55;MMV@UANJ MOX85A6,NL!>5:=2QAUP/_M_L$X3UGMFM=\UN*WD:FV,A?<*//`HQD(4]3+:! M!Z44'X('4O,&IY9BQATUK@D34+"!2<#$+7:_+:`ZSPS4MN#H M/@R.\X2]_'S_FH)USWV%83SX6L:9XFTN;V(M,C`Q,3`X,S%?8V%L+GAM;%54"0`#OA[I3KX> MZ4YU>`L``00E#@``!#D!``#%F5UOVS84AJ]3H/]!\RZR`I%E)2B0&/4*558: M8TKD631^QX^I*DC^,/']1P[ M2\@XHJ1W[+<[QPXD.2T0F?:.$:?N^?G["]<__OCKVS:P<,8; M)^I_#D:\1`(ZG$[$"C!XX@3%$A`5$-+YHA20.0-"Z!((Z:";'H>MYJM6JOQPRW M*9MZ\L$S;Q?8>OOFZ*@*[JXY>O#`ZFP7[GM_7<=I/H-SX"+"A4KU[D&.NKSJ MCVE>)?L,2Z'"0Z0?C>)HC_N6XGGSP%HG-^YA^$ M*:'_2>#1(UL&_L7%A5>-'D9+N4+*MB_?9J7<9O)Z+2V3RV08C8)L(`VWM\J MTS1+PM^NDK@?C=+H]]M!]K=^MC4>K\*X)@^KK,,@O;J,DS\-;-^]]*N0W=N; M`=I'/,>4EPPF;`H(^E:IAK*@I!@554.^/8<,K9K)Y!(1680@@%/9`]4+ MEK^D7M"4@>&20E.6IEW#&&4A90SFU:>"EL5ZEI&M M-7E6,J;1CQ#_HHQO98'.!$`R'ZB'=;VR+;CU[O8V\E#^PG)=*&MD[6_2>VO3 M$$/`9W+EU"WZ6J(EP-H.ZP9I6S`;[$T#'3*ZD#^"S1"#N\]*Z;U0)[L6ILWJ MMK`V9V":[$"^-LD4C3$,.(>"?Z:T6"&,91*)F$&F!?"3)K8X/YF(:=Q].-:S M9RLA6]@J,]-HU)X7&RUPME*V\&SMC!L2(/8'P"6\AD"U576Z']7#\"D/6UR?RL,T MZUC::D*ZE;)%;FMG_C24BK`8`EDVZ=Z$3=KVSL-Z?]-,TW+,X==2GKW14ML7 MRR-16Q0?&?\0WW9`7=0_C[+G/U!+`P04````"`!#B8X_PKUGT)T/``!T\``` M&``<`&%L>FTN;V(M,C`Q,3`X,S%?9&5F+GAM;%54"0`#OA[I3KX>Z4YU>`L` M`00E#@``!#D!``#M75N3&KD5?MZMVO]`O`^35"W#C!TGMFN=+0R,304/9,!Q MDIB&EC;S,AOVU>7_STM^^^_?$/S69C1+`?>=!O M3!\;O>[']AV-$(,-BF?L'A#X0Z/MKT$H!#IXN8H8)(U^&.(U8+P$^@/_Q[O\ M@7^W>B1HOF"-/W;^U'AY=?6F^?+J^KK1;(IR`A3^\D[\F`(*&US#D+Y_L6!L M]:[5NK^_OWR8DN`2DWF+)WS52@1??/?M-]](X75-2BRH900_S43L:;XJ'G]LOGJ^O*!^BE%9RAX M*J8]^,_GR^&'E@#BZLVKZY28R.A`!#))-AA<*5<_E-3"8@'L$!O(.SQN;/+W?];'DH9"T?+5L;F18(@A<-J>P[ M]KB"[U]0M%P%,/EL0>!,J4>BN`#_M8#]>Y%;J[1."ZX(\:(I;/)/82@:3H4Z MYN5>7N>GO)H^G($H8!5JG,V[4GWQ$J`J`\LG/7>Q%W&Z6_&Z'?B]DB#WVPQDF2^GOBC4'P6_+2SQM)OE+ M+8VS3QG`:PH*D?ATP/_=*1<^,!CZT$]*%B949:!4H)6C01EH.\/;\7#0[[8G MO>Z']J!]V^F-/_5ZDW$)/-5YGA1$=;&BU$VQ`?;295T$HKO$Y")MV46ZR;CG\<,,"C8G(!I`),2`C"%P?L+ MA5"K9E4Y%[#/_Z1%ZFX%:U*Y32EDM#VEC`"/*=3=$TJKNJU_;;*K-'>,278; M'[FK.5T!,$%PU,?$CBD6ZMN'>?X:H97HJ&ZA"G]M M$LOIT)N;S\ZK^MCIPAGD-<>_0:%8E>A@RJB:&)6TY9PHC^A_"1]9$^Z8=OH]B;48`^?VP`U:(`=5ZL4K:(4Z4!EO7[R<[ M$.+8+PRI/'$5VU>PTY*3P"&"=&9;U_=WX1H&6.[5C1F8PYX8YZ\(HI";@3S$ M^*PW6D8!8-#O1@2%\_T42BY+9^P4Y^5A=&!(8CP4^3T-02S<`2HR\,C="7=9 M*P;$;*>I6J/!=M_ZF`V8_<.N&YVO+E]S:7DR_)V'N:-Y8+U`RKV_H'"^S%D$ M:)WWG/.H?=>[G7SJ3?J=]N`4AYYW"ZCG!/2N#L_'H4U5S51Y:X]#IV8_(T"& M1&KFRXG0")+Q`A"#.9\RI0,[P$8`6#,F+B$*4Z5:6%/RSF#_8YQ9A.IYZ'> MD4.]\83__,S'/L.;X:AWUY[T^9<5C?+R\S[;`"^_^.>QW>]O;'<+63_T\!(. M,"VZ\98OZX!O5!AIW8AMJ^0-M[+#'1T*(^[*ARM(XB@1!0P=D$&MM&EKW>YQ M"W-$K*/S#JYA&"DWDY^^=H.*K376#:4WM2&<;VZ>%343M;P;5&CLM6[0/0$/ M?%C*%ENC]\A("=2*?F$E2C.0MLI"OT,A-WS1#OW4[HK^OJD^C3O$%-ANG>L: M$3R#E$I];J"RK\B(N<-(UD+K?-0M#M'F7.?&HBXBT..E40TG1:G[8I)HQ7-7;1D*R1 M!S^#$,SE>D#L\[%NGP+_.A471 M<`=@BLD=E&=631Q4KKP[K&AL5A!4X\P]8YGIBJ]+A&1M5!!1XX2\"U<$>DCN MR8B;^DM,&/I-_JN@1)?"'7*T=BMHJG$N+AOW+0[QGHTZ?Y8G[@Y!:HL5[-0X M9W\*%Z=G)2/F#AM9"Q4LU#A+_TH0@\/9;#A+;C!UX92)4VU)_#@%+P8)W6'* M!`4%=S7.Z<4)`8*FD5!I.$O",2KX4@B[PY'*6@4O-<[NY0A?+%GKAVD9,3?V MX[/66;=A4GR0YN@C18Z09(*`=7LG:Y55+MVJC%*^W^S&J;SO;^TJSK3L7LXW=A'QUF.-]*.*:JS33LR;B"_9Y=U.YP]0$+>9&ER9;1@%*<4=^#"A=I4ZWJC?54_`(H\ M<7H4!1%3WLPL2E4K1T453<=4QGSK1G%?H7@=%?KM->_ZYO`V$D`,9YG[CP7- MZ^!L'&AVAT-CW5%<4Q/,FNFQN=7*];$5_)B:<&1S?[XS7/[.\'@R[/S]TW#0 M[=V->__XTI_\N_J[PSEEU'&'.$>-Y[O$IJK&@9M$$#T:"!KV#?VYCSC=;[9Z*FGJ-6[HI,[K2_6OV=;.R)^R+]AY\+N!,5Q'W M]WAS3+9N(%F:FI^OST-._'CX*=GAEKC7M%+A?C[O#*?448TV\NCWE@6-AOJNN@+NI0<3IWB4L;;]V)1FUE.X*Q=$)W*=LQW[JCC;IZMITO MI6=11[0Z14;N@?[H9#+^> MX&V3;=9U'$O;#XQ<^.^^'3P$6VAY#Z_BE MS,)G3P[-R`U_>C`\UFU_BMCBB&FZN92``YRDS;%NXW-GQ'0'>4_EH0!N^^0) M5E2I(]ZQ.4U9#M2`$X%LW?YK.FR:\KQ92L0!ZG9-LG.C]",!(5/M4DP/6=\_ M,"<'^#L*(.NV5],!"$7HKBGK(NKA*&0C`I]^V/8\$D%_]REWN37\-#A+?:?@LW2V#M!='CKK=F&S)O&:NP+(UT>$ M+$SF))O[IENWF9I;`86[H2/P**;K$P)\<\YR$SO)7#X,UNV#9A5/HL5Z$2'< M[#:E4$;V2WD-7>2H([-SDF-3J.S;]33I-TITJV[2F0>!?5N;YJM6I1?S7*#Q M$#CLV\Y4:-\/UR)P6?D56EU&[I*KA<>^S]"D2A'J? MLR"=`Q0:&&_?BQ-II6\Q@\F:AP%1.^*.\;-KJGT/3N3VVYO`V%+I0Y9QT`@\9`*#BL=:UE^UJ'<.]X0R$W\S]P6@D"0U"C- M]0ZUO`-T:(Q5,%/C`H94=HSF(9HA#X1LH^^$@)`"69_B,#_BLCGE$\/XS/<= M]"!:*V/!E,0;EU<5D#G9GKV"/I5\8@CSES8K@5&1 M]9F@5)1^8CA'!*]X_7\*\$FDU69P)G4]JI MAS9\3,LG0\+M=N$:!K@ZSZ?(^ER#F_S23^[SGI;I*W)OV_S.YLFV19X8K1N` MB%RW^0R!^)_*)RN3;ZM!L*B,,Z%:I,:)D1Z(LPK5`+K)ZDRX;4H[N1>4S\N, M`!\G55T!57F?S0_F%W]B1,?1E,)?(_&"W;JRV4DFTS-AF"E7!][F<_%#1);@ MG_P/4$L#!!0````(`$.)CC]B`O$+*R```#&O`0`8`!P`86QZ;2YO8BTR,#$Q M,#@S,5]L86(N>&UL550)``.^'NE.OA[I3G5X"P`!!"4.```$.0$``-U=;6_D M-I+^O`OL?^!E@\$A8$MLFQ>UU*'4]CB+ M_>]'4E*W6N*;1(IB[Y>,8Y-5Q>(CB:PJ/OS^;Y^6"7A"),=9^L.KXS=O7P&4 M1EF,TXG[V6V^ MQ@4">;8HGB%!!V`6/\&4-3C)EJMU@0BX2-/L"1940WY`_R=Z&7;X^/P>$ATY/@]-=OV7_F,$>`6ICF/WSV6!2K;X^.GI^? MWWR:D^1-1AZ.:,>OCNJ&G_WICW_X`V_\[:<<[W1X_JIN?GSTWQ\N[Z)'M(2' M.,T+9FK9,SR?SZ\N7YWQ!SQ]NNOCAO-F*">'NATJ7QP_,TWWQSQOS9;4W%QL6G>E/Z7 MH_*/K=988<[&KW0N__`]R1)TBQ:`Z_RV>%FA'S[+\7*5H,^JWST2M!"+2P@Y M8OV/4O0`"Q0S1W[#''G\G\R1?ZY^?0GG*/D,L)8?;R^DEGVS(ZOL=.3+QAM$ MCOS?+[^D[#0VRN='3G[59`9-AUFY[EM:6+T_V MBTOZTX[1Z%.!TAC%M=E,CN(YYFKXFX()KB5G45/FJX2]+3/RJNF)5\WWR`+F MUR]'O]<_?J7DXR^1-*"\+?Q+]>IZU!P6Z[\S,(+R;$TBU-)`__EEB('W1S4@$,A(C M4GWGFX.%)*I_07_4V%JU.(J86:OBL#:;=U^0;-ES'FI+L@'>/9H&FE>PH&9< M+ZY7J+0OEP!1T-`:=G+E-B`KI8)L`;9R@\:6W`UM).DFP>LKK5IL7R_N"NK5 M*_1\D>=KMER2O\KD75R\PK0&V;VZEDOZSLJ9:("I8+HQ@`5801(:G$P\(7A% M&PI*O^]2&=1E*W3(K^!+W">H'L"8]E+TK"S M-5[[&6F#U5HN?55RP0"F],T9182]0=&G%4ISE*MP.OW0BLW69(SQ3?$<]O-1 M^QD<`M(IG[\;@E80QV?E9!@_>:UN(SQS8L-LGK9:!\`I6)72]PB$8G_HX:>: M*7_`XPNG"[XT/%T3^BVJ@D:/D(*CN<(J?RXP?5+N4$2;*A8QED*M0>MF4#:0 MOFLNN6-N`UAQ(PY`:<8!B#:&L'U?FA7AH=V-(]O/@DMX^'M2?D(L98+B&34) M/J"K]7*."-UY<*NOUP4+N[/,S3N8XVB6QJ=I`G4%'%RL90^-L,,[D`X8)D&WDA@92#3K*\D+V(]1WMW[G&QME`[QVDKT4J MMUX[AP8[9UA%M;!E.BL]T&,L.\&CHT0V^$_DNSWBZ69'W,M%R6;52!2A?@R@Y`J0[\7/T;,%)[.DRP M'4?:S@; MF62%U8T"P#01MIX#9/0],FQBO0L(I7:37M8G&FC65@ M:]J^O++'\G\G3S@J\OP]J#MD[Q;/3'7,;]3(P3%X)S_.DC@OA#66.50??;TACE<%S*_:Y M"KZ?&PV+X(=`8Y*2D;(&>;8N'C."?Y?6N:MZN"P1D9ECA=ZR*!UNA(8&3(/Q M*XI!U//A,0V[#=J>K`FARQA9WK7;T#[1*E5N@QS."P,J@:"A(S0$R8??R9UJ MG.\QPI[GJ)!]<:L_VL?,=Y388Z&4%]KT[XZR$_<6^'+<`/N`%GVEQ!9?M MZ9$V%BMV$-W>"@9,QJ?0>`:^11F(W.?0FU#'&:8$,Y<)H]QC)9\OH./Z1X M@2/V9%'7P/SQGCYE.8Q8D(=O!_@F(,=Q=<;J%D4(/TE7W)9"[>.43@9E5=>V M7:I4VTM6/%1D8=?BNO%;)YKH$`T>EWC+C&YY?Z_BG.RP%WMJ&5O'#4%+O%[* M5G_:?O8+0U/3K`HJ&DI86(0?ZXLK/:$!U]@CG?5EO]GRRN*U/>FJJ2T7MW7! MS24WP55L^S+$6+%RY`)F+9WW)PEDT`4'C[$\9@GU7LX6'\6+/JPA[N8RR*$T MS'Z;V_STLJ5G4]?G<)7EWX%2)7A]BN@7"1?!X<_468H`B<$T3A*SY9]Z?:"V M;.8R.KNCV,%I/2XT-.#(QJL(P0H\[;-,K*PL5I^[:[=R4`PF5.NR5CHT9$B& MW"WP4KAZK,#;:1:MV;9X0W)_"@M1Y$W9>ZZV.*I3'ZGD+\T<'M&#TV_=LS)"R:&EQ.8)BW!G.\">;8 M:_EJ0?!\7>Y`ZY"A=(4D;.RB9%5AA&6QZD9R<#A3#UM0BJIU_H2$++)8;*>= M>P(6%T"IB5)3ZN%W2OCD(E%A,.5Q@( MGQH+]P0^41^E=!E'E_H%Q"E;V:DYGM5]K+%B9))58(@KX*\6U%01&HJ,'-%& M58_)&6L#-Z,:8Z;U/($/@HW;[M^M-FQ"579YCDH@8!)#081TJ,UMF<*MOAE, M-!F*5B-'W"0N%1Y6WM@FS2^_0[O,V@U,1JVGTF::KCP-<+ M9O%YDCUK&3)571PD8/0&V:5;*OFL5HYI`%Q%:%@T<4,WCV(Z,?[P=8MR1(?] MR!:GZ`DEV4H?Q5+WL4:8D4DV$*L5E)?/;%6$AC$C1[1!UF-R/*>:3>KGQJB8 M&[-&SK(FSN]0RJPU?0N1XE*5[!:-)[11G*6QTS%,EITWJD<,IP)1PI\G>9QE MK<>B0702Q]X2(/+;*W$*HKTB0)2!R&@R/")I]\I6^KWJDH+*8&72U1YC/0RT MK'B47^";A'O>O(]_.ECL/8-CI=RJ`_#G.(]@\@^Z=)*734J;6B7B=`98%0U5 MK`6E<,"D!UE`J?-!,UEG-@L^=U"&D?Q>O#3]9'@8'?5VUR[O59) M]\[U@:;"?3G`/,!AW3W9P`D.I!B8YQ!4.S9UQW&+?G>,&[?0-S1HFONE5TFO M8-8F"7AV=SWFD4]%7Y[2M[>$>18S4=`I]?NIA84^+D*:GP=+5]\@XC4..Y_$[M)3F>MAC0<#H" M(,RZ0C),*;N,1XC5,,BRHJ8BP%HQ#0=EX7FM)#2(F7C#F-FJ,S^^.1G5])V[ M;1PQ-(Y&VADR8:.&JE/AZ`GV9/>*HKU6(W>[K'M7!7I\=RO:07T;&C3$8Y?N ME00>'Y?;L\+C+5HQUJ?T@5FREM]A)6GN@.M3;8@-6"K.S_H5LM$`2A6A(,;4 M%5T24)-)L2I';T8]S0X[Z'I8%9\;FN,NV!WHD09#/S3+RWO-RR1L2":U1=+F M+MF1G-<9-5F2]B'ZI_.%@D$IB`*72TS5Q[@)]/<9?3V>L*&3E%6_2_?O^IX. M-O+&YEF1"#"9H!(*F-30<-;#$=V=?<^)\DPP\(&^;`F&2<7O>D$7>4JR`6%[ M-\0#*E,LV4S:-\5LRE^*#.0AHUNBJ?0UD/ZN\F'@-C?,WR*5@1% MF!,M2Y[+G2;6SYI(H2$&Z/>PNF:+G8J3J4LU1TG&T>7@PKP$5U@5S^^,8PM94AM&DA1`7#S M9D=^C0'])5L7@%5E)IB_@-?KG#.@?L&N/*B,!=G&VN#"E:/.1;>,?70\3O0@ M2PKT&[<&,E[]GW#QN%T^GR-8T/V+R;-K(][MX^I@H`Z?T.!/>;CUG/)Y'A3I7,X0&"H/#/\[.^-C6..A6OKN-'%4Y.%UK=D4DV:&J0"394!'V:S,@G[;=/ MCWFR)!!DFVA>.JWD"NRVLJ0%E*JU.]?`8RWW(16P:X:[R^FG<;/WH_HL1?I( M/8Y3F$8[A((2O/40,!8!I<)8&S1JB"?/+ZYF5R=[23RI<)@AX:1V M>BJ;+/`P2-11!@8/Q8A`%<]0'($7G"47AOW>$. M,V02,)[NR1%>YCT%7W>WT'Y?P0F3JN+P7!V!!EW@4H2#?/QX, MD;MZT6'(I]8?=C?G`M49KDXS:R3*%-L=DUA!3,HMTA*RBU[3$.D'9$-O@T?M M=,^)T*LLS5JWI:FRH:+F;E*B"D.L]C;K:F^=K^=Y1/`JR'VUS@/"]*AV+KR> M-%^@/.>YYW,DW;1TFKDX42Y4;'F*?",3+%!XGR_9H`6'Q17N'OM2Z2WAWCG] MC>BPIZREDXNE)>JMWB7UU=)->D0N/12$&#A`=+VT<@*\'C>H(]BLFDAYD*#= MT,41`8ER!SD%3HISP(HW0T&*?MB"PG>ETSV>XV21$;[@;A?C2_"BZ&!_EE-K MC"5^N"Q&#U_^]$59>IB7MQ'P'QC#R1-,4(`7BNN]TSG?:3A7D\=J-Y<,#XW5 MB@2,%:M5&#MBK/;ZYNQVMI^7!"D<9ABKU4YO()$L%\%:I:1QHUO3A&OK.->> MQ6M-7-8KUA56Q/84+1`AN[9L+;R!+[QJ_0-:SJ5DB[U$.$CL]C?8+M-;Z@N4 M"V*(.[K)WJ$3Z#GR5JZG6?%#=3&]IB)&T\E-%$YKE/U)Z/I(&RHU*.\[FBP6 MI_6#,")G.#N>@78)YQFI*'EJPU08$[9W`R^5*9;T$-S/(&$*@D24:NA",.FG MP7=DAIV69#>Z#C@4W$.`HTA.'V,=1'A>7_(3NOPJWZU*L-4)YFB1D<#*2X>[ M3!P=ZC_!4]XIR(A[M#<$*#N-<->@R"CK7D%B:^$)_U9U\AGR^,'(=3'2%6Y./V>#2XW__ MX2MN2^XW>"K(<.1392>-O2=*5/9\J"?/^'";AIUBU+ MG=6G]CZ$JN43QEK3")_*/J?M9@X(N<6*[9E7:HFA04DVXB[=MLK7O@E8MBR; M$FATFCDB8>DJMH?&5F;0%\YTARXF.Y$Y?5RZDW.<(')"-PD/&9&3G>RVY+4A-$R3 M0YH%5\^3[+F^#"=]0CDOJ4]C`17*ENU.LS"P%NLD5>-B8%;O\?5JE?#D&DQ` MW.!#Y#//R:*V#<"-<<'5D;CRK2C@[PXU7I?/$4(Q+\QBP5^6 MB;E>-.[1DR^?-?U<+)_-3+.JT*L$,UPW;T<,#;?&SA`LG/M,U)3WA[5K9]2W MAIOW'^&&,(VI=C6C[-7!CY+C%*Q"+9'JZ1']35E&L^XO"I][;*& M9*BA!I4R.S8?A&.THK[%W.1)XA>"87>B%%(8AT"@>XH6.,(L?K)>KOGAEK(4 MH=U#\HPZ$#PB'6_?P5F>Y62ZZ$YLHZPN:BD>$8@;I+XYTQD:E-UYT9SO=QA& M_!]@+O>3B!=?R&EP9*V='4N6F.'D!'*2P33,:ZHTHY<=.%;.@M^0F2+LY29T MY0()3$YH4]\K<=5>]ZN1*8B M]V-Y'5Z4=9$N,K(L#]PH2F=,NMF5U/0PS&JI4=,U\@Q?65_74!4*;/JZ9*HHAZ<:=Y(%G7[N[2VSDS/:F?48&,;YKRP? M_I'Z@A2,<1QKZ7G4?>Q#R"8F6<65F0*.RQT5H8'/R`^=V+/YW'A&(&$'=3.;Q"I*0-Q1+\;ISA9%]*TH:Z7 M_9D2,[-LT'J%"D#?MCD[#[N#3_!ZSK3QA4%TI_R`L<*?$S3*('AC[M&OKYNZGP6!TVHSQ.'[,;F6+V8:C5R<)90I-2.=X-+!"A0 M#C?QB+NG`^5^GJ`:K4'N>Y.5?(/:991!5W<5:P8&NJEAVZ&$KE6%AK$^;I&6 MMQE/W+A<<8T3L9W44PL9AIT<,,F9&&5%'U86OC4//M?7UX'K\%*/_1S399XS MGRZ?E1[S'/VVI@_"V1,+?6@I@Z3M'51S:$RQJ]^HA8-2>M!E;%I7=*LSC*;% MYVFA>6%>3REK[>"TD-(,N]-"\V)?RB(U;N@>&S*8CBG(HVH^*]TQ$WD'A[10 M,F,<<4#5XD/#DMX!*LJ'/5UVN<75[.K MD]WKM(,K@1SN.<-[M8WGW7-FX#V!:2$@UN?+T'F?^[5[2G*32QAFOG62`7#1 MK.1L([N.MX2&;`LW"5,/-M/L80-!:$"T\`GW=6GX1SY`]K'H@IIJ^HW6HVLX216:H.@>Y2@U6.6 M(@X?S*ID`BSR$8^[C1*5MSU^75?LKCARCJ09T68+^Z]A5YW5;B-^PE0<6*#P MMAF"H7:^5#+7^BY^W023C6Z:[K9V5+0J-<-!0>I&=F@XT0Q=7%NJF0+?S&_R M6+^\G2,..,<1_;O@SPUIX_6&+A\K'50?FS_'>023Q;DAVR68E8_<(#:%FKC"\]';B%=[''%TOSO("+^F24QHZV&UD'SH0*K7! M#I7(BH(V,@_*_-0+^+GZ-^`7GM@;G8""8@XFSTQ51]_L,U,J06-EI@R,'S$S M=7US=CN[W\_,E('G##-3QO,>QCW@U\4C(A)DZ_N->O/WCFGV.2;%E=^A@=38 M*WWN]A;,F,]+O3<5>1\0(_Z0K?TZ[1Q_\LEJ[V5P70? MD*-+`ZM#P[QTU-W+R)40F:":O3QOP;9A6%ZP?U M6<"M#O`STQ+1TYNN*]DL7EF6J`>WAM0- M7\"P79@('7ON*>B?D)) M\OT[O$,SIER[FFXCV*EW?WL%9*(TI#HY!,0V'OS(5H-8!2B6A0,;8&]VS M3T8S,PU?D^25LM/$*5.3"\S4\ESN\(;:6&0%3&2;.Q-#IZD;Z0Y6Q2,5U#VE ME57\?:RB&S/H.L[MI!(#K4Z\5^1,Y170`7]0^SC$Z%Y2Y93YIS.[SV81W7X2 M=$.R>,W"R=65J1(8ZOLY(SC3FF8%0&K$(RSS8"N2K1"A'VV63D54Y2K$VCAC MM\B(T`RG;,JW846#TZ`=,7X;"KJ.\#:4&^B"Q"C9BG6[%'`[#.42H>=8PGBG MR_VA?Z?K@.?U:&U]VR1/Q+"((D&/*,WIHU[N_)6)$?/^+@[>]C/5\O':7%S* MM8$==:"FZ65AD>#HYGI[2G!@=\BL>LQQ(/*$(_0!IO"!Q\-5YW(DC>VS&DHC M;-"W%0GH=/.@;&@84P^^D[9N+$CJ9__UT>Q*A4;5JN8:+74G9Y7.:J-GLX&IMOX+>%Q`>N"^U(@ M7_6I#]7,K\,'3]-*9WG0\(C-M/>NK1I_27]B?ZN_A7]#V/"HK_Y?U!+`P04 M````"`!#B8X_5-'`+O03``!\0P$`&``<`&%L>FTN;V(M,C`Q,3`X,S%?<')E M+GAM;%54"0`#OA[I3KX>Z4YU>`L``00E#@``!#D!``#M75MSVSBR?IZIVO^@ MS3[X;-4XCI.=/4EJUY2%`G)V*$(#4#Z,K_^`*0H\=8` M*%$"L,F++U(#Z.ZO<6F@T?CI'X_+L'>/*,,D>G=R_OS%20]%/@EPM'AW@ADY M??WZQS>GYR?_^)\_??_3GT]/>V-*@L1'06_VU!M>?.C?L@3'J,?(/'[P*/JA MUP_NO4@0#,ARE<2(]JZBB-Q[,6^!_<#_\9__P+];/5&\N(M[_S7X:^_EBQ>O M3U^^.#_OG9Z*=D(<_?96_)AY#/4XAQ%[]^PNCE=OS\X>'AZ>/\YH^)S0Q1DO M^.HL)WSVI^^_^RXE?OO(<*G`PZN<_/SLGQ^O)_X=6GJG.&*Q8#4KR/!;EGY^ M3?R468TF>R"%^.\T)SL5'YV>OSQ]=?[\D04%1N(!,5M=1`KM9+ M!7D;/ZW0NV<,+U?U"_7_1KOYL*\"*(L;)TL^O M^0>EEM%CC*(`!7G;0HBN1!0LK'D(B5]L]B04ADKH25'BDT:)N9E]D;72G[&8 M>GZ<5Q5Z,Q2^.]$N=M:6RZ*A,>0_7Y#[LP#A5$GBCY3]TQ?GZQ[S%_[1EZSY M6[3`HM4HOO&6J,(P2%9DL`AEGY:9]:B?5\G_3'$\`>U\37&VXN->%)_Z=S@, M\M)S2I8M%)@S020R]!+&N2$K4=`+3WJ$!HAF8_91])\+,N75-NB]]+5C^BZ+ MUJSGE\?6\QA13+@,P847RQ1>IG-4\Q5AFR%X=2P(^IRE0+!U&7J+!M67OW=, MY17AFE7]MV.I.F-[P-FA7GC%9]''7]`3.*Q7Z1Q3/2!L,P0_'@N"04*%H)>8 M^5[X+^11>,P!21T#`A:Y&8N_'[D[D.621).8^+]-[KCP;)3$8DTMW#*X;\@* M.8:/CAJ:D?KOXR(U3F8A]B]#XE47S\TT3N)0$K)9[:^/J_9+'"(ZX!UV02@\ M6Y2IG%1]1=!FY;\Y\NB4#9ZW:$5HS+OBA.LQ8?"XU$SN)!R0Z(!K]N*XP/Q* MPH1KD696`R-2I7,2BIJP``9'\X\SMCZC,/PE(@_1!'F,1"BX8BQ!%,0"HG<2 M$U!X`)NC^]3;!=\E_Z2IAT"4CN$!"@P@<337NLQ8YO;K85&D=1J-DM``'AO_ M^Z>SFI#7_(-]MM8'HYO)Z/KJHC\=7KSO7_=O!L/)S\/A=++'?CI&& M]['FN<=FJ6$D['3A>:O,I%$8L_R3JFVO/_XB5@1(8#V:7^+(BWS,`2<,2[;9 M6Q7=JY-V(-;4FX75G0&`R%`GW04)T5$A40^T[=X!%KP/H2O^9W7LE!#:@DG) MC!JU7Q#..@3ZC*&8*;ISA<@6S=>,IJC]JF"PYGMCJZ-5$M*[[##QV!V@^_"85YW+XZ(>).%?[0$CP@,,00$>KJ/50Z2G@0,?R^\XM-R3R M-::7`IGU>-0%.]`Q_+ZZEVK<%3T?[.A\=^U>8V^&0QQCQ/A\EI[XWY&0<\7$ MW!8_*?PU[>)...'ZRK!N*59@7<_3EA0PC%5;DP00M-\;[_L^2:*8C;TGL2G' MA>6?T`0%!2F@<4^GJ#TX:OB7>LJP$4/!Y,0+/2J%JT3E&C)E$:T;_&Y(C'+# M`1`HD3BE_K)PUOF8?$6/N`ICN?JK5$XA4!/1.K^R+H_VK&\1%!W,]A8.3MV`-HC4A;3/#0D"G'$S]G!P%0V\%8X]:"\9HG8*%5!DZU8` M^?F$R,N`(I:J-)-/<1+34,`IB&2"6[<*N$#W*"3I:=XD]A9H*%;]*XH9XF)@ M'\?<#TZ62>C%*+A(*(X6U1(@FGM7[!CJ^RO2@<6)]J+$-'K=+D8L/"%2";CC MV87+N*E5HCB).F;T^[A_.[R9_CR<7@WZUX<(A2\W8"HNOLR%+<.8\,U;^UFE M0J:#L5T*C-?1_K>0^&\A\;NYX&./CFC*=)`ZJF-$T^O[:J\<+&D+1C7S`AQT M6`4V`Y@G\1VA^`\4J`&KE7`-J+K(UOGM&8OI35H(D1*)$Q"4A;+."U=E M78'I'-*^1C:58UU#G4SYSX]\73JZ'(V'M_WI%?^RHS5X<]U'7'XW,V#JG-PG M2[2Q$L62&Z(VOW1?:W17:;"",49P9U39CJ^FDSK2TX2*Q0E8/S% MYFM7P-C*8YU7L[:':+&^RJGJ*C"]*V!()+;._YEZC]P_B.]JB:L:"`SK7VE( M10R*QB5H%-);-X"-*9DCQE)^+A$X9]3(7,*D M+J-U(]4-B?`Z,'HMT06FR.>M,0DJJE(N@:34@'51#%/J\0Z>)5!#-/9PI![H MY&5F:V]&Z"U*P[YUAJE&>I=P MD4A]J%S@'>X*Z^X&NP5)74I5&G`3%U&X&GV<*3$*^DOQXL4?Z;\`*+(2+L$C ME1P`RJ!_GG;P&Q*1BHRR4:V)W"6(8)D!?`SZ\9OLC')<:F0NX5&7$<#!H.?^ MF>(8C>;ST3R_$'B!9K$(0ORV?=@8HZZ&;G`"1G8-+1@75G M*^DZ)N.\8&&J4!AY(5<`4\ENW8',V'L22QRV>4\F6LCVC3BW9;E M]WX5*SJ0W(GK&K"PULU*55;?>PS[(N(4ATD,7J]5E3*,DLK89%C5%&#=BNXS MPHL[SEK_GD^!"W23+&>(CN:U*ZR*+M:Z&B>Z7GOE6!?`JRN"7E?=M3;#:.]J MY+O80MLN?[RKWY/I:/#+SZ/KB^'M9/B_GZZF_^K^"GA#&V:N@C5 M]KEO=7D\DT7DXB21V%3J/V+E/?+&,K9`I;Y2WBRR=1!5 MV+P@2P]#L1[-M+9`(K.QZK%U@\36(5-(6/01B6D=/&.KTIEV360F!:1DRB7\ M3WI[NCE)M!1+>1E7<%5(;MT&05.NZ-Q11D%^$"(%KE45KN#83B_6.9F%7,_I M88L0@Z([+@F^7V^FRSNC=GE7`&VA$>O"';XE(C(]3#J6RK`LX$N[N!M8:RO# MNA4)P/HZ'^W.0#:4=QG))G58N!R!K5"60TE=SF7HBN);%WG("/0W56O1/FT)TR[4OMXMQEA!W>*K`QCTO+3?XO MYV[HO<*S+"_+3CO]PR@PO\^_VPF;,Q`V<2Y+X-(!D,<+9A[T)S]?7H\^'^`9 MJVW59D*7M^T;CU@>>.SN,B0/JCOSTB*FPQB]F6')MI/JJ0DG,OFDE M3&E,R3WF(]3[IT\,\=7N)EE.WX_Q??:$N/+!J[85V8*@:H796D'6H2Q>DL"Q M9.E?('`"E:)`G069Q(0[>(8CE0L>Z"WR2>3C$&T]G"D!S'&'U\\.TY83UG,@ M-5L7Y5),I0F&2Q=(G`"O+)2=X2@?J!?%T"GPK,WY:5>&M M"UEI-$$QY+"Q]R3<\"GU`GW4&@L[BEVS(N!H$^=19R/Z%"JWW&4)HI MMC#FR'(0[EB=H_:AJRQ)5,I_@,G49ZP]IG173:%)"9*@%>=@U]^QVWLKTPT3 M:*,0^T)<`.ZOHGN1>'/_'6I912[#*U60?0$J^27V*4GO&U'$Y0D2P3K*)BMH MYUI9S@D0-<2W+[BE/K=<<=U&"Q$=E7$]R)8;VK,L5-X)#%NHP[YWC/1'D;V' M5S?0;*,0^YX]`KC?9)#?=]:45>0RO%(%V?>J$F??1RA(\Y7G;PB)&P>;=$[P M>:^BG!,@:HAOWUM*1:9O2(SR/1L-J$KDSB%4%M:^IY0:Y^_U0P\ITVVVDQJ* M.@&8GA*`F`N#EY?TQ_.])SHW@&RC$`!.DSD7!>OIJ7#5(`'X)`6<@$LF,`"/ MP4T9P6T_"L0O$3M^[X7">>USBZ/TB1M7>I0O04I=UAG0--0`X/?*W3Q(!\?? ME5L4NL)`-O`W9V_()*M5F.K'"_-@]*MH3N@R`TEQ(4"SM!,VH*T*P`8,[OH4 M7S(#E[8%$B?P*`L%*'V'&TWFC[8JCUY)_9$JH2/0U04$`#2XZY)WSO_< M;@E&0H]J[6"8CW5QY@$":?>A,[&[:E%9FD*1(H?A8'VCXA;Y"-^#U^7WK-0=E/=0'&`*1M_0V&9327?F;]!# MOF,/38>R(D[`*!<:`&FSJW.`R_+;V71$%UZT#M\71D1"'&0*C()QH<7-H]-> MN)&9[7&GOBL.#GSUOBLV#8V[^_"L6*1V4[>I"6D?YK56]3Z$3U<[;\;P M:->I/97FN<[QL.[J]4V:$FHTWUX8A=R#.J'+L$MZ2\G!:%"/=1B6A!_SO_PG MU1`@+?(5X"I7F74OJGQBW`:'+,9++B?40RM$7P&*5;58>,/]'H5D)63BPBW0 M4&S]KBAF((BR$E\!HE*%67>9_AK_GN``QT];Z3X0'"VX=GQ$([$[!<"L4_(K M@%M+@8JK]0?U0]?W%@5+=UZT2*\0#RDE=$`H1>E61S?NIE9#1_,JM;@Q]EB? MDC55:IDV59A[DU#)HVJ1UZX.P\/-+KA6GBQLH[#C/VN_[5VWF/TFV/LD!KG8 MPY$X2>ID%&FN^6C#1G/S9CI0(R^*@4%>QIQWYW/(UGOHG$/]C1ZMHH;[O19. M%==-0Q\F^_=V*$H]RZXZ=T.U!A8$F[9-SXLY(]J3?:V`J="T[<%9G3E5E]8L M;,UD#J%4"E#35(B%&V_;%&"W*'TN>4!8S'3WX/1*FSY+;&6NY9%:4STF!^OF M"-E.!FR@ZJ,-VD#[5H5DJT/.)(6LBBYOL2S3+F^XZ^MAIHXWMVZ%-J9DQ5>; M3^-0C&K<4>2\IIN.G?1[N/:C=7V8!6.72IOY40P`ZG+F;LDV,Z8_#+2JPO!( MH(U?Y7)M"QV9'`^JB3`^$!(\X##,$T9V,BPH&SG:Z*#DI&V?:I1^CL,OJI:` M[M^JJ*$1H,!/E57],:!E)89&@5V0+`X$;55EYI14?KTFEKG75; M49ND:Y:^-G:T/FLQUT+4!CM4DX[+1^&`@"9[1_825R?]8UW5T7K(NCTSUIHU MKECL5HC,;6KEZ6ET7I@#R0VO6)LU7MF>`@0U>CC(*^52"B^Z$`S3S>E@<]7' M.QYL;M_0^6`C,ZH#0GDA0STVYZK(4I2^3Y'$B$[(/'[@W45_LMR]/M-GB5J8 M%L>`/51GUE_=W$/NR#7=UG=$+W3;:(<.YZ92J6]9IS)]9UZ_?TJ+&'410=TW M7J*WKEM=>IBF-Q<_(D_\+^(2MM]VT]54;1RM^ZD8Z:Q+*AJ2=%/=DH:Z[H:] M`D^JOBLO8[#SMD2IV*$5>C#9HZ]%AK)N.NZZJJ/USW5[AB+;T\85J^$*D:D@ M_)2+T?P:,89:K'+5Y0RO9ILQ*(7/JT4WZ\JF,1]CCQ8#_#N*=`7J/J(SV\Q` M9],FT(!DNE25,.:>;MDJI(AH<4K2I@:#4Z@F8F7_LX5N3/;E23)CZ/>$5SR\ M[RQ`JE;IT7IOK65360K+;"C3$@+DQI(LEOE1!J^"]*9C'!4XE-,I@D+OW$'7 MWX@?XFU9_LG_`U!+`P04````"`!#B8X_"8CIOD<&``"?+P``%``<`&%L>FTN M;V(M,C`Q,3`X,S$N>'-D550)``.^'NE.OA[I3G5X"P`!!"4.```$.0$``.U: M6W/:.!1^[L[L?]#F86EG8@Q)TR99:(<":9@E@0UT;R\=80NBJ;!<2AL:USOG/Y='1#C;=W MZO]]41V\,U*U8RV#E1)T`EZ=<3'OD"E.F&I6DNAS@AF=4A)"^(S,2:16!`K- M"HL949=X3F2,`[+&EO%GT7Y[>UN]/:QR,0.16MW_\Z(_,F'FCM\Q&GVRB==/ M3DY\TYJ+/I(T>=;0GI_F[E^1*3)AGZK[ MF#3W))W'C.QEWZX%F3;W,/LRK_*)EV?]8RQ(%5S+I01GH.F,7#?[H"*!<.-4 M?VD[A\`B>(3RB!D`X3$1BA*Y2/^>_\VB"LETUZA`A4;T.XZ)X@N\AP-6ZA,-Q96XMN^>;&OP[K"$/C:`& MS=@+ST5,E(&B%!4]7\%]T?`?(A8-)9*$@^B->7Y8Z9EF)N+26JVD[70>4&M1 MRC[E]'PE91TJ`\9E(LA`S'!$OQC3;9AQ.:.A>6E%X;`0_V!Z1B,8]2EFB[S+ M):??"M!%^H%F79.^-`0O15MZD5"PAG`4HJ(]Q*=H87'9=V39'8KLM8*`)Y&" MY5S[&D7A+&8,N/U#71-B2OU'' M1/]0BU;+56S"859RG5 MCRR<:31DX%".9[@J():,%=/?QO(:,J[_=#\G]`8SUYK#(>FL*>MB0FL;0LQ# M`:=DI9CK*P@1]AHZWQUR0QB/]3+*QHI#TL7*ZUAT]=5,3F7;QT6Q!#!0J8)4,%<><87K(=#]D.$T]#"?.6<(M M[)R^K1-%CK./#-)^RE0.5A*T.E"-QO#_1?=R/#@;#+M7K7$/&NUCFEUT7?&\ M7#NV+?#0X`PM$4N&[.44D7_&,9>_H-1`2>#*)H3*3WK?_B$*8';` M-%*.6K(+.LOIM6V+;S#,Q+."4C*RNBT$LR0<8IBL-QS`N$2=!R\OK:RD*,C` ME,[7]P*8!D4$L^2D60X=,K`MH\]V5^Y?6 MM;)6*9-;3.(HF4CR.8$PNS>N4\9',LYAR'IFOU1'J7[)P.HO)`&?DS&^LT\% MQ6;G":+CMQ*MB8SJ_R?E#;]P%0I>5NY)->@\YD*A]&)F9Z M//W)JQ]XA_7JG0PK*'IT>VW-I3!_5P=")7Q]<<:/DCD1--#F3[3Y^JNMS#_4 M_QH/>'3YM4[PR/O7CA1NS&D'CERFK5?LMK%F%*V7[GS"E,R_>,MK>"X7UMW< M0UN[\O!NIG[8POC:>YVI\>Q:)HHH8WC"0%>)1%]9U)<;3V/@AX>ZF)J5,!'& MLPHRU[FTN;V(M,C`Q,3`X M,S$N>&UL550%``.^'NE.=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`0XF. M/P"G3>ZS`P``2QX``!@`&````````0```*2!6$@``&%L>FTN;V(M,C`Q,3`X M,S%?8V%L+GAM;%54!0`#OA[I3G5X"P`!!"4.```$.0$``%!+`0(>`Q0````( M`$.)CC_"O6?0G0\``'3P```8`!@```````$```"D@5U,``!A;'IM+F]B+3(P M,3$P.#,Q7V1E9BYX;6Q55`4``[X>Z4YU>`L``00E#@``!#D!``!02P$"'@,4 M````"`!#B8X_8@+Q"RL@```QKP$`&``8```````!````I(%,7```86QZ;2YO M8BTR,#$Q,#@S,5]L86(N>&UL550%``.^'NE.=7@+``$$)0X```0Y`0``4$L! M`AX#%`````@`0XF./U31P"[T$P``?$,!`!@`&````````0```*2!R7P``&%L M>FTN;V(M,C`Q,3`X,S%?<')E+GAM;%54!0`#OA[I3G5X"P`!!"4.```$.0$` M`%!+`0(>`Q0````(`$.)CC\)B.F^1P8``)\O```4`!@```````$```"D@0^1 M``!A;'IM+F]B+3(P,3$P.#,Q+GAS9%54!0`#OA[I3G5X"P`!!"4.```$.0$` 7`%!+!08`````!@`&`"P"``"DEP`````` ` end XML 17 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)
12 Months Ended 146 Months Ended

Aug. 31, 2011

Aug. 31, 2010

Aug. 31, 2011

Net Income (loss) $ (2,534,520) $ (3,501,650) $ (28,096,219)

Depreciation 3,324 6,436 76,557

Stock based compensation expense 476,200 2,349,314 11,699,728

Amortization of debt discount 649,977 0 649,977

Accrued interest payable 273,245 118,176 683,438

Increase in prepaid expenses (6,215) 0 (12,396)

Accounts payable and accrued expenses 125,847 245,349 1,640,806

Other liabilities 0 (476) 0

Accrued liabilities 536,854 682,501 1,794,571

NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES (475,288) (100,350) (11,563,538)

Purchase of property and equipment (215) 0 (79,115)

Investment in patents (43,010) (48,821) (363,561)

NET CASH PROVIDED BY INVESTING ACTIVITIES (43,225) (48,821) (442,676)

Issuance of Common Stock 0 149,788 10,615,067

Proceeds from notes payable 539,186 17,030 1,957,699

Payments of notes payable 0 0 (528,232)

NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES 539,186 166,818 12,044,534

Increase (Decrease) in cash and cash equivalents 20,673 17,647 38,320

Cash and Cash Equivalents, at Carrying Value, Beginning Balance 17,647 0 0

Cash and Cash Equivalents, at Carrying Value, Ending Balance 38,320 17,647 38,320

Interest 0 0 4,500

Income taxes, net 0 0 0

Notes payable converted to warrants 0 107,077 107,077

Conversion of notes payable to stock 458,495 0 1,016,271

Liabilities converted to notes payable $ 2,953,365 $ 235,990 $ 2,953,365

Common stock issued at par 3650 131740 3650

X

- Definition

The component of interest expense representing the noncash expenses charged against earnings in the period to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate caption: Noncash Interest Expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 21

-Paragraph 16

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 8

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The increase (decrease) in cash, excluding cash equivalents, for an entity that has cash equivalents, but does not aggregate cash equivalents with cash on the balance sheet. For example, an entity that aggregates cash equivalents with investments discloses the balance of cash excluding cash equivalents on the balance sheet and the change in cash excluding cash equivalents on the statement of cash flows. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

No definition available.

+ Details

Name: us-gaap_CashPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

A description of the new financial instrument issued in a noncash (or part noncash) conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_ConversionOfStockNewIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 27

-Subparagraph f

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of accrued expenses and other operating obligations not separately disclosed in the statement of cash flows.

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in intangible assets (for example patents and licenses).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInterestPayableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other noncurrent operating assets less other noncurrent operating liabilities not separately disclosed in the statement of cash flows.

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow from financing activity for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash inflow or outflow from investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The value of notes retired (or transferred to another entity) in noncash investing or financing transactions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_NotesReduction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of significant noncash items other than depreciation, depletion, and amortization expense attributed to a reportable segment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 131

-Paragraph 27

-Subparagraph j

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_OtherMaterialNoncashItems

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The value of the noncash (or part noncash) consideration received in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireProductiveAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a borrowing supported by a written promise to pay an obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=6922042&loc=SL4591551-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A1, A4, A5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=6921930&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=6922042&loc=SL4591552-111686

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 5

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6921628&loc=SL4569616-111683

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. This element is not the recognition of equity-based compensation expense in pursuant to FAS 123R. That element is AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue (Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition, Value).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 30

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6743629&loc=d3e3913-113898

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 30

-Section 35

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418191&loc=d3e15009-113911

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 18 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "
"+ text.join( "

\n" ) +"
"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "
" + text[p] + "
\n"; } } }else{ formatted = '
' + raw + '
'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+'
'+formatted+'
'+ "\n"+'
'+ "\n"+'
'+raw+'
'+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 19 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6

Organization, Consolidation and Presentation of Financial Statements
12 Months Ended

Aug. 31, 2011

Organization, Consolidation and Presentation of Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Allezoe Medical Holdings, Inc., formerly Stanford Management, Ltd. (the “Company”), was incorporated under the laws of the State of Delaware on September 28, 1998 with the authorized common stock of 25,000,000 shares at $0.001 par value. On March 9, 2007, at the Annual General Meeting of Stockholders a Resolution was approved increasing the authorized share capital to 500,000,000 common shares with a par value of $0.001 per share.

The Company was organized for the purpose of acquiring and developing mineral properties. On February 18, 2011, all of the mineral properties and related development and exploration activities were disposed of as part of a series of transactions resulting in the acquisition of Organ Transport Systems, Inc. “OTS”. On January 24, 2011, the Company acquired all of the outstanding shares of Organ Transport Systems, Inc., a Nevada corporation and simultaneously disposed of the assets relating to its former activities in mining exploration, along with all related liabilities. Consequently, Organ Transport Systems, Inc. is considered to be the surviving entity and the financial results presented in this Report through January 24, 2011 are solely those of Organ Transport Systems, Inc. This acquisition has been reflected retroactively in the historic financial information presented in this Report.

OTS is a development stage company. It was organized under the laws of the State of Nevada on July 13, 1999 and is a medical technology company based in Frisco, Texas. OTS has developed human organ preservation technologies designed to revolutionize the organ transplantation industry by dramatically improving the quality and increasing the availability of vital organs. Its strategic goal is to be the worldwide leader of technologically advanced products and services for the entire organ preservation and enhancement market.

Nature of Operations [Text Block]
Nature of Operations

The Company’s assets at August 31, 2011 consisted of fixed assets and patents related to new organ transportation technology. The Company has developed a business plan that consists of providing new organ transportation technology to a target market. The Company’s strategy is to become the worldwide leader in a growing market for technologically advanced organ and tissue preservation and enhancement products and services. While OTS’ initial product, the LifeCradle® HR, is designed for the portable perfusion of the heart, the Company plans to offer a complete line of LifeCradle® products for all solid human organs including the heart, liver, kidney, lungs, pancreas, intestines and tissues such as limbs. The Company plans to also offer perfusion solutions for use in its devices, as well as static storage solutions as a replacement for the current‚ “picnic-cooler” technology.

Consolidation, Policy [Policy Text Block]
Principles of Consolidation

The consolidated financial statements presented herein include the accounts of the Company and its wholly-owned subsidiary, OTS. These financial statements reflect the financial position and results of operations, cash flows, and changes in equity of OTS from inception (July 13, 1999) through February 18, 2011, at which time the Company began reporting consolidated results.

Use of Estimates, Policy [Policy Text Block]
Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. A significant estimate in 2011 and 2010 included a 100% valuation allowance for deferred tax assets arising from net operating losses incurred since inception.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ materially from estimates

Development Stage Enterprises
Development Stage

The Company's financial statements are presented as those of a development stage enterprise. Activities during the development stage include company formation, equity issued for patents and technology, and fixed assets and further implementation of the business plan. The Company has not generated any revenues since inception.

Going Concern Note
As reflected in the accompanying financial statements, the Company has not yet emerged from the development stage, has a net loss of $2,534,520 and net cash used in operations of $475,288 for the year ended August 31, 2011; and negative working capital of $2,972,602 and an accumulated deficit of $28,096,219 at August 31, 2011.

The accompanying consolidated financial statements of the Company have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company is a development stage company and has suffered recurring losses and has no established source of revenue. Its ability to continue as a going concern is dependent upon achieving profitable operations and generating positive cash flows.

There can be no assurances that the Company will be able to achieve profitable operations or obtain additional funding. These factors create substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of the uncertainty.

Management intends to raise financing through private or public equity financing or other means and interests that it deems necessary to provide the Company with the ability to continue in existence. Upon FDA approval, the Company expects to begin actual manufacturing and sales operations. The Company is currently negotiating larger financing to initiate the FDA5-10K process which will be completed within 5-10 months.

X

- Definition

Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 3A

-Section 02, 03

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 18

-Paragraph 20

-Subparagraph a(2)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 97-2

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 96-16

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 46R

-Paragraph 4

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 46R

-Paragraph 4

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.3A-02)

-URI http://asc.fasb.org/extlink&oid=6959686&loc=d3e355033-122828

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 46R

-Paragraph 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph k

-Article 1

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 325

-SubTopic 20

-URI http://asc.fasb.org/subtopic&trid=2197087

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 860

-SubTopic 40

-Section 45

-URI http://asc.fasb.org/section&trid=2197723

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2196966

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 18

-Paragraph 5, 6, 16-19

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 140

-Paragraph 46

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6382870&loc=d3e33801-111570

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6921930&loc=d3e5614-111684

+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

If an entity is a development stage enterprise, or was a development stage enterprise in the prior fiscal year, discloses that fact and includes a description of the nature of the development stage activities in which the entity is engaged.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 7

-Paragraph 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38942-110933

+ Details

Name: us-gaap_DevelopmentStageEnterprises

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

If there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date), disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 948

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6490092&loc=d3e47214-110998

+ Details

Name: us-gaap_LiquidityDisclosureGoingConcernNote

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Name Statement of Position (SOP)

-Publisher AICPA

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592

+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6921930&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6970148&loc=SL6228881-111685

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Name Statement of Position (SOP)

-Publisher AICPA

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Name FASB Interpretation (FIN)

-Publisher FASB

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6359553&loc=d3e288-107754

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 11, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 20 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) (USD $)

Aug. 31, 2011

Aug. 31, 2010

Common stock, par value $ 0.001 $ 0.001

Shares authorized 500,000,000 500,000,000

Shares issued 140,080,039 18,717,740

Shares outstanding 140,080,039 18,717,740

X

- Definition

Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares issued and outstanding as of the balance sheet date.

+ References

No definition available.

+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 21 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value Measures and Disclosures
12 Months Ended

Aug. 31, 2011

Fair Value Measures and Disclosures

Fair Value Disclosures [Text Block]
Fair Value of Financial Instruments

The carrying amounts of the Company’s short-term financial instruments, including accounts payable and accrued liabilities, approximate fair value due to the relatively short period to maturity for these instruments.

Fair Value Measurements

The Company follows accounting guidance relating to fair value measurements. This guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows:

Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.

Level 2 – Inputs other than quoted prices included within Level 1 that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.

Level 3 – Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement date.

At August 31, 2011, the Company has no instruments that require additional disclosure. The carrying amounts of the Company’s short-term financial instruments, including accounts payable and accrued liabilities, approximate fair value due to the relatively short period to maturity for these instruments.

The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the unobservable inputs.

Recurring Fair Value Measurements

In accordance with accounting principles generally accepted in the United States of America, certain assets and liabilities are required to be recorded at fair value on a recurring basis.

X

- Details

Name: fil_FairValueMeasuresAndDisclosuresAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 17-22, 27, 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15C, 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13504-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-Subparagraph a-d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44A, 44B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 3, 10, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15B

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32, 33, 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6

Document and Entity Information (USD $)
12 Months Ended

Aug. 31, 2011

Document and Entity Information

Entity Registrant Name Allezoe Medical Holdings Inc

Document Type 10-K

Document Period End Date Aug. 31, 2011

Amendment Flag false

Entity Central Index Key 0001080602

Current Fiscal Year End Date --08-31

Entity Common Stock, Shares Outstanding 173,324,482

Entity Public Float $ 79,845,622

Entity Filer Category Smaller Reporting Company

Entity Current Reporting Status No

Entity Voluntary Filers No

Entity Well-known Seasoned Issuer No

Document Fiscal Year Focus 2011

Document Fiscal Period Focus FY

X

- Definition

If the value is true, then the document as an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, and Other.

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.

+ References

No definition available.

+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

No definition available.

+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Details

Name: fil_DocumentAndEntityInformationAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6

Leases
12 Months Ended

Aug. 31, 2011

Leases

Leases of Lessee Disclosure [Text Block]
The Company leases office and lab space in a two story, 50,000 square foot building located in Frisco, Texas under a license agreement which terminated on October 31, 2010. The license agreement provides the Company with five offices and lab space, and full access to building common areas including conference rooms, break room / kitchen, reception area and common lab areas. The agreement also covers telephone, wired and wireless internet access, and utilities. The required monthly payment under the license agreement is $4,267. The agreement automatically renewed on a month to month basis at the previous agreed upon terms until either party notifies the other in writing of its intention to terminate the license agreement 30 days prior to the termination date.

X

- Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 1,3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6452660&loc=d3e36991-112694

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12069-110248

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 16

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_LeasesOfLesseeDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONSOLIDATED STATEMENT OF OPERATIONS (USD $)
12 Months Ended 146 Months Ended

Aug. 31, 2011

Aug. 31, 2010

Aug. 31, 2011

Net Income (Loss)

Revenues $ 0 $ 0 $ 0

General & Administrative

Payroll and payroll taxes 1,178,409 2,154,510 13,130,805

Research and development 20,312 0 4,601,342

Professional fees 249,423 164,630 3,183,282

Directors fees 0 608,534 2,447,968

Travel and entertainment 6,335 13,167 837,601

Advisor fees 0 262,500 478,501

Rent 60,723 75,672 407,806

Organizational costs 0 0 287,344

Insurance 56,425 23,553 240,977

Office expense 2,739 7,870 181,334

Management contract 0 0 160,350

Telephone and internet 6,652 4,333 147,588

Contract labor 0 58,277 137,553

General and administrative 18,165 1,027 118,090

Depreciation and amortization expense 3,324 6,436 76,557

Dues and subscriptions 937 1,970 49,539

Repairs and maintenance 5,107 0 29,059

Bad debt expense 0 0 11,996

Contributions 0 0 9,700

Total Expenses 1,608,551 3,382,479 26,537,392

Loss from operations (1,608,551) (3,382,479) (26,537,392)

Other income (expense)

Finance cost (133,494) 0 (133,494)

Interest, net (792,475) (119,171) (1,425,333)

Income (loss) before income taxes (2,534,520) (3,501,650) (28,096,219)

Income taxes 0 0 0

Net income (loss) qualified $ (2,534,520) $ (3,501,650) $ (28,096,219)

Earnings Per Share:

Net loss per common share (basic and diluted) $ (0.03) $ (0.07) $ (0.47)

Weighted average number of common shares outstanding

Weighted average number of shares outstanding during the period - basic and diluted 59,510,063 52,170,000 59,510,063

X

- Definition

Value of property contributed in noncash investing and financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_ContributionOfProperty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total costs of sales and operating expenses for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents equipment expense including depreciation, repairs, rentals, and service contract costs. This item also includes equipment purchases which do not qualify for capitalization in accordance with the entity's accounting policy. This item may also include furniture expenses.

+ References

No definition available.

+ Details

Name: us-gaap_EquipmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations attributable to the parent which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6921628&loc=SL4613673-111683

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph b(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.13)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_IncomeLossFromContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph h

-Subparagraph 1(i)

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(1)(i))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 27

-Subparagraph f

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period net of cash paid for interest that is capitalized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 27

-Subparagraph e

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Rental expense incurred for leased assets including furniture and equipment which has not been recognized in costs and expenses applicable to sales and revenues; for example, cost of goods sold or other operating costs and expenses.

+ References

No definition available.

+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NetIncomeLossAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Noninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.14)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_NoninterestExpenseDirectorsFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents a sum total of expenses not separately reflected on the income statement for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4,6)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of general expenses not normally included in Other Operating Costs and Expenses.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 6

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.6)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherGeneralExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OtherIncomeAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of payroll tax expense, compensation, postemployment and benefit-related expenses not elsewhere specified in the taxonomy (such as health plan, profit sharing, incentives, tuition reimbursement, other fringe benefits and perquisites) incurred in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherLaborRelatedExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of other expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating expense recognized during the period. Such amounts may include: (a) unusual costs, (b) loss on foreign exchange transactions, (c) losses on securities (net of profits), and (d) miscellaneous other expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for loan and debt issuance costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18, 19, 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.6-07.2(a),(b),(c),(d))

-URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section 45

-Paragraph 3

-Subparagraph (k)

-URI http://asc.fasb.org/extlink&oid=6488370&loc=d3e13550-115849

+ Details

Name: us-gaap_ProfessionalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

A contract to provide coverage or protection in exchange for a payment or "premium". Examples of insurance protection include liability and property insurance. The entity paying the premiums for the protection will have insurance expense and possibly an asset, Prepaid Insurance (if the premiums are paid in advance).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.6)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_RealEstateInsurance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph g

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 1

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs related to delivering management services during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(d))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_ServiceManagementCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Fees paid to advisors who provide certain management support and administrative oversight services including the organization and sale of stock, investment funds, limited partnerships and mutual funds.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_SponsorFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Taxes, excluding payroll, income and excise taxes, if not included elsewhere, that could include production, real and personal property, and other selling and distribution-related taxes.

+ References

No definition available.

+ Details

Name: us-gaap_TaxesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Expenses incurred for travel and entertainment during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_TravelAndEntertainmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Utilities costs incurred during the reporting period for services, such as water, sewer, gas, electricity and telephone required to operate a building.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_UtilitiesCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating basic and diluted EPS.

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_WriteOffOfDeferredDebtIssuanceCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 25 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6

Property, Plant, and Equipment
12 Months Ended

Aug. 31, 2011

Property, Plant, and Equipment

Property, Plant and Equipment Disclosure [Text Block]
A summary of property and equipment as of August 31, 2011 and August 31, 2010 is as follows:

August 31, 2011

August 31, 2010

Electronic equipment

$ 73,788

$ 73,788

Furniture and equipment

 5,112

 5,112

Software

 215

 -

 79,115

 78,900

Less accumulated depreciation

 (76,557)

 (73,233)

$ 2,558

$ 5,667

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13-14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230

+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6

Cash and Cash Equivalents
12 Months Ended

Aug. 31, 2011

Cash and Cash Equivalents

Cash and Cash Equivalents Disclosure [Text Block]
Cash and Cash Equivalents

The Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents. The Company had no cash equivalents at August 31, 2011 and 2010, respectively.

The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. There were no balances that exceeded the federally insured limit at August 31, 2011 and 2010, respectively.

X

- Details

Name: us-gaap_CashAndCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9, 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 6.H.3)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13728-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section H

-Subsection 3

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6

Related Party Disclosures
12 Months Ended

Aug. 31, 2011

Related Party Disclosures

Related Party Transactions Disclosure [Text Block]
As of August 31, 2011, Healthcare of Today, Inc. had acquired 60% of the common capital stock issued, on a non-diluting basis, as part of the transfer of Organ Transport Systems, Inc. to the Company. Healthcare of Today, Inc. also provides financial, accounting, legal, administrative and similar services to the Company at a monthly fixed fee of $10,000, commencing March 1, 2011.

X

- Details

Name: fil_RelatedPartyDisclosuresAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 3A

-Section 04

-Paragraph b

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 1-4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph k

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6

Research and Development
12 Months Ended

Aug. 31, 2011

Research and Development

Research, Development, and Computer Software Disclosure [Text Block]
Research and Development Costs

Costs incurred in the research and development phase of the Company’s products are expensed as incurred. Research and development expenses include direct costs for salaries, employee benefits, subcontractors, facility related expenses, and stock-based compensation related to employees involved in the Company’s research and development.

X

- Details

Name: us-gaap_ResearchAndDevelopmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Audit and Accounting Guide (AAG)

-Number AAG-FGC

-Chapter 3

-Paragraph 56, 57

-IssueDate 2006-05-01

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23218-108380

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 68

-Paragraph 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

+ Details

Name: us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6

Intangible Assets, Goodwill and Other
12 Months Ended

Aug. 31, 2011

Intangible Assets, Goodwill and Other

Goodwill and Intangible Assets Disclosure [Text Block]
Intangible Asset

The cost of patent assets has been capitalized and is not being amortized as revenues relating to the asset have not been generated. The Company will test for impairment of this asset on an annual basis by comparing the carrying amount to its estimated fair value.

X

- Details

Name: fil_IntangibleAssetsGoodwillAndOtherAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6905597&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6905858&loc=d3e16265-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 42, 43, 44, 45, 46, 47

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6905858&loc=d3e16373-109275

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6905858&loc=d3e16323-109275

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6905597&loc=d3e13854-109267

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6

Debt
12 Months Ended

Aug. 31, 2011

Debt

Debt Disclosure [Text Block]
The following is a summary of notes payable at August 31, 2011 and August 31, 2010:

Description

August 31, 2011

August 31, 2010

NTEC, Inc.

Note payable to NTEC, Inc. The note accrues interest at 7% per annum and matures on August 31, 2012.

$ 235,629

$ 129,350

The Realtime Group

Related party note payable to The Realtime Group, president Marshall Wenrich served as OTS’ Director of Engineering. The note accrues interest at 7% per annum and matures on December 31, 2011.

 131,433

 122,834

Musculoskeletal Transplant Foundation

Note payable to Musculoskeletal Transplant Foundation (MTF). The note accrues interest at the WSJ prime rate plus 2% and matures on December 31, 2011.

 907,664

 822,217

University of Texas Southwestern Medical Center

Note payable to the University of Texas Southwestern Medical Center. The note accrues interest at 7% per annum and matures on the December 31, 2011.

 349,162

 326,320

Employees and consultants

Notes payable to related parties – employees and consultants. The notes accrue interest at 7% per annum and mature December 30, 2011.

 109,402

 102,768

Convertible debentures - officers

Convertible notes payable to related parties – officers by OTS. The notes accrue interest at 12% per annum, mature December 15, 2012, and are convertible one year after issuance into shares of Company common stock at a price discounted from average trading price. $1,408,579 less discount at $909,507 for conversion.

 499,072

 -

Ambrose and Keith

Note payable to Ambrose and Keith. The note accrues interest at 9% per annum and mature April 30, 2011 and is convertible into shares of the Company’s common stock at a price discounted from average trading price.

 25,000

 -

Asher Enterprises, Inc.

Note payable to Asher Enterprises, Inc. The note accrues interest at 8% per annum and mature April 11, 2012 and is convertible 180 days after issuance into shares of the Company’s common stock at a price discounted from average trading price. $53,000 Note less discount of $35,917 for conversion.

 17,083

 -

Asher Enterprises, Inc.

Note payable to Asher Enterprises, Inc. The note accrues interest at 8% per annum and mature May 18, 2012 and is convertible 180 days after issuance into shares of the Company’s common stock at a price discounted from average trading price. $44,000 Note less discount of $33,320 for conversion.

 6,680

 -

Crystal Falls Investments, LLC.

Convertible notes payable to Crystal Falls. The notes accrue interest at 9% per annum and mature January 31, 2012 and are convertible into shares of Allezoe common stock at a price discounted from the average trading price. $100,000 Note less discount of $59,185 for conversion.

 40,815

-

Ambrose and Keith

Demand loan to Ambrose and Keith. The note does not accrue interest and matured April 30, 2011.

 5,000

 -

Total

 2,326,940

 1,503,489

Less: current portion

 1,827,868

 129,350

Long-term debt

$ 499,072

$ 1,374,139

Notes payable consist of borrowings under convertible debenture arrangements. In July 2011, the Company entered into an arrangement with a creditor in which the Company borrowed $53,000 with interest payable at 8% per annum with a maturity date of January 31, 2012. The indebtedness including interest is convertible into common stock at 58% of the average lowest three (3) trading prices during the ten (10) trading day period ending on the latest complete trading day prior to conversion. In August 2011, the Company entered into an arrangement with a creditor in which the Company borrowed $40,000 with interest payable at 8% per annum with a maturity date of January 31, 2012. The indebtedness including interest is convertible into common stock at 58% of the average lowest three (3) trading prices during the ten (10) trading day period ending on the latest complete trading day prior to conversion. In July 2011, the Company entered into an arrangement with a creditor in which the Company borrowed $100,000 with interest payable at 9% per annum with a maturity date of January 31, 2012. The indebtedness including interest is convertible into common stock at $.29 per share. The Company accounted for the borrowings under these arrangements in accordance with ASC 470-20 Debt with Conversions and Other Options. The fair value of the beneficial conversion feature is calculated using the intrinsic value method at the time of issuance or commitment date. The company records a debt discount for the calculated value, which is amortized over the debt term.

X

- Details

Name: fil_DebtAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6

Income Taxes
12 Months Ended

Aug. 31, 2011

Income Taxes

Income Tax Disclosure [Text Block]
The Company accounts for income taxes in accordance with accounting standards for Accounting for Income Taxes which require the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and tax credit carry-forwards. Additionally, the standards require the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets.

As of the acquisition date, February 18, 2011, Organ Transport Systems, Inc. had net operating losses for Federal income tax purposes totaling approximately $15,205,761 which expire in 2030, when it was acquired by the Company. The following is a schedule of deferred tax assets as of August 31, 2011, and August 31, 2010:

August 31, 2011

August 31, 2010

Net operating loss

$

17,274,178

$

14,739,658

Future tax benefit at 34%

5,873,221

5,011,484

Less: Valuation allowance

 (5,873,221)

(5,011,484)

Net deferred tax asset

$

--

$

--

The valuation allowance changed by approximately $861,737 during the year ended August 31, 2011.

Under Sections 382 and 269 (the ‘shell corporation’ rule) of the Internal Revenue Code, following an “ownership change,” special limitations (“Section 382 Limitations”) apply to the use by a corporation of its net operating loss, or NOL, carry-forwards arising before the ownership change and various other carry-forwards of tax attributes (referred to collectively as the ‘Applicable Tax Attributes’). The Company had NOL carry-forwards due to historical losses of Stanford of approximately $368,374 at November 30, 2010, and OTS had net operating loss carry-forwards of $14,739,698 at August 30, 2010 and $17,274,178 at August 31, 2011. As a result of the acquisition of OTS and the disposition of the former mining operations, the Company experienced an ownership change, and Section 382 Limitations will apply to the Applicable Tax Attributes of the Company.

The Company has adopted the provisions of FASB ASC 740-10-25. As a result of its implementation, the Company performed a comprehensive review of its uncertain tax positions in accordance with recognition and measurement standards established by FASB ASC 740-10-25. In this regard, an uncertain tax position represents the Company’s expected treatment of a tax position taken in a prepared and filed tax return, or expected to be taken in a tax return, that has not been reflected in measuring income tax expense for financial reporting purposes. The Company does not expect any reasonably possible material changes to the estimated amount of liability associated with uncertain tax positions through August 31, 2011. The Company’s continuing policy is to recognize accrued interest and penalties related to income tax matters in income tax expense.

X

- Details

Name: fil_IncomeTaxesAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 136, 172

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 43, 44, 45, 46, 47, 48, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (USD $)

Total

Common Stock

Additional Paid-in Capital

Deferred Equity

Accumulated Other Comprehensive Income (Loss)

Stockholders' Equity at Jul. 12, 1999

Stock issued during period, Value, founder shares $ 6,281 $ 6,281 $ 0 $ 0 $ 0

Stock issued during period, Shares, founder shares 6,280,530 6,280,530 0 0 0

Stock issued during period, Value 10,325,876 9,525 10,316,351 0 0

Stock issued during period, Shares 9,524,820 9,524,820 0 0 0

Stock issued during period, Value, services 502,280 413 501,867 0 0

Stock issued during period, Shares, services 413,520 413,520 0 0 0

Stock issued during period, Value, conversion of notes 559,701 996 558,705 0 0

Stock issued during period, Shares, conversion of notes 995,510 995,510 0 0 0

Stock issued during period, Value, warrants 139,403 1,346 138,057 0 0

Stock issued during period, Shares, warrants 1,346,390 1,346,390 0 0 0

Adjustments to paid in capital 8,365,651 ^[1] 0 8,365,651 0 0

Net income (loss) qualified (22,060,049) 0 0 0 (22,060,049)

Stockholders' Equity at Aug. 31, 2009 (2,160,857) 18,561 19,880,631 0 (22,060,049)

Shares issued, at Aug. 31, 2009 18,560,770 18,560,770 0 0 0

Stock issued during period, Value, services 125,929 84 125,845 0 0

Stock issued during period, Shares, services 84,000 84,000 0 0 0

Stock issued during period, Value, conversion of notes 107,077 0 107,077 0 0

Stock issued during period, Shares, conversion of notes 0 0 0 0 0

Stock issued during period, Value, warrants 23,859 73 23,786 0 0

Stock issued during period, Shares, warrants 72,970 72,970 0 0 0

Adjustments to paid in capital 2,349,314 ^[2] 0 2,349,314 0 0

Net income (loss) qualified (3,501,650) 0 0 0 (3,501,650)

Stockholders' Equity at Aug. 31, 2010 (3,056,328) 18,718 22,486,653 0 (25,561,699)

Shares issued, at Aug. 31, 2010 18,717,740 18,717,740 0 0 0

Stock issued during period, Value, founder shares 0 111,707 (111,707) 0 0

Stock issued during period, Shares, founder shares 111,707,260 111,707,260 0 0 0

Stock issued during period, Value, services 423,727 8,727 2,095,000 (1,680,000) 0

Stock issued during period, Shares, services 8,727,373 8,727,373 0 0 0

Stock issued during period, Value, conversion of notes 511,854 928 510,926 0 0

Stock issued during period, Shares, conversion of notes 927,666 927,666 0 0 0

Adjustments to paid in capital 1,554,412 ^[3] 0 1,554,412 0 0

Net income (loss) qualified (2,534,520) 0 0 0 (2,534,520)

Stockholders' Equity at Aug. 31, 2011 $ (3,100,855) $ 140,080 $ 26,535,284 $ (1,680,000) $ (28,096,219)

Shares issued, at Aug. 31, 2011 140,080,039 140,080,039 0 0 0

[1] Stock option warrants issued for services, 2000 - 2009

[2] Stock option warrants issued for services

[3] Discount on notes payable

X

- Definition

Adjustment to Additional Paid in Capital resulting from the recognition of deferred taxes for the temporary difference of the convertible debt with a beneficial conversion feature. A beneficial conversion feature is a nondetachable conversion feature that is in-the-money.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 55

-Paragraph 51

-URI http://asc.fasb.org/extlink&oid=6909077&loc=d3e34017-109320

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Beneficial Conversion Feature

-URI http://asc.fasb.org/extlink&oid=6505963

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 05-8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of shares of stock issued during the period pursuant to acquisitions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 53

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares issued during the period as a result of the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4, 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4, 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of stock issued pursuant to acquisitions during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The gross value of stock issued during the period upon the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4, 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4, 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfUnits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 33 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

Accounting Policies
12 Months Ended

Aug. 31, 2011

Accounting Policies

Significant Accounting Policies [Text Block]
Earnings per Share

In accordance with Financial Accounting Standards Board “FASB” Accounting Standards Codification “ASC” Topic 260, “Earnings per Share,” Basic earnings per share (“EPS”) is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period, excluding the effects of any potentially dilutive securities. Diluted EPS gives effect to all dilutive potential of shares of common stock outstanding during the period including stock options or warrants, using the treasury stock method (by using the average stock price for the period to determine the number of shares assumed to be purchased from the exercise of stock options or warrants), and convertible debt or convertible preferred stock, using the if-converted method. Diluted EPS excludes all dilutive potential of shares of common stock if their effect is anti-dilutive. The computation of basic and diluted loss per share for the period from July 13, 1999 (inception) to August 31, 2011, is equivalent since the Company has had continuing losses. The Company also has no common stock equivalents.

Compensation Related Costs, Policy [Policy Text Block]
Accounting for Stock-Based Compensation

The Company adopted the provisions of FASB ASC 718-20, Stock Compensation – Awards Classified as Equity, which require companies to expense the estimated fair value of employee stock options and similar awards based on the fair value of the award on the date of grant. The cost is recognized over the period during which an employee is required to provide service in exchange for the award, usually the vesting period. The Company’s stock-based compensation plans and assumptions used in determining stock-based compensation expense common stock are computed using the treasury stock method which assumes that the increase in the number of shares is reduced by the number of shares which could have been repurchased by the Company with the proceeds from the exercise of the options and warrants (which were assumed to have been made at the average market price of the common shares during the reporting period). Diluted loss per common share is the same as basic loss per share as the effect of potentially dilutive securities are anti-dilutive. Weighted average common shares outstanding prior to February 18, 2011 have been adjusted based upon a ratio of post merger to pre merger shares.

Non-Employee Stock Based Compensation

Share-based payment awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the share-based payment, whichever is more readily determinable.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f(1))

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 5, 6, 7, 9, 11, 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Name Statement of Financial Accounting Standard (FAS)

-Publisher FASB

-Number 123R

-Paragraph 4, 9-15, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

+ Details

Name: us-gaap_CompensationRelatedCostsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 22

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 32 124 1 true 4 0 false 3 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://ALZM.OB/20110831/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information true false R2.htm 000020 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://ALZM.OB/20110831/role/idr_CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS false false R3.htm 000030 - Statement - CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) Sheet http://ALZM.OB/20110831/role/idr_CONSOLIDATEDBALANCESHEETSPARENTHETICAL CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) false false R4.htm 000040 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS Sheet http://ALZM.OB/20110831/role/idr_CONSOLIDATEDSTATEMENTOFOPERATIONS CONSOLIDATED STATEMENT OF OPERATIONS false false R5.htm 000050 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Sheet http://ALZM.OB/20110831/role/idr_CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY false false R6.htm 000060 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS Sheet http://ALZM.OB/20110831/role/idr_CONSOLIDATEDSTATEMENTOFCASHFLOWS CONSOLIDATED STATEMENT OF CASH FLOWS false false R7.htm 200000 - Disclosure - Organization, Consolidation and Presentation of Financial Statements Sheet http://ALZM.OB/20110831/role/idr_DisclosureOrganizationConsolidationAndPresentationOfFinancialStatements Organization, Consolidation and Presentation of Financial Statements false false R8.htm 250000 - Disclosure - Accounting Changes and Error Corrections Sheet http://ALZM.OB/20110831/role/idr_DisclosureAccountingChangesAndErrorCorrections Accounting Changes and Error Corrections false false R9.htm 275000 - Disclosure - Risks and Uncertainties Sheet http://ALZM.OB/20110831/role/idr_DisclosureRisksAndUncertainties Risks and Uncertainties false false R10.htm 290000 - Disclosure - Accounting Policies Sheet http://ALZM.OB/20110831/role/idr_DisclosureAccountingPolicies Accounting Policies false false R11.htm 300000 - Disclosure - Cash and Cash Equivalents Sheet http://ALZM.OB/20110831/role/idr_DisclosureCashAndCashEquivalents Cash and Cash Equivalents false false R12.htm 360000 - Disclosure - Property, Plant, and Equipment Sheet http://ALZM.OB/20110831/role/idr_DisclosurePropertyPlantAndEquipment Property, Plant, and Equipment false false R13.htm 370000 - Disclosure - Intangible Assets, Goodwill and Other Sheet http://ALZM.OB/20110831/role/idr_DisclosureIntangibleAssetsGoodwillAndOther Intangible Assets, Goodwill and Other false false R14.htm 460000 - Disclosure - Debt Sheet http://ALZM.OB/20110831/role/idr_DisclosureDebt Debt false false R15.htm 760000 - Disclosure - Research and Development Sheet http://ALZM.OB/20110831/role/idr_DisclosureResearchAndDevelopment Research and Development false false R16.htm 770000 - Disclosure - Income Taxes Sheet http://ALZM.OB/20110831/role/idr_DisclosureIncomeTaxes Income Taxes false false R17.htm 815000 - Disclosure - Fair Value Measures and Disclosures Sheet http://ALZM.OB/20110831/role/idr_DisclosureFairValueMeasuresAndDisclosures Fair Value Measures and Disclosures false false R18.htm 831000 - Disclosure - Leases Sheet http://ALZM.OB/20110831/role/idr_DisclosureLeases Leases false false R19.htm 845000 - Disclosure - Related Party Disclosures Sheet http://ALZM.OB/20110831/role/idr_DisclosureRelatedPartyDisclosures Related Party Disclosures false false R20.htm 870000 - Disclosure - Subsequent Events Sheet http://ALZM.OB/20110831/role/idr_DisclosureSubsequentEvents Subsequent Events false false All Reports Book All Reports Process Flow-Through: 000020 - Statement - CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Aug. 31, 2009' Process Flow-Through: 000030 - Statement - CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) Process Flow-Through: Removing column 'Aug. 31, 2009' Process Flow-Through: 000040 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS Process Flow-Through: Removing column '122 Months Ended Aug. 31, 2009' Process Flow-Through: 000060 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS alzm.ob-20110831.xml alzm.ob-20110831.xsd alzm.ob-20110831_cal.xml alzm.ob-20110831_def.xml alzm.ob-20110831_lab.xml alzm.ob-20110831_pre.xml true true XML 35 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6

Subsequent Events
12 Months Ended

Aug. 31, 2011

Subsequent Events

Subsequent Events [Text Block]
In November 2011, the Company entered into an arrangement with a creditor in which the Company borrowed $50,000 with interest payable at 12% per annum with a maturity date of November 4, 2012. The indebtedness including interest is convertible into common stock at 50% of the average lowest price during the ten (10) trading day period ending on the latest complete trading day prior to conversion.

In November 2011, the Company entered into an arrangement with a creditor in which the Company borrowed $260,000 with interest payable at 12% per annum with a maturity date of November 4, 2012. The indebtedness including interest is convertible into common stock at 50% of the average lowest price during the ten (10) trading day period ending on the latest complete trading day prior to conversion. This was an assignment of part of the convertible notes payable to related parties – officers by OTS (See Note 8) where $261,453 was assigned to a creditor for $260,000. In November 2011, the Company converted $100,000 of the note into 7,497,585 shares of common stock.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)	12 Months Ended		146 Months Ended
CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)	Aug. 31, 2011	Aug. 31, 2010	Aug. 31, 2011
Net Income (loss)	$ (2,534,520)	$ (3,501,650)	$ (28,096,219)
Depreciation	3,324	6,436	76,557
Stock based compensation expense	476,200	2,349,314	11,699,728
Amortization of debt discount	649,977	0	649,977
Accrued interest payable	273,245	118,176	683,438
Increase in prepaid expenses	(6,215)	0	(12,396)
Accounts payable and accrued expenses	125,847	245,349	1,640,806
Other liabilities	0	(476)	0
Accrued liabilities	536,854	682,501	1,794,571
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	(475,288)	(100,350)	(11,563,538)
Purchase of property and equipment	(215)	0	(79,115)
Investment in patents	(43,010)	(48,821)	(363,561)
NET CASH PROVIDED BY INVESTING ACTIVITIES	(43,225)	(48,821)	(442,676)
Issuance of Common Stock	0	149,788	10,615,067
Proceeds from notes payable	539,186	17,030	1,957,699
Payments of notes payable	0	0	(528,232)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	539,186	166,818	12,044,534
Increase (Decrease) in cash and cash equivalents	20,673	17,647	38,320
Cash and Cash Equivalents, at Carrying Value, Beginning Balance	17,647	0	0
Cash and Cash Equivalents, at Carrying Value, Ending Balance	38,320	17,647	38,320
Interest	0	0	4,500
Income taxes, net	0	0	0
Notes payable converted to warrants	0	107,077	107,077
Conversion of notes payable to stock	458,495	0	1,016,271
Liabilities converted to notes payable	$ 2,953,365	$ 235,990	$ 2,953,365
Common stock issued at par	3650	131740	3650

Organization, Consolidation and Presentation of Financial Statements	12 Months Ended
	Aug. 31, 2011
Organization, Consolidation and Presentation of Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Allezoe Medical Holdings, Inc., formerly Stanford Management, Ltd. (the “Company”), was incorporated under the laws of the State of Delaware on September 28, 1998 with the authorized common stock of 25,000,000 shares at $0.001 par value. On March 9, 2007, at the Annual General Meeting of Stockholders a Resolution was approved increasing the authorized share capital to 500,000,000 common shares with a par value of $0.001 per share. The Company was organized for the purpose of acquiring and developing mineral properties. On February 18, 2011, all of the mineral properties and related development and exploration activities were disposed of as part of a series of transactions resulting in the acquisition of Organ Transport Systems, Inc. “OTS”. On January 24, 2011, the Company acquired all of the outstanding shares of Organ Transport Systems, Inc., a Nevada corporation and simultaneously disposed of the assets relating to its former activities in mining exploration, along with all related liabilities. Consequently, Organ Transport Systems, Inc. is considered to be the surviving entity and the financial results presented in this Report through January 24, 2011 are solely those of Organ Transport Systems, Inc. This acquisition has been reflected retroactively in the historic financial information presented in this Report. OTS is a development stage company. It was organized under the laws of the State of Nevada on July 13, 1999 and is a medical technology company based in Frisco, Texas. OTS has developed human organ preservation technologies designed to revolutionize the organ transplantation industry by dramatically improving the quality and increasing the availability of vital organs. Its strategic goal is to be the worldwide leader of technologically advanced products and services for the entire organ preservation and enhancement market.
Nature of Operations [Text Block]	Nature of Operations The Company’s assets at August 31, 2011 consisted of fixed assets and patents related to new organ transportation technology. The Company has developed a business plan that consists of providing new organ transportation technology to a target market. The Company’s strategy is to become the worldwide leader in a growing market for technologically advanced organ and tissue preservation and enhancement products and services. While OTS’ initial product, the LifeCradle® HR, is designed for the portable perfusion of the heart, the Company plans to offer a complete line of LifeCradle® products for all solid human organs including the heart, liver, kidney, lungs, pancreas, intestines and tissues such as limbs. The Company plans to also offer perfusion solutions for use in its devices, as well as static storage solutions as a replacement for the current‚ “picnic-cooler” technology.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements presented herein include the accounts of the Company and its wholly-owned subsidiary, OTS. These financial statements reflect the financial position and results of operations, cash flows, and changes in equity of OTS from inception (July 13, 1999) through February 18, 2011, at which time the Company began reporting consolidated results.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. A significant estimate in 2011 and 2010 included a 100% valuation allowance for deferred tax assets arising from net operating losses incurred since inception. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ materially from estimates
Development Stage Enterprises	Development Stage The Company's financial statements are presented as those of a development stage enterprise. Activities during the development stage include company formation, equity issued for patents and technology, and fixed assets and further implementation of the business plan. The Company has not generated any revenues since inception.
Going Concern Note	As reflected in the accompanying financial statements, the Company has not yet emerged from the development stage, has a net loss of $2,534,520 and net cash used in operations of $475,288 for the year ended August 31, 2011; and negative working capital of $2,972,602 and an accumulated deficit of $28,096,219 at August 31, 2011. The accompanying consolidated financial statements of the Company have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company is a development stage company and has suffered recurring losses and has no established source of revenue. Its ability to continue as a going concern is dependent upon achieving profitable operations and generating positive cash flows. There can be no assurances that the Company will be able to achieve profitable operations or obtain additional funding. These factors create substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of the uncertainty. Management intends to raise financing through private or public equity financing or other means and interests that it deems necessary to provide the Company with the ability to continue in existence. Upon FDA approval, the Company expects to begin actual manufacturing and sales operations. The Company is currently negotiating larger financing to initiate the FDA5-10K process which will be completed within 5-10 months.

CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) (USD $)	Aug. 31, 2011	Aug. 31, 2010
Common stock, par value	$ 0.001	$ 0.001
Shares authorized	500,000,000	500,000,000
Shares issued	140,080,039	18,717,740
Shares outstanding	140,080,039	18,717,740

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Aug. 31, 2011
Document and Entity Information
Entity Registrant Name	Allezoe Medical Holdings Inc
Document Type	10-K
Document Period End Date	Aug. 31, 2011
Amendment Flag	false
Entity Central Index Key	0001080602
Current Fiscal Year End Date	--08-31
Entity Common Stock, Shares Outstanding	173,324,482
Entity Public Float	$ 79,845,622
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2011
Document Fiscal Period Focus	FY

CONSOLIDATED STATEMENT OF OPERATIONS (USD $)	12 Months Ended		146 Months Ended
CONSOLIDATED STATEMENT OF OPERATIONS (USD $)	Aug. 31, 2011	Aug. 31, 2010	Aug. 31, 2011
Net Income (Loss)
Revenues	$ 0	$ 0	$ 0
General & Administrative
Payroll and payroll taxes	1,178,409	2,154,510	13,130,805
Research and development	20,312	0	4,601,342
Professional fees	249,423	164,630	3,183,282
Directors fees	0	608,534	2,447,968
Travel and entertainment	6,335	13,167	837,601
Advisor fees	0	262,500	478,501
Rent	60,723	75,672	407,806
Organizational costs	0	0	287,344
Insurance	56,425	23,553	240,977
Office expense	2,739	7,870	181,334
Management contract	0	0	160,350
Telephone and internet	6,652	4,333	147,588
Contract labor	0	58,277	137,553
General and administrative	18,165	1,027	118,090
Depreciation and amortization expense	3,324	6,436	76,557
Dues and subscriptions	937	1,970	49,539
Repairs and maintenance	5,107	0	29,059
Bad debt expense	0	0	11,996
Contributions	0	0	9,700
Total Expenses	1,608,551	3,382,479	26,537,392
Loss from operations	(1,608,551)	(3,382,479)	(26,537,392)
Other income (expense)
Finance cost	(133,494)	0	(133,494)
Interest, net	(792,475)	(119,171)	(1,425,333)
Income (loss) before income taxes	(2,534,520)	(3,501,650)	(28,096,219)
Income taxes	0	0	0
Net income (loss) qualified	$ (2,534,520)	$ (3,501,650)	$ (28,096,219)
Earnings Per Share:
Net loss per common share (basic and diluted)	$ (0.03)	$ (0.07)	$ (0.47)
Weighted average number of common shares outstanding
Weighted average number of shares outstanding during the period - basic and diluted	59,510,063	52,170,000	59,510,063

Related Party Disclosures	12 Months Ended
Related Party Disclosures	Aug. 31, 2011
Related Party Disclosures
Related Party Transactions Disclosure [Text Block]	As of August 31, 2011, Healthcare of Today, Inc. had acquired 60% of the common capital stock issued, on a non-diluting basis, as part of the transfer of Organ Transport Systems, Inc. to the Company. Healthcare of Today, Inc. also provides financial, accounting, legal, administrative and similar services to the Company at a monthly fixed fee of $10,000, commencing March 1, 2011.

Accounting Policies	12 Months Ended
Accounting Policies	Aug. 31, 2011
Accounting Policies
Significant Accounting Policies [Text Block]	Earnings per Share In accordance with Financial Accounting Standards Board “FASB” Accounting Standards Codification “ASC” Topic 260, “Earnings per Share,” Basic earnings per share (“EPS”) is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period, excluding the effects of any potentially dilutive securities. Diluted EPS gives effect to all dilutive potential of shares of common stock outstanding during the period including stock options or warrants, using the treasury stock method (by using the average stock price for the period to determine the number of shares assumed to be purchased from the exercise of stock options or warrants), and convertible debt or convertible preferred stock, using the if-converted method. Diluted EPS excludes all dilutive potential of shares of common stock if their effect is anti-dilutive. The computation of basic and diluted loss per share for the period from July 13, 1999 (inception) to August 31, 2011, is equivalent since the Company has had continuing losses. The Company also has no common stock equivalents.
Compensation Related Costs, Policy [Policy Text Block]	Accounting for Stock-Based Compensation The Company adopted the provisions of FASB ASC 718-20, Stock Compensation – Awards Classified as Equity, which require companies to expense the estimated fair value of employee stock options and similar awards based on the fair value of the award on the date of grant. The cost is recognized over the period during which an employee is required to provide service in exchange for the award, usually the vesting period. The Company’s stock-based compensation plans and assumptions used in determining stock-based compensation expense common stock are computed using the treasury stock method which assumes that the increase in the number of shares is reduced by the number of shares which could have been repurchased by the Company with the proceeds from the exercise of the options and warrants (which were assumed to have been made at the average market price of the common shares during the reporting period). Diluted loss per common share is the same as basic loss per share as the effect of potentially dilutive securities are anti-dilutive. Weighted average common shares outstanding prior to February 18, 2011 have been adjusted based upon a ratio of post merger to pre merger shares. Non-Employee Stock Based Compensation Share-based payment awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the share-based payment, whichever is more readily determinable.